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INTRODUCTION. 
CHAPTER 1 
1 
1.1 General Introduction 
The anthracyclines constitute a group of natural antibiotics isolated from cultures of various 
Streptomyces. Of these, daunomycin (1) and adriamycin (2, Figure 1.1) have been very well 
investigated over the past 30 years because of their high therapeutic value in cancer 
chemotherapy1 a_d. Adriamycin2 (doxorubicin3, 2), the most prominent representative of these 
anti-tumor antibiotics, has been in clinical use since 1974. After this time, it is still one of the 
most widely used anti-tumor compounds, as it has the widest spectrum of anti-tumor activity 
and it can be used with a high degree of efficacy against many human cancers. The major side 
effect which restrict its use is dose-related cardiotoxicity1·2·4. This has stimulated intensive 
research into the synthesis of analogs of adriamycin that are less cardiotoxic. Other goals for 
synthetic chemists in this area have been to prepare analogs that have greater anti-tumor 
activity, especially for human cancers that are insensitive to adriamycin, or analogs that might 
be administered orally. A more recent goal is to find analogs that are able to overcome the 
phenomenon of multi-drug resistance in cancer cells5a,b. 
Figure 1 1 
R3 = H (daunomycin) 
R3 « H (adriamycin) 
R3 = H (carmynomycin) 
R3 - H (юашЫст) 
R3 » OH (4'-epirubPCin) 
1.2 History of discovery and evaluation of anti-tumor anthracyclines. 
A start for the search of bacterial antibiotics was made by Waksman et al.6 in 1942 when they 
reported the isolation of the antibiotic actinomycin from a strain of Streptomyces sp. In the 
mid-1950s, Farmitalia in Italy, initiated a program to study anti-tumor compounds produced by 
novel strains of microbes isolated from soil. In 1957, they isolated a colony of Streptomyces 
peucetius which produced a red pigment. This compound was called daunomycin (1, Figure 1.1) 
and in 1963, Di Marco et al1 demonstrated the anti-tumor activity of this new compound. At 
about the same time, a compound called rubidomycin was isolated by Dubost et α/.8 of Rhone 
о он ο ι 
χ = O C H 3 R, =. Η R 2 » он 
X = ОСН3 R, » OH R2 = OH 
X = OH R, = H R2 • OH 
X= Η R, - Η R2 = ОН 
X =. OCH3 R, « OH R2 = Η 
2 
Poulenc (France). Daunomycin and rubidomycin were later found to be the same substance and 
the combined name of daunorubicin was agreed. The name daunomycin is still used in organic 
chemistry and this name will be maintained in this thesis. 
In 1969, Arcamone et aL9 reported the isolation of adriamycin3 (doxorubicin, 2) from a variant 
strain of Streptomyces peucetius named caesius. The compound was quickly introduced into 
clinical trials. In 1974, adriamycin was approved for marketing in the United States. In the early 
seventies, a third related compound with an hydroxy group instead of a methoxy group at the C4 
position (3) was isolated by a Russian group10 from Actionomadura carminate. This compound 
(carmynomycin) is no longer in clinical trials since its anti-tumor activity is inferior to that of 
adriamycin. 
To date, more than 2,000 analogs of adriamycin have been prepared, most of them by 
semi-synthesis, and they have been evaluated for anti-tumor efficacy. No analog has yet been 
found which is superior to adriamycin. Apart from daunomycin and adriamycin, two other 
derivatives are being used world-wide, these are idarubicin (4-demethoxydaunomycin; 4) and 
4'-epirubicin (4'-epiadriamycin; 5). 
1.3 Mechanism of action and SAR studies. 
Since the discovery of the anti-tumor anthracyclines, a large amount of work has been expended 
in the elucidation of their mode of action. The generally accepted view is that the anthracyclines 
exert several parallel cytotoxic mechanisms of anti-tumor activity, including intercalation 
between DNA bases, covalent binding of reactive metabolites to DNA, free radical formation, 
interaction with the cell membrane and topoisomerase-II-mediated DNA strand breaks1,2·4,5. The 
cardiotoxic effect is mainly ascribed to free radical formation5*. 
The main modifications in the structures of adriamycin and daunomycin which have been 
evaluated in order to find compounds with a higher therapeutic index or to get more insight in 
the mechanism of action are shown in Figure 1.2. 
C 1 3 - 0 = > CH2, CHOH, C=N-R. 
R, = ^ H, OR, SR, OCOR. 
Н-С4.-ОН=ф C=0, H-C-l, HO-C4-H (epi-diastereomer) 
NHj.HCI = Ф NHCOR, N О 
NC 
Χ = Φ ОСН3. ОН, Η. 
figure 1.2 
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Anthracyclines of the daunomycin type are composed of an aglycone moiety (ABCD rings) 
which is named anthracyclinone, and a sugar component, the amino sugar, daunosamine. The 
aglycone has two chiral centers at C7 and C9 in the A ring with the S,S configuration, and the 
sugar has four chiral centers with the configuration of a L-lyxo-hexose. For anti-tumor activity, 
the S,S configuration is essential. The majority of the new analogs have been prepared by 
semi-synthesis, starting with daunomycin or adriamycin, by transformation of the C^-carbonyl 
group (6), substituent Rj (7), a carbonyl group in the С ring or by modifications in the sugar part 
(8,9). Modifications in the D (10) or В rings of the aglycone have been less studied, as these can 
only be achieved by total synthesis. The most promising derivative that has been discovered so 
far is idarubicin (4-demethoxydaunomycin, 4). It is used world-wide against acute leukemias but 
was not able to replace adriamycin against other tumors. Most efforts at modification of the 
sugar part of the molecule have been concentrated on modification of the 4' position or the 
amino group. This has resulted in the compound 4'-epirubicin (4'-epiadriamycin, 5), having a 
4'-equatorial hydroxy group. The compounds is claimed to have lower cardiotoxicity than 
adriamycin. Another promising analog has the amino group transformed into a cyanomorpholine 
group (9). This compound is still under evaluation. 
A small number of these derivatives has been prepared by microbial cultures1·1; a discussion of 
these particular derivatives is beyond the scope of this thesis. 
Relatively few analogs prepared by total synthesis have been evaluated, although total synthesis 
will certainly allow the highest possibilities for alterations in both the basic structure and its 
substituents. The complexity of total synthesis of this size of molecules which generally needs 
more than 15 steps, may be a major obstacle for evaluation of any further analogs that might be 
obtained in this way. 
1.4 Total synthesis of daunomycin and analogs. 
Although most of the analogs of daunomycin and adriamycin have been prepared by 
semi-synthetic methods, these methods will not be reviewed here, as they are beyond the scope 
of this thesis. When total synthesis of daunomycin analogs is indicated, it implies synthesis of 
both the aglycone and the sugar part, and then coupling of the protected sugar with the aglycone 
followed by deprotection. 
Coupling of the protected sugar was originally achieved via the well known Koenings-Knorr 
method11 in which a labile halo-daunosamine is coupled to the aglycone using a mixture of 
mercury salts (HgO/HgBr2). A modification to this method was published by Arcamone et aL12, 
in which silver triflate was used instead of mercury salts. 
Both methods gave predominately the desired α-glycoside, but also some of the undesired 
ß-glycoside. A third method was published in 1984 by Terashima and colleagues13. They used 
4 
trimethylsilyl trinate and a stable protected sugar with /7-nitrobenzyl groups at the 1 and 4 
positions. Only the desired α-glycoside was formed using this method and it is now the most 
commonly used method for the synthesis of daunomycin and its analogs. 
Synthesis of the sugar daunosamine has been studied by many groups. A review article14 shows 
many possibilities to synthesize daunosamine from cheap chiral (carbohydrate) precursors. We 
have applied the synthesis method from the commercially available a-methyl-D-manno-
pyranoside as published by Horton and Weckerle15, with some modifications. 
Synthesis of the aglycones of anthracyclines (anthracyclinones) are, in the first instance, 
directed to daunomycinone-type aglycones which can easily be transformed into adriamycinone 
type aglycones1" by bromination and subsequent substitution of the bromine atom by a hydroxy 
group. 
Excellent reviews have been published on the synthesis of anthracyclinones16a'd. Krohn16c 
divided the described methods into four main type of reactions: 
1 Friedel-Crafts; 
2 Anionic; 
3 Diels-Alder; 
4 Transition-metal-mediated. 
As our approaches to the construction of the anthracyclinones involve Diels-Alder reactions, the 
Diels-Alder strategies previously described by others are surveyed in this Chapter with special 
attention to those strategies that are important for our approach17""0. A priori, several 
Diels-Alder routes are possible and the more important routes are shown in Figure 1.3 in a 
conceptual fashion. 
Figure 1 3 
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The first route (I, Figure 1.3, the DCB + A approach) was used by Kende et al18 and Lee et 
al.19. These two groups presented, independently at the same time, the first Diels-Alder 
approach leading to a useful synthesis of (4-demethoxy)daunomycinone. The Diels-Alder 
reaction of the quinizarinequinone 17 (obtained from dimethoxyanthraquinone 16) with 
2-alkoxybutadiene gave product 18 (mixture of regioisomers), which had to be functionalized at 
C-7 (Scheme 1.1). This functionalization is possible but rather cumbersome, and yields of not 
more than 50% were achieved188. 
Scheme 1.1 
O OCH, 
Ö ÒCH, 
16 
o o 
AflO 
OR 
Il II и - ^ — + 
o o 
!Z R » COCH, 
O O 
O o 
18 
OR 
To circumvent functionalization at C-7 at a later stage, Stoodley20 used 1-methoxy-
3-trimethylsilyloxybuta-l,3-diene (20a) in the Diels-Alder reaction with 19 (prepared from 17 
by selective oxidation). To prevent cycloaddition to the internal double bond of 17, this bond 
had to be protected. Product 21 was converted into 7-0-methyl-4-demethoxydaunomycinone. 
Removal of the methyl group from the methoxy function at the 7 position by solvolysis in 
trifluoroacetic acid was possible, but chromatographic separation of the mixture consisting of 
cis- and trans-7,9-dihydroxy isomers appeared to be extremely tedious21. 
Scheme 1.2 
О О 
"Χ" 
о О 
17 
•:R=CH, 
О О 
О О 
19 
„ОЭ(СН3)3 
¿? Ш 0 0 
OR 
АсО ОАс 
OSi(CHj)3 
О О OR 
21 
Ь: R = •—( V ОАс с: R = ш-( V 0C0C6H4-p-N02 
0 -
сн, 
Two years later, Stoodley22 was able to synthesize (+)-4-demethoxydaunomycinone using diene 
20b, made from optically active 2,3,4,6-tetra-O-acetyl-a-D-glucopyranosyI bromide. 
Recently, Brasca et al.23 described a method for synthesis of (+)-4-demethoxydaunomycinone 
using chiral diene 20c. Protected daunosamine was used as chiral auxiliary and no glycosidation 
of the aglycone was necessary. The disadvantages of these methods are the restricted availability 
of the dienophile (substituted quinizarinequinones are very difficult to synthesize and to 
epoxidize) and the reduced reactivity of dienes 20b and 20c compared with diene 20a. The 
dienes 20b and 20c react only with activated dienophiles, such as 19. It appeared, in our hands, 
not sufficiently reactive with quiñones, such as naphthazarin 15 (Scheme 1.3). 
Potman24 tried to synthesize several analogs of the quinizarinequinone which could be used for 
the synthesis of D ring analogs of daunomycinone, but either synthesis or oxidation of the 
dimethoxyanthraquinones analogs was not possible. Therefore, he concluded that this approach 
is a straightforward route for the synthesis of 4-demethoxydaunomycinone but the scope of the 
method is seriously limited by the difficult availability of suitable substituted 
quinizarinequinones. 
A second method published by Kelly et al.25 (A + BCD approach) includes steps IV and I 
(Figure 1.3) to synthesize daunomycinone in a regioselective manner starting from 
commercially available naphthazarin 15a (Scheme 1.3). After protection of one of the hydroxy 
groups of 15b, the daunomycinone skeleton 25 is constructed via two subsequent Diels-Alder 
reactions with 1-methoxycyclohexadiene 22 and l,3-bistrimethylsilylbuta-l,3-diene 24, 
respectively. 
Scheme 1 3 
° H - ° MlKH.Pb02CH3° ° H - ° 
15 23 
CH3O о ,
н
 о 
23a 
OSi(CH3)3 
с н
э ° 0 4 u O OSi(CH3)3 
Π 
25 
a R=H b R = COOCH2C6H4 ρ N 0 2 
Synthesis of other D ring derivatives is possible but limited by the availability of the appropriate 
cyclohexadienes. 
Several methods for the synthesis of daunomycinone via route II (Figure 1.3, the AB + CD 
approach) have been described. Broadhurst26 reported a multigram synthesis of 4-demethoxy­
daunomycinone by using dienophile 28 and diene 27, which had been generated in situ (Scheme 
1.4). The method is limited by the rather difficult synthesis of the dienophile 28. 
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Scheme 1 4 
OAc 
Qcf pAc 
OAc 
28 
An approach via route ΠΙ and V (Figure 1.3) was developed by Krohn et al.27 for the synthesis 
of 4-demethoxydaunomycinone. Naphthazarin 15a was used as the ВС fragment, which was 
converted into cycloadduct 30 with l,3-bistrimethylsilyloxybuta-l,3-diene 24 (Scheme 1.5). 
After functionalization of ring A (30 to 31a) and a second Diels-Alder reaction with 
1-methoxybutadiene 32,4-demethoxydaunomycinone 33 was formed in an overall yield of 29%. 
By using suitable dienes, this method opens a way for synthesizing a variety of D ring 
functionalized daunomycinone analogs. Limitations of this method are the conversion of 30 into 
31a. which is not stereospecific, and separation of the formed cis- and trans-hydroxy compounds 
31a and 31b by preparative thin-layer chromatography. Analogous problems are encountered in 
further functionalization of 25 (Scheme 1.3). Furthermore, no regioselectivity is expected in 
conversion of 31 to daunomycinone derivatives with a functionalized D ring. 
Scheme 1 5 
^ о а ( с н 3 ) 3 ^ 
I] J 24 I 32 
OH O y¿ — OH Ο «ι] Н-С=С-МдВг ОН О
 0 » І ^ ~ О ОН о 
ОН О ОН О ОН ОН О R,R2 о он он 
15а 30 3 1 a R , - H , R 2 = OH 33 
31b R, =. ОН, R¡¡ = Η 
The strategies for the synthesis of the aglycones described in this thesis are based on the 
methods of Kelly et al.25 and Krohn et al.27. Limitations of these described methods have been 
overcome by several modifications and changes of essential steps, so that it is now possible to 
synthesize the anthracyclinones on a gram scale. 
1.5 Outline of this thesis. 
This thesis describes the total synthesis of known and some new daunomycin analogs and 
evaluation of the anti-tumor activity of the new analogs in order to find analogs with higher 
therapeutic indices. Regioselective syntheses of the anthracyclinone part have been developed 
which allow substituent variations in the A and D rings. An approach is also presented for 
introducing the necessary chirality into ring A via cycloaddition reactions. 
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In Chapter 2, multigram syntheses of daunomycinone and 4-demethoxydaunomycinone via the 
A + BCD approach are described which are based on the method of Kelly et aL25 (steps IV and 
I, Figure 1.3). To make this method more practical, essential steps were modified and a step 
which is not reproducible has been circumvented. Chapter 3 deals with the synthesis of 
daunomycinone and 4-demethoxydaunomycinone via the ABC + D approach (steps V and Ш, 
Figure 1.3). This route was first applied by Krohn et aL27 to synthesize anthracyclinones in a 
non-regioselective way. This method has been made more stereoselective by changing the used 
diene and the Grignard reagents. Regioselectivity is obtained by regioselective protection of the 
ABC fragment. 
In Chapter 4, an approach is studied for obtaining optically active aglycones by using chiral 
l-oxysubstituted-3-trimethylsilyloxybuta-l,3-dienes. The preparation of the dienes and their 
cycloadditions with naphthazarin, juglone, naphthoquinone and benzoquinone are described. 
Diastereomeric excesses up to 99% are accomplished depending on the dienes and quiñones 
used. A model is presented to explain the diastereomeric excess observed. 
Chapter 5 describes the synthesis of Cj3,Ci4-ethynyl analogs of daunomycin and 4-demethoxy-
daunomycin. The necessary racemic anthracyclinones are prepared according to methods 
described in Chapter 2. Glycosidation with the chiral protected sugar, daunosamine, followed by 
separation of the diastereomers and deprotection, yields the chiral ethynyl analogs. 
The synthesis of pyridine D ring analogs of daunomycin are described in Chapter 6. The 
followed route towards the anthracyclinone is an extension of the method described in Chapter 
3. The pyridine D ring is constructed via a Diels-Alder reaction of the ABC fragment with 
l-dimethylamino-3-methyl-l-aza-l,3-butadiene. Coupling of the pyridine-containing anthra-
cyclinone with the sugar moiety and isolation of the enantiopure D ring derivative is analogous 
to the preparation of the ethynyl analogs as described in Chapter 5. 
Chapter 7 gives an overview of the current status with respect to anti-tumor activity and 
mechanisms of action of daunomycin and its known derivatives. Five mechanisms of action are 
described which are proposed to contribute to the cytotoxicity effect. Factors that may cause 
cardiotoxicity are also presented. An overview is then given of derivatives that are currently in 
clinical use or under evaluation. The results of systematic modification at four different sites of 
the anthracyclines, e.g., C13,C]4-side chain (A ring), ВС rings, D ring and modifications in the 
sugar part are discussed. 
In Chapter 8, the results of biological tests of the newly synthesized daunomycin analogs are 
evaluated. The ethynyl analogs (Chapter 5) and the pyridine analogs (Chapter 6) have been 
tested against five human tumor cell lines for in vitro cytotoxicity. The test results of the four 
most active compounds (in vitro) with respect to their acute toxicity (MTD and lethal dose) are 
also described. For the same four compounds, the in vivo L-1210 tests are also presented. 
Finally for these derivatives, the results of an in vitro cardiotoxicity test are given. The Chapter 
ends with a critical evaluation of the obtained test results. The thesis is concluded with 
summaries in English and Dutch. 
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CHAPTER 2 
A + BCD APPROACH TO DAUNOMYCINONE AND DERIVATIVES. 
2.1 Introduction. 
This chapter describes the synthesis of both symmetrical and non-symmetrical D ring 
derivatives of daunomycinone via the A + BCD approach, as outlined in the preceding chapter. 
Kelly et al.1 used this approach for the synthesis of (+/-)-daunomycinone Ц (Scheme 2.1). 
Some fundamental improvements to this approach will be described, which allow synthesis of 
(+/-)-daunomycinone and its analogs on a multigram scale. 
Scheme 2.1 
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Kelly's first approach to the daunomycinone type of compounds was suggested by two earlier 
published examples. 
Fariña et al.2 indicated that substituted naphthazarins exist primarily in the tautomeric form 12, 
12 
which is favored, but there is an equilibrium with tautomeric form 12a which can be trapped in a 
Diels-AIder reaction (Scheme 2.2). 
Scheme 2.2 
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Together with a method for the synthesis of polycyclic quiñones via Diels-AIder addition of 
l-methoxycyclohexa-l,3-diene to a quinone (Scheme 2.3, Ì and 3), followed by oxidation, this 
Diels-AIder reaction of the tautomerized product (Scheme 2.3, 14a + 15) and thermal 
elimination of the ethano bridge, afforded the concept for the synthesis of daunomycinone П 2 
from napthazarin3. In this way, the daunomycinone skeleton can be built up in four steps 
(Scheme 2.3). 
Scheme 2.3 
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Unfortunately, mainly the undesired regioisomer of the biologically active daunomycinone is 
formed and, therefore, Kelly and colleagues developed a method in which the regioselectivity 
was reversed. 
To achieve this reversal, two important concepts were applied: 
the reaction of juglone 18 with 1-methoxybutadiene 17 afforded a regioselective adduct 19 
(Scheme 2.4) because of the Η-bonding interaction, which makes the C-4 carbonyl group 
more electron-poor than the C-l carbonyl3. 
acetylation of the hydroxy group (Figure 2.1, 20) reverses the selectivity, although not 
completely". The electron-donating properties of the acyloxy-oxygen make the C-4 
carbonyl more electron-rich. 
Scheme 2.4 
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The combination of these effects, Η-bonding interaction of the free hydroxy group and 
acetylation of the other hydroxy group by an RCO group (as indicated in Figure 2.1, 21) gave 
complete regioselectivity in the cycloaddition of 2 (with 3) and 4a (with 5, Scheme 2.1). 
the second important concept for the synthesis of daunomycinone was "acyl-Wanderung". In 
order to use the protecting group for both cycloadditions with full regioselectivity, the RCO 
group must be transferred intramoleculary (Scheme 2.1, equilibrium between 4 and 4a). 
This principle of "acyl-Wanderung" had been observed earlier by Brockmann et al.5 and 
Alvarado et al.6. Kelly used it for the equilibrium between 4 and 4a. 
A key step in the Diels-Alder approach is the use of l-alkoxy-3-trimethylsilyloxy-l,3-butadienes 
or l,3-bis(trimethylsilyloxy)-l,3-butadiene (Scheme 2.1, 5). These dienes offer the possibility 
for functionalizing the A ring of the molecule at an early stage. The ketone group of 8 can easily 
be transferred into the necessary a-hydroxy.acetyl functionality at the 9 position of 
daunomycinone ÌI (Scheme 2.1). The free hydroxy group at the 7 position is obtained by 
hydrolysis of the alkoxy group of the diene. 
In trying to repeat the sequence as described by Kelly, we encountered three serious problems: 
we were not able to reproduce oxidation of the cycloadduct of dienophile 2 and diene 3 
(Scheme 2.1). Kelly and his group7 also reported problems with the use of KH/Pb02 and in 
isolating 4 (Scheme 2.1) in acceptable yields. The particle size of commercial KH seemed 
to be very important. The amount of KH was adjusted to 0.05 equivalent, which made the 
reaction much slower but suppressed cleavage of the protective group, which had become a 
major side reaction. We were not able to repeat this procedure and we always found 
cleavage of the protecting group. In addition, we tried a variety of other oxidation methods 
without success. 
another problem in this synthesis of daunomycin is the reaction with the Grignard reagent 
(steps 8 to 9, Scheme 2.1) in order to convert the ketone into a α-hydroxy, a-ethynyl 
functionality. Firstly, the necessary use of 30 equivalents of ethynyl magnesium bromide is 
very inefficient. Furthermore, we encountered serious problems with upscaling the reaction 
in this and similar examples. The yields were reasonable at the 100 mg scale but dropped 
dramatically when performing the reaction at a gram scale8. 
finally, the formation of both cis- and trans-7,9-dihydroxy compounds 9 is unsatisfactory as 
it necessitates subsequent difficult separation of diastereomers. 
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2.2 Synthesis of (+/-)-daunomycinone. 
We have developed a gram scale synthesis of (+/-)-daunomycinone via the Diels-Alder 
approach taking advantage of Kelly's method but circumventing the disadvantages, as shown in 
Scheme 2.5. 
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First, we tried other protecting groups for \ (Scheme 2.5) which would give the desired 
"acyl-wanderung". Only Kelly's 4-nitrobenzyloxycarbonyl group appeared to be successful. 
Other ester or carbamate groups could be attached to naphthazarin 1 but neither oxidation nor 
intramolecular shift was achieved. 
Finally we decided to change the order of the reaction steps and to protect the oxidized 
cycloadduct 14 (Scheme 2.5) instead of oxidizing the protected cycloadduct. Of the protective 
groups we tried (i.e., acetate, benzoate, benzyloxycarbonyl and mandelate), only the /?-nitro-
carbobenzoxy group was successful. Three possible products can be formed (14, 29 and 30). In 
order to find optimal selectivity for this reaction, we tried several bases, such as NaH, KO-f-Bu, 
Na2C03, DABCO and CaH2 and we made numerous attempts in varying the equivalents of base 
15 
and /7-nitrobenzyl chloroformate. This reaction appeared to be quite successful when 1 
equivalent of the protecting agent and 1.6 equivalents of calcium hydride were used. Only minor 
amounts of the undesired mono-protected 29 (Figure 2.2) and di-protected cycloadducts 30 
(Figure 2.2) were formed. Some unreacted naphthazarin was also recovered after column 
chromatography. 
Figure 2 2 
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Initially, the reaction was very slow (6 days at room temperature, conversion 30-40%), but 
acceleration was accomplished by the using a Direct Immersion Sonic Horn9 (Cell disrupter) 
and a glass rosette cell (Figure 2.3) and/or an ultrasonic cleaning bath. The reaction time 
decreased to 30 h and the conversion increased to 75-80%. The isolated yield after column 
chromatography was 50%. All the side products formed are easily reconverted into naphthazarin 
and can be used again. 
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The mono-protected ethanoanthracene derivative 4/4a underwent a Diels-Alder reaction with 
l-ferf-butoxy-3-trimethylsilyloxybuta-l,3-diene 22 to give the adduct 23 in a yield of 80% 
(Scheme 2.5). 
Diene 22 was synthesized according to the method of Potman etaLÏO or according to the method 
of Danishefsky etal.n (Scheme2.6). 
The advantages of using the fórf-butoxy diene 22 instead of the trimethylsilyloxy group (5, 
Scheme 2.1) are stability of the cycloadduct and high stereoselectivity for the subsequent 
introduction of the acetylene functionality. We found that, when the trimethylsilyloxy group is 
16 
deprotected in an early stage (conversion 6 to 7, Scheme 2.1), partial aromatization to compound 
38 cannot be avoided and purification of the reaction mixtures is almost impossible (as is also 
the case in Kelly's method). 
Danishefsky et al " 
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Introduction of the ethynyl functionality in compound 24 via the Grignard reaction in the desired 
manner trans to the tert-butoxy group occurs with a higher stereoselectivity than in compound 8 
trans to the hydroxy group12. However, partial aromatization to compound 38 cannot be avoided 
and purification of the reaction mixture is almost impossible (as is also the case in Kelly's 
method). 
A major breakthrough was the use of 2-trimethylsilylethynyllithium13. No more than 6 
equivalents were necessary and formation of 38 (Figure 2.4) is strongly suppressed. Clearly, the 
trimethylsilyl acetylide behaves more as a nucleophile and less as a base. We also found that no 
better results were obtained when using cerium acetylides as described for related reactions13. 
When using 2-trimethylsilylethynyllithium, only the cis-7-r-butoxy-9-hydroxy-isomer could be 
detected by • H - N M R spectroscopy. The fact that only the cis isomer is formed is due to the 
quasi-axial position8 of the tert-butoxy and the bulkiness of the 2-trimethylsilylethynyl group. 
Separation of the (+/-)-daunomycinone and its (+/-)-7-epimer is then no longer necessary. The 
reaction was performed at a 5-gram scale and the yields were comparable with the reaction at 
the 100 mg scale. Further upscaling should, therefore, be possible. 
The isolation of pure product 25 was very difficult because of the formation of some bis adduci, 
probably 39 (Figure 2.4), and spontaneous air oxidation to product 26. After oxidation with 
Pb(OAc)4 and retro-Diels-Alder reaction in o-xylene, we were able to obtain compounds 27 by 
crystallization from diethyl ether (yield 74%). 
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Transformation of the 2-trimetylsilylethynyl functionality (Scheme 2.5, 27 to 28) to the acetyl 
group has been done by simple treatment with mercury (Π) oxide in dilute sulfuric acid in 
tetrahydrofuran. Because of the higher reactivity of the 2-trimethylsilylethynyl functionality and 
better solubility of compound 27, compared to the unsubstituted ethynyl compound 10, the 
reaction is much faster (3 h and 1 night, respectively) and gives better yields (91% and 75%, 
respectively). 
After treatment with trifluoroacetic acid at room temperature, product 28 gives (+/-)-dauno-
mycinone 11 in an overall yield of 21%. The obtained (+/-)-daunomycinone after 
recrystallization from chloroform, exhibits spectral and physical properties identical to those 
reported previously (Scheme 2.5). 
2.3 Synthesis of (+/-)-4-demethoxydaunomycinone. 
The advantages of using l-terf-butoxy-3-trimethylsilyloxybuta-l,3-diene 22 and lithium 
trimetylsilylacetylide are generally applicable to the synthesis of anthracyclinones of the 
daunomycinone type. This is further illustrated in the synthesis of 4-demethoxydaunomycinone 
(Scheme 2.7). 
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The Diels-Alder reaction of naphthazarin 1 with cyclohexa-l,3-diene 40 was, as expected, much 
slower than in the former case with l-methoxycyclohexa-l,3-diene 3. Compounds 40 and i had 
to be refluxed for 5 days in tetrahydrofuran to yield 75% of 41. 
As regioselectivity does not have to be controlled, the second Diels-Alder reaction of 41a with 
the l-terf-butoxy-3-trimethylsilyloxybuta-l,3-diene 22 leads to the daunomycinone skeleton in 
two steps (Scheme 2.7). 
The ABCD fragment was functionalized by the use of 2-trimethylsilylethynylIithium to give 
product 43 with the desired high cis stereoselectivity of the Cg OH group and the C7 O-r-Bu 
group. After reaction with 2-trimefhylsilylethynyllithium the crude product (no purification) was 
oxidized with Pb(OAc)4 and subsequently purified by column chromatography to give 44 
(76%). A retro-Diels-Alder reaction in refluxing o-xylene afforded compound 45 in 91%. This 
compound could be easily converted into (+/-)-4-demethoxydaunomycinone 47 by hydration 
with mercury(II) oxide in dilute sulfuric acid/tetrahydrofuran and subsequent treatment with 
trifluoroacetic acid. The overall yield was 30%. 
2.4 Conclusions. 
A multigram synthesis for (+/-)-daunomycinone and (+/-)-4-demethoxydaunomycinone has been 
described. To accomplish this, in essence the method of Kelly et al. was used starting from 
naphthazarin by the A + BCD approach (Chapter 1, Figure 1.3) but, essential steps were 
modified. In order to circumvent the tedious oxidation step of using potassium hydride and 
lead(IV) oxide, first, the Diels-Alder adduci was formed. This adduct was easily oxidized by 
oxygen under basic conditions and could then be protected. The Grignard reaction with ethynyl 
magnesium bromide was also adapted. By using 2-trimethylsilylethynyllithium, the reaction was 
more efficient (only 6 equivalents of reagent was needed in stead of 30 equivalents of ethynyl 
magnesium bromide). Now it was possible to accomplish this reaction at a gram scale. 
Application of l-tert-butoxy-3-trimefhylsilyloxybuta-l,3-diene, instead of the 1,3-bis-trimethyl-
silyloxybuta-l,3-diene, together with the use of 2-trimethylsilylethynyllithium resulted in the 
exclusive formation of the desired cis-7-i-butoxy-9-hydroxy-isomer. 
(+/-)-Daunomycinone and (+/-)-4-demethoxydaunomycinone were isolated on a gram scale with 
an overall yield of 20% and 30%, respectively. In principle this method will also allow the 
synthesis of other symmetric or non-symmetric, D ring derivatives of daunomycinone. The 
scope of these reactions depends on the availability and the reactivity of the cyclohexadienes 
which are used. 
2.5 Experimental section. 
General remarks: 
^-NMR spectra were measured on a Braker WH-90 spectrometer using (CH3)4Si as internal 
standard. CDCI3 was used as solvent. Melting points were taken using a Reichert Thermpan 
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microscope and are uncorrected. IR spectra were obtained using a Perkin Elmer 298 infrared 
spectrometer. Mass spectra were taken using a double focussing VG 7070 E mass spectrometer. 
For column chromatography, either Merck Silicagel 60 or Merck Silicagel Art. 9385 (flash 
chromatography) were used. 
1,4,9,10-Tetrahydro-5,8-dihydroxy-l-methoxy-9,10-dioxo-l,4-ethanoanthracene (\4). 
To a solution of 20.9 g (0.11 mol) of 5,8-dihydroxy-l,4-naphthoquinone I in 330 ml of 
dichloromethane were added 28.4 g of l-methoxycyclohexa-l,3-diene 3 (technical grade 65%, 
0.177 mol). The mixture was refluxed for 6 h. In order to circumvent formation of by-products, 
the temperature of the oil-bath did not exceed 50°C. The solvent was evaporated and the residue 
stirred with 330 ml of pentane for 5 minutes. The solution was then cooled to 0°C and the 
yellow/brown solid (30.0 g, 91%) was collected by filtration, rinsed with petroleum ether 
(40/65) and directly used in the next reaction. 
The crude product was dissolved in a solution of 22.0 g (0.55 mol) of sodium hydroxide in 
825 ml of water. Air was passed through the solution and the color of the mixture changed from 
green to blue. After completion of the reaction, monitored by TLC (Eluent ethyl 
acetate/n-hexane, 2 : 5), 46.2 ml of concentrated HCl (37%) were added. The product 
precipitated as a red solid and it was filtered off and then dried in vacuo over P 2 0 5 to give 27.0 g 
of 14 (83% overall from 1). A sample of product 14 was re-crystallized in ethyl acetate/n-hexane 
to give yellow needles of 14; m.p. 169-17PC (dec., Lit.14 170°C, Lit.15 167-169°C). MS., m/e 
(EI) 298, 283, 270, 252, 240, 224; Ή-ΝΜΙΙ (CDCU, 90 MHz): δ = 1.39-1.92 ppm (4H, m, 
CH2-CH2), δ = 3.69 ppm (3H, s, OCH3), δ = 4.47-4.61 ppm (IH, m, H4), δ = 6.40 ppm (IH, dd, 
J=5.6 Hz and J=8 Hz), δ = 6.64 ppm (IH, dd, J=8 Hz and J=1.5 Hz), δ = 7.12 ppm (2H, s, ArH), 
δ = 12.60 ppm (IH, s, ArOH), δ = 13.06 ppm (IH, s, ArOH). Anal, caled, for C 1 7 H 1 4 0 5 : C, 
68.45; H, 4.73. Found: C, 68.01; H, 4.77. 
l,4,9,10-tetrahydro-8-hydroxy-l-methoxy-5-(4-nitrobenzyloxycarbonyloxy)-l-methoxy-9,10-
dioxo-l,4-ethanoanthracene (4). 
To 12.0 g (0.04 mol) of 14, dissolved in 300 ml of dry THF (distilled from sodium 
benzophenone ketyl) were added 12.6 g (0.062 mol) of /7-nitrobenzyl chloroformate and 1.7 g 
(0.04 mol) of powdered calcium hydride. The suspension was sonicated with a Direct 
Immersion Sonic Hom9 (Cell disrupter) in a glass rosette cell9 at 0°C for 6 hours in order to 
activate the calcium hydride. The mixture was then poured into a 500 ml round bottom-flask and 
sonicated for 24 h in an ultrasonic cleaning bath. The color of the solution changed from red to 
yellow and progress was monitored by TLC (ethyl acetate/n-hexane, 2 : 5 ) . After the reaction 
was almost complete, the reaction mixture was quenched by addition of 500 ml of an aqueous 
solution of 5% NaH2P04 and the mixture was then extracted twice with 500 ml of chloroform. 
The chloroform extract was washed with brine, dried over anhydrous sodium sulfate and 
evaporated in vacuo. The crude product was purified by flash column chromatography (silicagel, 
ethyl acetate/ toluene/n-hexane, 1 : 5 : 5). After concentration in vacuo, the solid residue was 
stirred overnight in 200 ml of diethyl ether. Filtration gave 9.6 g (50%) of pure 4. m.p. 
136-137°C (Lit.1 115-116°C, recrystallized from ethyl acetate/diethyl ether); MS, m/e (СГ) 478, 
450, 405, 299, 271;]H-NMR (90 MHz, CDC13) : δ = 1.33-1.89 ppm (4H, m, CH2-CH2), δ = 3.66 
ppm (3H, s, OCH3), δ = 4.30-4.47 ppm (IH, m, H4), δ = 5.44 ppm (2H, s, CH2), δ = 6.34 ppm (IH, dd, J=5.6 Hz and J=8 Hz, H3), δ = 6.61 ppm (IH, dd, J=8 Hz and J=1.5 Hz, H2), δ = 7.28 
ppm (2H, s, ArH), δ = 7.54 ppm (2H, AB, J=8.5 Hz, ArH), δ = 8.26 ppm (2H, AB, J=8.5 Hz, 
ArH), δ = 12.72 ppm (IH, s, ArOH). Anal, caled, for C 2 5 H 1 9 N0 9 : C, 62.89; H, 4.01; N, 2.93. 
Found: C, 62.41; H, 3.92; N, 2.95. IR (KBr): 1765 cm 1 . 
l-tert-Butoxy-3-trimethylsilyloxybuta-l,3-diene (22). 
Compound 22 was prepared as described by Potman et al.10 from 101 g of 1-fórf-butoxy-
l-buten-3-one. Yield 107.5 g (71%), b.p. 57-60°C/0.75 Torr (Lit10 50-53°C/0.25 Torr). 
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7-tert-Butoxy-l,4,6a,7,8,10a-hexahydro-5-hydroxy-4-methoxy-12-(4-nitrobenzyloxycarbonyl-
oxy)-6,9,11-0OH)-trioxo-1,4-ethanonaphthacene (21). 
To a solution of 7.5 g (0.016 mol) of 4 in 175 ml of dry (distilled from sodium 
benzophenone ketyl) THF under an argon atmosphere, 6.75 g (0.032 mol) of 1 -férr-butoxy-3-tri-
methylsilyloxybuta-l,3-diene 22 were added and the reaction mixture was stirred at room 
temperature for 2 days. The color of the solution changed from yellow/orange to yellow/green. 
The reaction was monitored using TLC (ethyl acetate/n-hexane, 2 : 5). Subsequently, the 
cycloadduct was hydrolysed by cooling the reaction mixture to 0°C and adding 7.5 ml of IN 
HCl. After 15 minutes, 175 ml of water were added and the mixture was extracted twice with 
125 ml of dichloromethane. The combined organic layers were washed with brine and dried 
over anhydrous sodium sulfate. Evaporation of the solvent yielded the crude product, which was 
then stirred overnight in 300 ml of diethyl ether. Filtration gave 7.8 g (80%) of product 23. m.p. 
147-150°C; MS, m/e (CI) no mol mass peak found, 440; ^-NMR (90 MHz, CDC13, mixture of 
isomers, ratio 7 : 3): δ = 0.74 ppm (9H, s, C(CH3)3), δ = 1.43-1.93 ppm (4H, m, CH2-CH2), δ = 
2.08-2.62 ppm (3H, m, Hi0(ax), H8(ax) and H8(eq)), δ = 3.23-3.70 ppm (3H, m, H6 a, H10(eq) and 
H,0 a), δ = 3.72 and 3.75 ppm (3H, 2 χ s, OCH3), δ = 4.11-4.26 ppm (IH, m, H7), δ = 4.43-4.56 
ppm (IH, brs, H,), δ = 5.42 ppm (2H, brs, CH2), δ = 6.26-6.80 ppm (2H, m, H-C=C-H), δ = 
7.56-8.33 ppm (4H, 2 χ AB, ArH), δ = 13.19 and 13.23 ppm (IH, 2 χ s, ArOH). Anal, caled, for 
C 3 3 H 3 3 NO n : С, 63.97; H, 5.37; Ν, 2.26. Found: С, 63.33; Η, 5.27; Ν, 2.26. IR (КВг): 1770 (carbonyl carbonate), 1720 (A ring carbonyl) and 1630 (quinone carbonyl). 
7-tert-Butoxy-l, 4,6a, 7,8,10a-hexahydro-5,12-dihydroxy-4-methoxy-l, 4-ethanonaphthacene-6,9, -
ll-(10H)-trione (Ш 
То a stirring solution of 5.0 g (0.008 mol) of 23 in 20 ml of THF, 20 ml of glacial acetic 
acid and 5.2 g (0.08 mol) of zinc were added. The zinc was first activated by the procedure 
described by Perrin et al.16. After 15 min another 5.2 g of zinc were added. Progress of the 
reaction was monitored by TLC (ethyl acetate/n-hexane, 3 : 5) until the reaction was complete 
(approx. 30 min). The mixture was then diluted with 250 ml of dichloromethane and the acetic 
acid was neutralized (to pH 6) with saturated NaHC03. The layers were separated and the 
aqueous layer was extracted twice with 150 ml of dichloromethane. The combined organic 
layers were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. 
The residue was stirred overnight in 500 ml of dry diethyl ether. After cooling the solution to 
0°C, solid 24 was filtered off (3.45 g, 97%). Analytically pure material was obtained as an 
off-white solid, m.p. 134-136°C by recrystallization from diisopropyl ether; MS, m/e (EI) 440, 
412, 356, 336, 320; 'H-NMR (90 MHz, CDC13, mixture of isomers, ratio 7 : 3): δ = 0.71 ppm (9H, s, C(CH3)3), δ = 1.38-1.89 ppm (4H, m, CH2-CH2), δ = 2.22-2.64 ppm (3H, m, H10(ax), 
H8(ax) and H8(eq)), δ = 3.33-3.75 ppm (3H, m, H6 a, H10(eq) and H ] 0 a ), δ = 3.71 and 3.75 ppm (3H, 2 χ s, OCH3), δ = 4.34-4.62 ppm (2H, m, Щ and H7), δ = 6.44 ppm (IH, dd, J=8 Hz and 
J=6.5 Hz, H-C=C), δ = 6.70 ppm (IH, dd, J=8 Hz and J=1.5 Hz, H-C=C), δ = 11.87 and 11.93 
ppm (IH, 2 χ s, ArOH), δ = 12.94 and 13.00 ppm (IH, 2 χ s, ArOH). Anal, caled, for С 2 5 Н 2 8 0 7 : 
С, 68.17; H, 6.41. Found: С, 67.91; H, 6.21. IR (КВг): 1720 (A ring carbonyl) and 1650 and 
1620 (quinone carbonyl). 
Cis-(+l-)-7-ten-butoxy-7^9,10-tetrahydro-4-methoxy-6,9,ll-trihydroxy-9-[trimethylsilylethy-
nyl]-5,12-naphthacenedione (27). 
5.7 g (0.058 mol) of 2-trimethylsilylacetylene (96%) were dissolved in 750 ml of dry THF 
(distilled from sodium benzophenone ketyl) under an argon atmosphere. The reaction mixture 
was then cooled to -78°C and 37.9 ml of BuLi in n-hexane (1.5 M) were added dropwise over 10 
min. The reaction mixture was stirred for 30 min at -78°C and then 5.0 g (0.0114 mol) of 24 
were added. Progress of the reaction was monitored by TLC (ethyl acetate/n-hexane 2: 5) and 
the color of the solution changed from green to yellow/green). After 2 h, the reaction mixture 
was allowed to warm up to room temperature and 250 ml of a 10% aqueous solution of NH4C1 
were then added. The mixture was stirred for 15 min. 500 ml of water was added, and aqueous 
layer was extracted twice with 500 ml of chloroform. The combined organic layer was washed 
with brine, dried over anhydrous sodium sulfate and then concentrated in vacuo. 
The residue was dissolved in 100 ml of glacial acetic acid and 5.5 g (0.012 mol) of lead 
tetraacetate were added. The mixture was stirred overnight at room temperature. The color of 
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the mixture changed from yellow/red to red. The reaction mixture was then poured into 400 ml 
of water, the red solid which precipitated was filtered off and then dissolved in chloroform. The 
organic layer was washed twice with a solution of saturated sodiumhydrogen carbonate, washed 
with water and brine, dried over NaS 20 4 and evaporated in vacuo. After column filtration (silicagel 60, 1:4, ethyl acetate/n-hexane) and evaporation of the solvent in vacuo, the solid 
residue was dissolved in 50 ml of o-xylene and refluxed for 3 h (temperature of the oil bath 
150°C). After evaporation of the solvent, the product was recrystallized from dry diethyl ether to 
give 4.2 g (74%) of orange crystals 27. m.p. 247-250°C; MS, m/e (EI) 508, 493, 452, 434, 416; 
Ή-NMR (90 MHz, CDCI3) : δ = 0,23 ppm (9H, s, Si(CH3)3), δ = 1.39 ppm (9H, s, C(CH3)3), δ 
= 1.99 ppm (IH, dd, J=15 Hz and J=3 Hz, H8(ax)), δ = 2.72 ppm (IH, d, J=15 Hz, H8(eq)), δ = 
2.98 ppm (IH, d, J=20 Hz, H10(ax)), δ = 3.64 ppm (IH, d, J=20 Hz, Hi0(eq)), δ = 4.05 ppm (3H, 
s, OCH3), δ = 5.30-5.40 ppm (IH, m, H7), δ = 5.92 ppm (IH, s, 8-OH), δ = 7.35 ppm (IH, dd, 
J=8.25 Hz and J=1.0 Hz, H3), δ = 7.74 ppm (IH, t, J =8 Hz and J=8.25 Hz, Hj), δ = 8.00 ppm (IH, dd, J=8 Hz and J=l Hz, H2), δ = 13.30 ppm (IH, s, ArOH), δ = 14.10 ppm (IH, s, ArOH). 
The compound was not obtained completely pure due to some elimination of the trimethylsilyl 
group. 
Cis-(+l-)-7-tert-butoxy-7,8,910-tetrahydro-9-acetyl-4-methoxy-6,9,ll-trihydroxy-5,12-naphtha-
cenedione (28). 
2.5 g (0.0049 mol) of 27 were dissolved in 120 ml of THF and 1.07 g (0.0049 mol) of HgO 
and 60 ml of 3M H 2 S0 4 were added. The mixture was stirred for 3 h at room temperature, 
poured into 250 ml of IN HCl and extracted three times with 250 ml of chloroform. After drying 
over anhydrous sodium sulfate and evaporation in vacuo, the solid was recrystallized from 
chloroform/ n-hexane to give 2.05 g (91%) of 28. m.p. 244-245°C (dec); ]H-NMR (90 MHz, 
CDC13): δ = 1.39 ppm (9H, s, C(CH3)3), δ = 1.91 ppm (IH, dd, J=14.5 Hz and J=3 Hz, H8(ax)), 
δ = 2.37 ppm (IH, brd, J=14.5 Hz, H8(eq)), δ = 2.42 ppm (3H, s, CH3), δ = 2.99 ppm (IH, d, 
J=19.2 Hz, H10(ax)), δ = 3.26 ppm (IH, d, J=19.2 Hz, H10(eq)), δ = 4.08 (3H, s, OCH3), δ = 
5.40-5.49 ppm (IH, m, H7), δ =5.99 ppm (IH, s, 8-OH), δ = 7.36 ppm (IH, dd, J=7.5 Hz and 
J=1.0 Hz, Нд), δ = 7.75 ppm (Ш, t, J =7.7 Hz and J=7.5 Hz, H,), δ = 8.00 ppm (IH, dd, J=7.7 
Hz and J=l Hz, H2)f δ = 13.32 ppm (IH, s, ArOH), δ = 14.09 ppm (IH, s, ArOH). 
(+/-)-daunomycinone (11). 
2.05 g (0.0045 mol) of 28 were dissolved in 40 ml of trifluoroacetic acid and stirred for 10 
min at room temperature. The reaction mixture was diluted with 100 ml of dichloromethane and 
extracted twice with 75 ml of water, dried over anhydrous sodium sulfate and concentrated in 
vacuo to give 1.75 g (95%) of (+/-)-daunomycinone U. m.p. 212-214°C (lit 212-213°C); 
Spectral data were in accordance with earlier published1. 
l,4,9,10-Tetrahydro-5,8-dihydroxy-9,10-dioxo-l,4-ethanoanthracene (A\). 
19.0 g (0.1 mol) of 5,8-dihydroxy-l,4-naphthoquinone i and 12.5 g (0.16 mol) of cyclo-
hexa-l,3-diene 40 were refluxed for 5 days in 190 ml of THF. After completion of the reaction, 
as was monitored by TLC (eluent; ethyl acetate/n-hexane, 2 : 5) and the color of the reaction 
mixture changed from red to yellow/brown, the solvent was removed in vacuo the residue was 
stirred in 200 ml of petroleum ether (40/65) for 1 h The solid was collected by filtration, rinsed 
with petroleum ether and used directly in the next reaction. 
The yellow solid was added to a solution of 20.0 g of sodium hydroxide in 750 ml of water. 
The reaction mixture was stirred while air was bubbled through the solution. The reaction was 
monitored by TLC (ethyl acetate/n-hexane, 2 : 5). After 1 h, 35 ml of cone. HCl (37%) were 
added, the red solid which precipitated was filtered off and dissolved in chloroform. The organic 
layer was washed with saturated NaHC03, water, brine, dried over anhydrous sodium sulfate 
and then evaporated to give 20.1 g (75%) of a red solid residue 41. m.p 203-204°C; MS, m/e 
(EI) 268, 240, 212,183;^H-NMR (90 MHz, CDC13): δ = 1.16-1.58 ppm (4H, m, CH2-CH2), δ = 
4.47-4.65 ppm (2H, m, Щ and H4), δ = 6.35 ppm (2H, dd, J=7.5 Hz and J=2.5 Hz, H-C=C-H), δ 
= 7.03 ppm (2H, s, ArH), δ = 12.48 ppm (2H, s, ArOH). Anal, caled, for Ci 6 H 1 2 0 4 : C, 71.64; H, 
4.51. Found: C, 71.15; H, 4.47. 
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7-tert-Butoxy-l,4,6a,7,8,10a-hexahydro-5,12-dihydroxy-l,4-ethanonaphthacene-6,9,ll-(10H)-
trione (42). 
To a solution of 19.4 g (0.072 mol) of 41/41a in 300 ml of dry toluene were added 23.2 g 
(0.108 mol) of l-te/í-butoxy-3-trimethylsiIyloxybuta-l,3-diene 22 at room temperature and the 
reaction was stirred under an argon atmosphere for 5 days. After completion of the reaction, 
monitored by TLC (eluent; ethyl acetate/n-hexane, 2 : 5), the solvent was concentrated in vacuo 
and the residue was dissolved in 190 ml of cold THF (0°C). 9.7 ml of IN HCl were added and 
the reaction mixture was stirred at 0°C for 15 min until TLC (ethyl acetate/n-hexane, 2 : 5) 
showed the reaction to be complete. 500 ml of water was added and the mixture was extracted 
twice with 500 ml of dichloromethane. The dichloromethane layers were combined, washed 
with brine, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was 
stirred overnight in dry diethyl ether (200 ml) and the yellow solid was filtered off. The filtrate 
was evaporated in vacuo and the remaining solid was purified by flash chromatography (ethyl 
acetate/n-hexane, 2 : 5) to give a total of 22.2 g (75%) of 42. m.p. 154-158°C; MS, m/e (EI) 410, 
382, 354, 326; *H-NMR (90 MHz, CDC13, mixture of isomers, ratio 1 : 1): δ = 0.68 and 0.71 
ppm (9H, 2 χ s, C(CH3)3), δ = 1.38-1.72 ppm (4H, m, CH2-CH2), δ = 2.23-2.62 ppm (3Η, m, 
Н10(ах) + H8(eq) + Н8(ах)), δ = 3.30-3.66 ppm (3H, m, H 1 0 a+ H 6 a + H10(eq)), δ = 4.38-4.50 ppm (IH, m, H7), δ = 4.53-4.69 ppm (2H, m, Щ + H4), δ = 6.48 ppm (IH, d, J=3.5 Hz, H-C=C), δ = 
6.51 ppm (IH, d, J=3.5 Hz, H-C=C), δ = 11.89 and 11.94 ppm (IH, 2 χ s, ArOH), δ = 12.34 and 
12.35 ppm (IH, 2 χ s, ArOH). Anal, caled, for C 2 4 H 2 6 0 6 : C, 70.23; H, 6.38. Found: С, 70.45; H, 
6.48. 
Cis-(+l-)-7-tert-butoxy-l,4,7,8,9,10-hexahydro-5,9,12-trihydroxy-9-[trimethylsilylethynyl]-
l,4-ethanonaphthacene-6,ll-dione (44). 
То a solution of 4.2 g (0.043 mol) of trimethylsilylacetylene in 450 ml of dry (distilled from 
sodium benzophenone ketyl) THF at -78°C under an argon atmosphere were added 26.2 ml of 
1.6 M n-BuLi in hexane (0.042 mol). After stirring the reaction mixture at -78°C for 30 min, 3.1 
g (0.0076 mol) of 42 were added. The reaction was monitored by TLC (ethyl acetate/n-hexane, 2 
: 5). After 3 h the reaction mixture was allowed to return to room temperature and 150 ml of 
10% aqueous solution of NH4C1 were added. The mixture was stirred at room temperature for 
15 min and 300 ml of water were added. The mixture was extracted twice with 300 ml of 
chloroform and the organic layers were combined, washed with brine, dried over anhydrous 
sodium sulfate and then concentrated in vacuo. The residue was dissolved in 60 ml of glacial 
acetic acid and 3.4 g (0.0077 mol) of lead tetraacetate were added to the solution. After stirring 
the reaction mixture overnight, 200 ml of water were added and the red solid which precipitated 
was dissolved in 300 ml of chloroform. The organic layer was washed successively with a 
saturated solution of NaHC03, water and brine and dried over anhydrous sodium sulfate. The 
solution was evaporated in vacuo and the residue was purified by column chromatography (ethyl 
acetate/n-hexane, 1 : 4) to give 2.9 g (76%) of red solid 44. m.p. 116-118°C; JH-NMR (90 MHz, 
CDCI3, Mixture of isomers): δ = 0.27 ppm (9H, s, Si(CH3)3), δ = 1.40 ppm (9H, s, C(CH3)3), δ = 
1.20-1.80 ppm (4H, m, CH2-CH2), δ = 1.94 ppm (IH, dd, J=14.5 Hz and J=3 Hz, H8(ax)), δ = 
2.67 ppm (IH, d, J=14.5 Hz, H8(eq)), δ = 3.04 ppm (IH, d, J=17.5 Hz, H10(ax)), δ = 3.55 ppm (IH, d, J=17.5 Hz, H10(eq)), δ = 4.63 ppm (2H, m, Щ + H4), δ = 5.27 ppm (IH, m, H7), δ = 5.72 
ppm (IH, s, OH), δ = 6.48 ppm (2H, dd, H-C=C-H), δ = 12.95 ppm (IH, s, ArOH), δ = 13.12 
ppm (IH, s, ArOH). The compound was not obtained completely pure due to some elimination 
or the trimethylsilyl group. It was used without further purification in the following step. 
Cis-(+l-)-7-tert-butoxy-7&9J0-tetrahydro4All-trihydroxy-94trimethylsilylethynyl)-5,12-
naphthacenedione (45). 
A solution of 2.9 g (0.006 mol) of 44 in 30 ml of o-xylene was refluxed for 5 h The solution 
was evaporated in vacuo and the solid residue was recrystallized in dry diethyl ether to give 2.5 
g (91%) of 45. m.p. 214-216°C; MS, m/e (EI) 478, 463, 422, 404, 389; 'H-NMR (90 MHz, 
CDC13): δ = 0.18 ppm (9H, s, Si(CH3)3), δ = 1.40 ppm (9H, s, C(CH3)3), δ = 1.99 ppm (IH, dd, 
J=14.5 Hz and J=3 Hz, H8(ax)), δ = 2.76 ppm (IH, d, J=14.5 Hz with long-range coupling, 
H8(eq)), δ = 3.02 ppm (IH, d, J=19.5 Hz, H10(ax)), δ = 3.67 ppm (IH, dd, J=19.5 Hz and J=1.5 
Hz, H10(eq», δ = 5.31-5.39 ppm (Ш, m, H7), δ = 5.87 ppm (IH, s, OH), δ = 7.72-7.87 ppm (2H, 
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m, ArH), δ = 8.25-8.39 ppm (2Η, m, ArH), δ = 13.33 ppm (IH, s, ArOH), δ = 13.67 ppm (IH, s, 
ArOH). Anal, caled, for C ^ H ^ S i : С, 67.76; H, 6.32. Found: С, 67.53; H, 6.28. 
Cis-(+l-)-7-tert-butoxy-7,8,9,10-tetrahydro-9-acetyl-6,9,ll-trihydroxy-5,12-naphthacenedione 
(Ш 
То a solution of 2.5 g (0.005 mol) of 45 in 110 ml of THF were added 1.2 g (0.005 mol) of 
HgO and 55 ml of 3M H 2S0 4. The reaction mixture was stirred for 24 h at room temperature, 
then poured into 270 ml of IN HCl and extracted three times with 200 ml of chloroform. After 
drying over anhydrous sodium sulfate and removal of the solvent in vacuo, the solid was 
purified by column chromatography (ethyl acetate/n-hexane, 2 : 5) to give 1.6 g (91%) of 46. 
m.p. 217-220°C; MS, m/e (EI) 424, 368, 350, 332, 307; •H-NMR (90 MHz, CDC13) : δ = 1.39 
ppm (9H, s, C(CH3),), δ = 1.88 ppm (IH, dd, J=14.5 Hz and J=3 Hz, H8(ax)), δ = 2.37 ppm (IH, 
d, J=14.5 Hz, H8(eq)), δ = 2.42 ppm (3H, s, CH3), δ = 3.04 ppm (IH, d, J_em=19 Hz, Нш(ах)), δ 
= 3.25 ppm (IH, d, J „
m
=
1 9 Η ζ
· H10(eq)), δ = 5.35-5.44 ppm (IH, m, H7f, δ = 5.94 ppm (IH, s, 
OH), δ = 7.71-7.84 ppm (2H, m, ArH), δ = 8.21-8.33 ppm (2H, m, ArH), δ = 13.26 ppm (IH, s, 
ArOH), δ = 13.61 ppm (IH, s, ArOH). Anal, caled, for C 2 4 H 2 4 0 7 : C, 67.92; H, 5.70. Found: С, 
68.19; H, 5.65. 
(+ /•) -4-demethoxydaunomycinone (ΑΊ). 
1.6 g (0.004 mol) of 46 were dissolved in 20 ml of trifluoroacetic acid. After 10 min, 50 ml 
of water were added and the water layer was then extracted twice with 75 ml of 
dichloromethane. The combined organic layers were washed with water and brine, then dried 
and evaporated in vacuo. Crude 47 was recrystallized from chloroform/diefhyl ether to give 1.2 
g (85%) of pure 4-demethoxydaunomycinone. m.p. 183-184°C (Lit.17 182.5-183°C); MS, m/e 
(EI) 368, 350, 332, 307, 290, 279; 'H-NMR (90 MHz, CDC13) : δ = 2.16 ppm (IH, dd, J=14 Hz 
and J=5 Hz, H8(ax)), δ = 2.36 ppm (IH, dt, J=14 Hz, J=2 Hz and J=2 Hz, H8(eq)), δ = 2.44 ppm (3H, s, CH3), δ = 2.91 ppm (IH, d, J=18.5 Hz, H10(ax)), δ = 3.23 ppm (IH, dd, J=18.5 Hz and 
J=2 Hz, H,0(eq)), δ = 3.80 ppm (IH, d, J=5.5 Hz, 7-OH), δ = 4.54 ppm (Ш, s, OH), δ = 5.30 
ppm (IH, brs, H7), δ = 7.76-7.88 ppm (2H, m, ArH), δ = 8.26-8.40 ppm (2H, m, ArH), δ = 13.25 
ppm (IH, s, ArOH), δ = 13.53 ppm (IH, s, ArOH). JH-NMR data are in full agreement with 
those described17. 
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CHAPTER 3 
ABC + D APPROACH TO DAUNOMYCINONE AND DERIVATIVES. 
3.1 Introduction. 
In the ABC + D approach to daunomycinone and its derivatives, as outlined in Chapter 1, the 
introduction of the D ring via a Diels-Alder reaction is the key step in the last part of the 
synthesis. Mixtures of regioisomers are always obtained when the method is used for the 
synthesis of unsymmetrically substituted D ring derivatives, as there is no control over 
regioselectivity in the Diels-Alder addition. Based on the method of Krohn et al.1, we have 
developed a practical gram-scale approach which allows the regioselective synthesis of 
daunomycin and some derivatives. 
3.2 Synthesis of the ABC fragment. 
Krohn and Tolkiehn1 have published a method in which naphthazarin I and l,3-bis-(trimethyl-
silyloxy)-buta-l,3-diene 2 were used for the synthesis of the ABC fragment 3 of daunomycinone 
(Scheme 3.1). 
Scheme 31 
ОН О ОН О ОН О 
он о osi(CH3)3 он о оа(сн3)3 он о он 
1 ? 3 4 
ι] ВгМдОСН 
и] Oj/OH" 
ш] Hg0/H2S04 
Raceme mixture of cis-7,9-0H,0H 6 R = OH, R = H 
After hydrolysis, treatment with 30 equiv. of ethynylmagnesium bromide, oxidation and 
hydration with mercury(II) oxide, the ABC fragment 5 was used in another Diels-Alder reaction 
with l-methoxybuta-l,3-diene 7 to give rise to 4-demethoxydaunomycinone 8 (Scheme 3.1). 
Separation of the ABC fragments 5 and 6 (Scheme 3.1* was very difficult and was only 
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accomplished after preparative thin-layer chromatography. The Diels-Alder reaction of 
l-methoxycyclohexa-l,3-diene, instead of 7, with 5, gave after oxidation and retro Diels-Alder 
reaction, a mixture of daunomycinone 9 and isodaunomycinone 10 in yields of 17% and 32%, 
respectively (Figure 3.1). 
Figure 3 1 
О ОН о CH30 О ОН о 
CH3O О ОН НО j ( R a c „,,„, 0 f c l s . 7 i 9 0H,OH) О ОН НО 10 ( Rae. mixt of cis-7,9-OH,OH) 
Repeating the reaction sequence of Scheme 3.1 in our laboratory showed more disadvantages 
than just the lack of regioselectivity already described by Potman2. 
One of these major disadvantages is aromatization of compound 4. The hydroxy group of 
compound 4 easily undergoes elimination and, when followed by enolisation and 
spontaneous air oxidation, the aromatic compound Ц is formed (Figure 3.2). 
Figure 3 2 
11 
Compounds 5 and 6 have very low solubilities, which makes it necessary to use large 
amount of solvent for the subsequent conversion step. 
The requirement for an excess of Grignard reagent (30 equivalents) limits the practical 
value of this synthetic approach and makes it unsuitable for multigram syntheses. 
Formation of both cis-(5)- and trans-(6)-l,3-di-hydroxy isomers (Scheme 3.1), after the 
Grignard reaction, made it necessary to separate those isomers after hydrolysis with HgO 
and H 2 S0 4 in order to isolate the desired (+/-)-demethoxydaunomycinone 8. 
Potman2 has employed the l-férf-butoxy-3-trimethylsilyloxybuta-l,3-diene 12 (Scheme 3.2) in 
order to reduce the aromatization of product 14 and to improve the solubility of the product 16. 
Scheme 3.2 
ОН О 
ОН О 
ОН О 
и] NH4CI/H20 
OH O O t-Bu 
15 
ОН О O-t Bu 
16 
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Instead of the bromomagnesium acetylide, he used ethynyllithium, which was needed only in 
five-fold excess. Due to the bulky ferr-butoxy group, the cis-1-fcrr-butoxy, 3-hydroxy-isomer 15 
was formed predominantly, while only a trace of the trans isomer of compound 15 was detected 
by NMR spectroscopy. We encountered some problems in the synthesis of the ABC fragment on 
a multigram scale. The decrease of yield with increasing scale of the reaction was mainly 
ascribed to increasing aromatization of 14, leading to Ц (Figure 3.2). For practical reasons the 
concentration of Li-C=C-H was increased for large scale reactions. This higher concentration of 
Li-C^C-H leads to higher amount of trimeric (or even polymeric) organolithium compounds, 
which do not give addition to the carbonyl group, but which can act as strong bases, causing 
aromatization. Using of for example, Li-CH(OCH3)=CH2, as acyl equivalent, we observed the 
same problems. 
We expect that the bulky trimefhylsilyl group of 2-trimethylsilylethynyllithium prevents 
formation of trimers and polymers from the organolithium compounds. By using this 
2-trimethylsilylethynyllithium, easily prepared from the commercially available 2-trimethyl-
silylacetylene and n-butyllithium, we were able to synthesize compound 17 on a 2.5 g scale 
(Scheme 3.3). 
Scheme 3.3 
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Although a low concentration of the 2-trimethylsilylethynyllithium (approximately 0.08 
mmol/ml) is still necessary to obtain reasonable yields, further upscaling of this reaction should 
be possible, at least in principle, because yields at the mg scale were the same as at gram scale. 
Another advantage of using the more bulky 2-trimethylsilylethynyllithium is the exclusive 
formation of the cis-l-tert-butoxy-3-hydroxy compound 17. No trans product was detected by 
^-NMR spectroscopy. 
In 1984 Suzuki and Terashima3 reported the use of 2-trimethylsilylethynylcerium(III) dichloride 
as an alternative for the bromomagnesiumacetylide. The cerium reagent was formed by the 
addition of dry CeCl3 to 2-trimethylsilylethynyllithium. The examples described all had no 
functionality at the 1 position (Scheme 3.4). We have also tried to use 2-trimethylsilylethynyl-
cerium(ni) dichloride in the reaction with triketone 14. However, no advantages for this cerium 
reagent were found. Yields were not improved and the experimental conditions were more 
complex (especially the preparation of the cerium reagent). 
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Scheme 3.4 
О ОН 
(CH3)3SCsC-CeCI, 
3.3 Synthesis of daunomycinone. 
The practical multigram scale approach to 17 opens attractive routes to the synthesis of 
'symmetrically' substituted D-ring derivatives but the lack of regioselective control must still be 
solved. 
As described earlier, Krohn and Tolkiehn1 isolated only 17% of daunomycinone 9, while 32% of 
isodaunomycinone 10 was formed (Figure 3.1). The regioselectivity of the cycloaddition used is 
not appropriate with regard to formation of the desired daunomycinone. Therefore, we tried to 
increase the regioselectivity of the cycloaddition by protecting of one of the aromatic hydroxy 
groups of compound 17. In Chapter 2, we described selective protection of the DCB fragment 
with p-nitrobenzyl chloroformate. This protected DCB fragment reacted regioselectively with 
l-/e/?-butoxy-3-trimethylsilyloxybuta-l,3-diene. Therefore, we tried to apply the same 
p-nitrocarbobenzoxy group for the protection of the ABC fragment 17 in order to increase the 
regioselectivity of the subsequent Diels-Alder reaction (Scheme 3.6). 
We expected that the bulky tert-butoxy group in 17 would shield the hydroxy group at the 8 
position. Indeed, reaction of 17 with 1.1 equivalent of p-nitrobenzyl chloroformate yielded one 
predominant product, namely regioisomer 20 (Scheme 3.6). 
Scheme 3.6 
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After column chromatography, 70% of 20 was isolated and only small amounts of the other 
mono protected compound (8 position) and of the diprotected compound (5 and 8 positions) 
were found, together with a small amount of unreacted 17. 
The Diels-Alder reaction of 20 with l-methoxycyclohexa-l,3-diene 2J. (Scheme 3.7) was rather 
slow. After stirring a solution of 17 and l-methoxycyclohexa-l,3-diene 2\ in chloroform at 
room temperature for 7 days no more than 50% of 20 was converted into the Diels-Alder 
adJucts : : ' : . ! (Scheme 3.7). 
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Ρ 
осн3 
21 
О О 
Ή 
гО 
N0, 
%¡ÍX^^=^SÍI,CH¿3
 DAreacdon 
ü L I JOH • 
Y о о 
у<гО-NO, 
О ОН Ο-t-Bu 
20 
Rae. mixt. of cis-1,3-OlBu,OH 
R.T. or 
65°Cor 
R.T./12 kBar 
= - S i ( C H 3 ) 3 
OH 
OCH, 
OH 
'OH 
O OH O-t-Bu 
Overall уюИ 21% i 5 
o-Xylene 
O-t-Bu 
X = H. Y = 
X = 
OCH, 24 
* = Rae. mlxt. of cls-7,9-OtBu,OH 25' 
At 65°C, the reaction was considerably accelerated (2 days, 95% conversion). High pressure (12 
kbar) also accelerated the Diels-Alder reaction (70%, 16 h, 25°C, chloroform). Regioselectivity 
was not complete since JH-NMR showed that two products were formed. The main product 
(>90%) was 22 with the methoxy group and the fert-butoxy group on the same side of the 
molecule. Oxidation of 22/23 with OH"/02, as described by Krohn and Tolkiehn
1
, was not 
possible. Thin-layer chromatography showed that fast deprotection occurred, but oxidation of 
the bond between the С and D rings was rapidly followed by aromatization of the A ring. With 
5% sodium carbonate, complete deprotection was achieved (although not so rapidly). Oxidation 
was very slow but aromatization did not occur. The reaction was monitored by thin-layer 
chromatography and the reaction was stopped after all deprotected 22/23 had disappeared. A 
mixture of 24/25 was obtained, which was separated into the two components by column 
chromatography. Due to the long exposure (24 h) to Na 2C0 3, deprotection of the ethynyl 
function had also occurred. 
The regioselectivity of the above reactions was determined by comparison of the 'H-NMR 
spectra of reaction mixture of 24/25 (Scheme 3.7) with the previously prepared compound 
(Chapter 2, 27). The position of the aromatic hydroxy groups is very characteristic. The largest 
shift difference between the two hydroxy protons is found when the methoxy group and the 
rert-butoxy group are on the same side of the molecule. 
Retro Diels-Alder reaction of 25 yielded 26 (Scheme 3.7), which was isolated pure after 
crystallization from diethyl ether (overall yield of 21% starting from 20). This product was 
further converted into daunomycinone in the same way as compound 27 (Chapter 2). 
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3.4 Conclusions 
In this chapter, the synthesis of daunomycinone according to the ABC + D approach has been 
worked out. By modifying essential steps in the method of Krohn and Kolkiehn1 the ABC 
fragment was synthesized on a gram scale. The use of l-fert-butoxy-3-trimethylsilyloxy-l,3-
butadiene (12) made the Diels-Alder adduct more soluble and, together with the use of 
2-trimethylsilylethynyllithium, this resulted in exclusive formation of the cis-1-fór/-
butoxy-3-hydroxy compound Í7. By regioselective protection of the hydroxy group of 17 at the 
5 position (Scheme 3.6) with a p-nitrocarbobenzoxy group, the regioselectivity in the subsequent 
Diels-Alder reaction was strongly increased, changing from 1:2 (compound 9 : 10, Figure 3.1) to 
9:1 (compound 24 : 25, Scheme 3.7). Although daunomycinone was synthesized in this way, the 
method described in Chapter 2 is preferred, as in this case no separation of regioisomers was 
necessary. This method is however, a good way to prepare D ring derivatives of daunomycine, 
as described in Chapter 6, in which the total synthesis of pyridine D ring derivatives of 
daunomycin by this method is described. 
3.5 Experimental section. 
General remarks: 
'H-NMR spectra were measured on a Bruker WH-90, a Bruker AM-100 or a Bruker AM-400 
spectrometer using Me4Si as internal standard. CDCI3 was used as solvent. Melting points were 
taken with a Reichert Thermpan microscope and are uncorrected. Mass spectra were taken using 
a double focusing VG 7070 E mass spectrometer. For column chromatography, either Merck 
Silicagel 60 or Merck silicagel Art. 9385 (flash chromatography) were used. 
/ -tert-Butoxy-3,4,4a, 9a -tetrahydro-5,8-dihydroxy-3,9,10(2H) -anthracenetrione (\A). 
To a solution of 9.0 g (0.047 mol) of 5,8-dihydroxy-l,4-naphthoquinone i in 175 ml of dry 
THF (distilled from sodium benzophenone ketyl) under an argon atmosphere, 14.2 g (0.066 mol) 
of l-terr-butoxy-3-trimethylsilyloxybuta-l,3-diene 2 were added. Progress of the reaction was 
monitored by TLC (ethyl acetate/n-hexane, 2:5). After 1 h, the reaction mixture was cooled to 
0°C and 5.75 ml of IN HCl were added. After 10 min, 125 ml of water were added and the 
reaction mixture was extracted twice with 225 ml of chloroform. The combined organic layers 
were then washed with 125 ml of water, 125 ml of brine and dried over anhydrous sodium 
sulfate. The solvent was evaporated in vacuo and the remaining solid was rinsed overnight with 
300 ml of diethyl ether. After cooling the solution to 0°C a light yellow solid was collected by 
filtration and washed with cold diethyl ether. The yield was 12.1 g (78%). m.p. 180°C. (Lit5 
180°C); 'H-NMR (90 MHz, CDC13) : δ = 0.75 ppm (9H, s, C(CH3)3), δ = 2.37 ppm (IH, dd, 
J=15.6 Hz and J=7.5 Hz, CH2), δ = 2.58 ppm (2H, d, J=2.5 Hz, CH2), δ = 3.33-3.73 ppm (3H, 
m), δ = 4.42-4.50 ppm (IH, m, Hj). δ = 7.25 ppm (IH, AB, J=8.5 Hz, ArH), δ = 7.31 ppm (IH, 
AB, J= 8.5 Hz, ArH), δ = 12.10 ppm (IH, s, ArOH), δ = 12.30 ppm (IH, s, ArOH). 
l-tert-Butoxy-l,2,3,4-tetrahydro-3,5,8-trihydroxy-3-(2-trimethylsilylethynyl)-9,10-anthracene-
dione (17). 
To a solution of 6.0 g (0.061 mol) of trimethylsilylacetylene in 740 ml of dry THF (distilled 
from sodium benzophenone ketyl) at -78°C under an argon atmosphere were added 24.1 ml of 
2.45M n-BuLi in n-hexane (0.060 mol). After stirring the reaction mixture at -78°C for 30 min 
4.0 g (0.012 mol) of 14 were added. The reaction was monitored with TLC (ethyl 
acetate/n-hexane, 2:5). After 3 h, the reaction mixture was allowed to return to room 
temperature and 150 ml of a 10% aqueous solution of NH4C1 were then added. The mixture was 
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stirred at room temperature for 15 min and then 300 ml of water were added. The mixture was 
extracted twice with 300 ml of chloroform and the organic layers were combined, washed with 
brine and evaporated in vacuo. The residue was dissolved in 100 ml of glacial acetic acid and 
5.3 g (0.012 mol) of lead tetraacetate were then added to the solution. After stirring the reaction 
mixture overnight, 200 ml of water were added and the red solid which precipitated was 
dissolved in 300 ml of chloroform. The organic layer was washed successively with a saturated 
solution of NaHC03, water and brine and dried over anhydrous sodium sulfate. The solution 
was evaporated in vacuo and rinsed overnight in 100 ml of dry diethyl ether to give 2.6 g (50%) 
of a red solid 17. m.p. 191-193°C; ]H-NMR (90 MHz, CDC13): δ = 0.18 ppm (9H, s, Si(CH3)3), 
δ = 1.33 ppm (9H, s, C(CH3)3), δ = 1.87 ppm (IH, dd, J=3.7 Hz and J=14.5 Hz, H2(ax)) ( δ = 
2.64 ppm (IH, d, J=14.5 Hz, H2(eq)), δ = 2.77 ppm (IH, d, J=20 Hz, H4(ax)), δ = 3.47 ppm (IH, 
d, J=20 Hz, H4(eq)), δ = 5.19 ppm (IH, m, Η,), δ = 5.57 ppm (IH, s, OH), δ = 7.18 ppm (2H, s, 
ArH), δ = 12.56 ppm (IH, s, ArOH), δ = 12.69 ppm (IH, s, ArOH). Anal, caled, for C 2 3 H 2 8 0 6 S i : 
C, 64.46; H, 6.59. Found: C, 64.94; H, 6.61. 
l-tert-Butoxy-l,2,3,4-tetrahydro-3,8-dihydroxy-5-(4-nitrobenzyloxycarbonyloxy)-3-(2-trimethyl-
silylethynyl)-9,10-dioxoanthracene (20). 
To a solution of 5.0 g (0.012 mol) of 17 and 3.0 g (0.014 mol) of 4-nitrobenzyloxycarbonyl-
chloride in 150 ml of dry THF (distilled from sodium benzophenone ketyl), 0.5 g (0.012 mol) of 
powdered sodium hydride were added. The suspension was sonicated with a Direct Immersion 
Sonic Hom4 (Cell disrupter) in a glass rosette cell4 at 0°C for 4 h and then the reaction mixture 
was poured into a 250 ml round-bottom flask and sonicated for 24 h in an ultrasonic cleaning 
bath at 60°C. The color of the solution changed from red to yellow and progress was monitored 
by TLC (ethyl acetate/ n-hexane, 2 : 5). After TLC indicated that the reaction was nearly 
complete, the reaction mixture was quenched by addition of 500 ml of 5% aqueous solution of 
NaH2P04 and the mixture was then extracted twice with 500 ml of chloroform. The chloroform 
extract was washed with brine, dried over anhydrous sodium sulfate and then evaporated in 
vacuo. The crude product was purified by column chromatography (ethyl acetate/n-hexane, 1 : 
4). The remaining solid residue after evaporation in vacuo was stirred overnight in 50 ml of 
diisopropyl ether. Filtration gave 5.0 g (71%) of pure 20. m.p. 164°C; 'H-NMR (400 MHz, 
CDC13, TMS as internal standard) : δ = 0.20 ppm (9H, s, Si(CH3)3), δ = 1.36 ppm (9H, s, 
С(СНз)3). δ = 1.90 ppm (IH, dd, J=3.75 Hz and J=14.5 Hz, H2(ax)), δ = 2.67 ppm (IH, d, 
J=14.5Hz, H2(eq)), δ = 2.77 ppm (IH, d, J=20 Hz, H4(ax)), δ = 3.47 ppm (IH, d, J=20 Hz, 
H4(eq)), δ = 5.21 ppm (IH, s, Щ), δ = 5.43 ppm (2H, s, CH2), δ = 5.54 ppm (IH, s, 3-OH), δ = 
7.33 ppm (2H, dd, H6+H7), δ = 7.69 ppm (2H, AB, J=8.6 Hz, ArH), δ = 8.29 ppm (2H, AB, J= 
8.6 Hz, ArH), δ = 12.47 ppm (IH, s, ArOH). Anal, caled, for C 3 1H 3 3NOi 0Si: C, 61.27; H, 5.47; 
N, 2.30. Found: C, 61.27; H, 5.54; N, 2.38. 
Cis-(+l-)-7-tert-butoxy-l,4,7,8,9,10-hexahydro-9-ethynyl-5,9,12-trihydroxy-l,4-ethanonaphtha-
cene-611-dione (25). 
1.5 g of l-Methoxy-l,3-cyclohexadiene 21 (0.014 mol, 3.3 equivalents) were added to a 
solution of 2.5 g (0.004 mol) of 20 in 75 ml of chloroform and stirred at 65°C for 35 hours. After 
evaporation in vacuo the residue was dissolved in 200 ml of THF and 400 ml 5% aqueous 
solution of Na 2C0 3 were added while air was bubbled through the solution. After TLC showed 
no more starting material (24 h), the reaction mixture was neutralized with acetic acid until its 
color turned red. The water layer was then extracted three times with 250 ml of chloroform. The 
combined organic layers were washed with 250 ml of a solution of saturated sodium hydrogen 
carbonate, with 250 ml of water and 250 ml of brine. After drying over anhydrous sodium 
sulfate and concentration under reduced pressure, the residue was purified by column 
chromatography to give 0.8 g (42%) of pure 25. m.p. 156-158°C (dec.); 'H-NMR (100 MHz): δ 
= 1.35 ppm (9H, s, C(CH3)3), δ = 1.20-1.98 ppm (5H, m, CH2-CH2 and H2(ax)), δ = 2.33 ppm (IH, s, OCH), δ = 2.69 ppm (IH, d, J=14.6 Hz, H9eq)), δ = 2.81 ppm (IH, d, J=20 Hz, H7ax)), 
δ = 3.47 ppm (Ш, d, J=20 Hz, H7(eq)), δ = 3.74 ppm (3H, s, OMe), δ = 4.55 ppm (IH, d, J=6 
Hz, H4), δ = 5.23 ppm (IH, s, H ] 0), 6 = 5.77 ppm (IH, s, 8-OH), δ = 6.45 ppm (IH, dd, J=8 Hz 
and J=6 Hz, H3), δ = 6.70 ppm (IH, d, J=8 Hz, H2), δ = 12.84 ppm (IH, s, ArOH), δ = 13.64 ppm (lH.s, ArOH). 
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Cis-(+l-)-10-tert-butoxy-7,8,9,10-tetrahydro-8-ethynyl-l-methoxy-5,8,12-trihydroxynaphtha-
cene-6,ll-dione (26). 
A solution of 0.8 g (0.0017 mol) of 25 in 100 ml of o-xylene was refluxed for 30 minutes. 
After evaporation in vacuo and tituration with diethyl ether, 0.45 g of orange solid was isolated 
which was recrystallized in ethyl acetate/n-hexane to give 0.38 g (51%) of 26. m.p. 260-262°C; 
]H-NMR (100 MHz): δ = 1.39 ppm (9H, s, С(СН3)з), δ = 2.03 ppm (IH, dd, J=14.5 Hz and 
J=2.5 Hz, H2(ax)), δ = 2.56 ppm (IH, s, C=CH), δ = 2.77 ppm (IH, d, J=14.5 Hz, H9(eq)), δ = 
2.96 ppm (IH, d, J=19.7 Hz, H7(ax)), δ = 3.65 ppm (IH, d, J=19.7 Hz, H7(eq)), δ = 4.07 ppm (3H, s, OMe), δ = 4.55 ppm (IH, d, J=6 Hz, H4), δ = 5.37 ppm (IH, brs, H1 0), δ = 6.03 ppm (IH, 
s, 8-OH), δ = 7.35 ppm (IH, d, J=8 Hz, H3), δ = 7.74 ppm (IH, dd, J=8 Hz and J=7 Hz, H3), δ = 
7.99 ppm (IH, d, J=7 Hz, H2), δ = 13.28 ppm (IH, s, ArOH), δ = 14.08 ppm (IH, s, ArOH). 
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CHAPTER 4 
HIGH DIASTEREOMERIC INDUCTION IN D I E L S - A L D E R R E A C T I O N S O F 
QUIÑONES WITH CHIRAL 1 - O X Y - 3 - T R I M E T H Y L S I L Y L O X Y B U T A - 1 . 3 - D I E N E S 
HAVING SUBSTITUENTS WITH π OR ρ E L E C T R O N S I N A P P R O P R I A T E 
POSITIONS. 
4.1 Introduction. 
In several syntheses of daunomycinone and D ring substituted a n a l o g s , a s d e s c r i b e d in this 
thesis and elsewhere1'4, the Diels-Alder reaction of a quinone p r e c u r s o r w i t h l-a lkoxy-3-tr i-
methylsilyloxybuta-l,3-diene is a key step (Scheme 4.1). 
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In our laboratory, diastereoselective control of this reaction has b e e n s t u d i e d e a r l i e r b y P o t m a n 4 
with dienes (4) having chiral auxiliary groups R, such as men thy l o r b o r n y l . A m a x i m u m 
diastereomeric excess (d.e.) of 30% was established in the cycloaddi t ion of 4 (R = b o m y l ) wi th 
naphthazarin (2). Stoodley and colleagues5 and Brasca and P e n c o 6 s t u d i e d 2 ,3 ,4 ,6 - t e t r a -O-
acetyl-ß-D-glucopyranoside 4a and amino protected-a-D-daunosamine 4 b , r e spec t i ve ly , as 
chiral alkoxy groups in the cycloaddition reaction with the h i g h l y r e a c t i v e d i enoph i l e 
quinizarine quinone epoxide Ц . In our hands, diene 4a appeared t o b e n o t su f f ic ient ly r e a c t i v e 
to give satisfactory conversions with less reactive quiñones such as n a p h t h a z a r i n 2 1 · 7 · 8 and 
l,4,9,10-tetrahydro-5,8,-dihydroxy-9)10-dioxo-l,4- ethanoanthracene 3 u s e d in o u r 3 (Chap te r 2) 
and other approaches2. Therefore, we have studied in a sys temat ic w a y t h e d i a s t e r e o m e r i c 
induction of a series of more electron-rich substituted l - o x y - 3 - t r i m e t h y l s i l y l o x y b u t a - l , 3 - d i e n e s 
(4) in the cycloaddition reaction with quiñones. 
3 4 
4.2 D i e l s - A l d e r react ion of l-alkoxv-3-trimethylsilyloxy-1.3-butadienes with several 
d i e n o p h i l e s . 
W e f i rs t i n v e s t i g a t e d dienes having secondary alkoxy groups, in the cycloaddition with 
n a p h t h a z a r i n (2) a n d j u g l o n e (1_) (Scheme 4.1). The dienes were synthesized according to the 
m e t h o d of D a n i s h e f s k y et al.9 from racemic alcohols ROH (Scheme 4.2). 
Scheme 4.2 
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T h e f o r m e d c y c l o a d d u c t s (5-7) were hydrolysed to the corresponding ketones (8-10). The d.e.10 
v a l u e w a s d e t e r m i n e d b y ' H - N M R spectroscopy11 and HPLC analysis of both the crude reaction 
m i x t u r e a n d t h e i so la ted cycloadducts. The highest d.e. (30%), when R5 is an aliphatic group, 
w a s m e a s u r e d f o r e n t r y 3 (9e. Table 4.1). There is an obvious but low steric effect of the size of 
t h e R 5 g r o u p o n t h e diastereomeric induction. 
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reactions w e r e e a r n e d out using racemic dienes 4 In THF (0 1 molar solutions with the dienes in 50% excess) The cycloadditren was 
complete after 1 6 - 2 0 h at room temperature The yields are isolated yields after precipitation in THF/n hexane 
diastereomeric excess (d e ) in % determined by 'H-NMR spectroscopy The de of the reaction mixture determined using HPLC 
for the cycloaddinons of 2 showed the same ratios as found using 1H NMR 
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However, the chiral dienes 4 with R4 = alkyl and R5 = phenyl (entries 5-7) gave unexpectedly 
high d.e. values (Table 4.1). The highest induction (70%) was found for the cycloaddition of 
naphthazarin (2) with l-[l-phenylethoxy]-3-trimethylsilyloxybuta-l,3-diene (entry 5). This is 
clearly higher than would be expected on the basis of steric differences between R4 and R5. This 
effect was also observed for other alkoxy groups with R5 having π electrons or non-bonded 
electron pairs close to the chiral center, such as 2-methoxyisopropoxy (entry 8) and 
1-vinylethoxy (entry 9). Increasing the size of the R4 group for R5 = phenyl (entries 5 -7) lowers 
the d.e. Increasing the distance of the chiral center to the mefhoxy or phenyl substituent in R5 
leads to a large decrease in the d.e. (e.g., entries 10 and 11). 
The effect of the electron density of the phenyl group in R5 on the d.e. is presented in Table 4.2. 
Juglone (1), naphthoquinone (14) and benzoquinone (15) were studied in addition to 
naphthazarin (2). For juglone and benzoquinone, as shown in Table 4.2, we found that d.e. 
decreases with decreasing electron density of the phenyl ring in the chiral group. For 
naphthazarin, this decrease was also noted, but the values for the para-methyl- and 
para-chloro-substituted phenyl analogs were not as expected. The d.e. of the reaction with 
naphthoquinone showed no good correlation with the decreasing electron density of the phenyl 
ring. In every case however, lowest induction was found with diene 4g having the strongest 
electron-withdrawing CF3 substituent (entry 5). The largest d.e. was found in the reaction of 
benzoquinone (15) with l-[l-(p-methoxyphenyl)-ethoxy]-3-trimethylsilyloxybuta-l,3-diene 
(entry 12). 
4.3 Diels-Alder reaction of chiral l-(l-phenvlethoxv)-3-trimethylsilYloxv-1.3-butadienes with 
benzoquinone. 
In the reaction of benzoquinone (15) with l-[l-(p-methoxyphenyl)-ethoxy]-3-trimethylsilyloxy-
buta-l,3-diene (4n), only one isomer was detected using ^-NMR spectroscopy. Because the 
optically active l-(p-methoxyphenyl)-ethanol was not available, we used S-(-)- and 
R-(+)-l-phenylethanol to determine the absolute configuration of the Diels-Alder adduci with 
benzoquinone 15. The d.e. found for this reaction was 90% and we were able to isolate the pure 
diastereomer after several crystallization steps. 
Table 4 2 
Diels-Alder reaction of dienes 4 with dienophiles 1, 2,14 and 15 
об · Г"' -£• ofcf 
FVfR5 R4-H5 
H H 
1,2, 14and15 4flandrw 8,9,16and17 
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Table 4 2 continued 
Entry 
12 
13 
5 
14 
15 
16 
Diene 
4 n 
4o 
4fl 
4j> 
4 g 
4r 
«4 
Me 
Me 
Me 
Me 
Me 
Et 
R 5 
p-MeO-Ph 
p-Me-Ph 
Ph 
p-CI-Ph 
p-CF3-Ph 
p-CF 3 Ph 
OH 0 
rYYY 
kAJLJ 
он о 0 
9 R < + R * 
^ Η 
d e * * 
92 
64 
70 
84 
57 
56 
yield 
54 
50 
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55 
51 
78 
О 
fú 
LjL· 
ОН О 
8 
d e " 
68 
67 
66 
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• v -^N Í - 0 
О 
R H - R 5 
Η 
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55 
79 
44 
53 
78 
О 
fa kJkf. 
0 
16 
d e " 
77 
84 
90 
90 
64 
S ^ - N ^ O 
О 
Η 
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60 
50 
53 
19 
49 
-
О 
Í Y Y 
Υ Υ 
Μ I 
О о 
17 R < + R s 
— H 
d e * * 
99 
97 
90 
60 
63 
-
yield 
49 
60 
53 
52 
55 
-
reactions were earned out using racemlc (tenes 4 in THF (0 1 molar solutions with the diene in 50% excess) The cycloaddition was 
complete after 16-20 h at room temperature The yields are isolated yields after precipitation in THF/n hexane 
diastereomerlc excess (d e ) in % determined by Ή NMR spectroscopy The d e of the reaction mixture determined using HPLC for 
the cydoaddrtions of 4g and n o with 2 showed the same ratios as found using Ή NMR 
Low isolated yield due to problems with precipitation and small quantities, conversion (TLC) almost complete 
X-ray analysis (Figure 4.1) of the cycloadduct of benzoquinone 15 and S-(-)-diene 4g showed 
that the formed chiral center also has the S configuration at the position at which the chiral 
alkoxy group is attached. 
Figure 4 1 
Breitmaier et al. who independent from us have studied cycloadditions of quiñones with 
l-(l-phenylethoxy)-2-methyl-buta-l,3-dienes, explained the found diastereoselectivity using a π 
stacking model, which had previously been used by Trost et al.13 for related cycloadditions of 
butadienyl-O-methyl mandelates (Figure 4.2). In this model, overlap of the orbitals of the phenyl 
ring would lead to two equilibrating complexes in which the phenyl ring is in a nearly parallel 
plane above or below the plane of the diene. 
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Figure 4.2 
The large (L) and small (S) substituents make conformation В (Figure 4.2) sterically more 
favored12. Diastereoselectivity is obtained by preferred approach of the dienophile to the 
unshielded diene side. From models, it can be easily seen that in the case of l-[l-phenyl-
ethoxy]-3-trimethylsilyloxybuta-l,3-diene, the diene plane forms a wide angle with the plane of 
the phenyl ring so that π-π interactions will be weak. 
For cycloadditions of o-quinodimethanes also having the 1-phenylethoxy group as chiral 
auxiliary (Scheme 4.3), Charlton et al.u showed that π stacking could not explain the found 
diastereoselectivity. He suggested that the preferred conformation for the diene is as in 19 
(Scheme 4.3). The approach of the dienophile to 19 is determined by the difference in steric 
bulkiness of the methyl group and the R group. 
Scheme 4.3 
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In a more recent paper. Tucker et al.15 retreated from the π stacking model because of a 
molecular mechanics study of the Diels-Alder reactions of chiral 1,3-butadienyl-O-methyl-
mandelate. Their results support an earlier statement of Siegel and Thornton16 based on 
experimental results indicating that the orientation of the phenyl ring is perpendicular to the 
diene plane. In the most favored perpendicular conformation, the methoxy group is proposed to 
be preferentially eclipsed with the carbonyl oxygen15 (Figure 4.3). 
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Figure 4.3 
Dtenophile 
Most favored 
perpendicular 
conformation υ •· I * ' 0 M e 
Siegel and Thornton16 also showed that the chiral cyclohexyl analog of 1,3-butadienyl-O-methyl 
mandelate, which is not capable of π stacking, had almost equal facial selectivity and the same 
direction of enantioselectivity. 
In agreement with the published results discussed above, two models may explain our results. 
Analogous to the model of Charlton et al.14 (Scheme 4.3), the diene adopts in the transition state 
(TS), a conformation as in Figure 4.4. The diene is most easily approached from the (less 
hindered) rear side of the molecule (with the methyl substituent) as shown in Figure 4.4. 
Figure 4.4 
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The higher induction for R = phenyl over R = /-butyl can be ascribed to a larger effective size of 
the phenyl substituent due to specific and stronger solvation by the used solvent toluene14. 
However, we found practically the same induction for cycloadditions of diene 4g in the solvents 
cyclohexane, THF and benzene, which makes this model unlikely. Furthermore, higher 
induction is expected in the donor solvent THF for dienes having electron-withdrawing phenyl 
substituents, whereas we found the opposite effect. 
The second model, the perpendicular TS model analogous to that proposed by Siegel and 
Thornton16 for cycloadditions of 1,3-butadienyl-O-methylmandelates (Figure 4.3), can help to 
explain all of our results. This model is presented in Figure 4.5. 
Figure 4.5 
Dienophile 
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In the sterically favored perpendicular conformation, the quinone will approach the diene in the 
Diels-Alder reaction from a side opposite to the aryl group, for steric reasons, and also to avoid 
electrostatic repulsion between the electron-rich phenyl ring and one of the oxygen atoms of the 
quinone. For that reason, induction is affected by substituents on the phenyl ring, leading to 
higher d.e. in the case of donating substituents (Table 4.2) 
Other substituents close to the chiral center having π electrons or non-bonding electron pairs (in 
the appropriate position) can cause the same electrostatic effects (Table 4.1, entries 8-11). 
Finally, induction will decrease when the methyl group at the chiral center is replaced by a 
larger alkyl group due to decreasing steric difference between both sides of the molecule (Table 
4.1, entries 5-7). 
4.4 Attempted synthesis towards chiral (+)-daunomvcinone. 
In order to apply chiral dienes in the synthesis of (+)-daunomycinone, preliminary studies were 
carried out to synthesize the optically active Diels-Alder adducts (+)- and (-)-9g . They were 
prepared from dienes (+)- and (-)-4g having either (+)- or (-)-phenylethoxy groups (Scheme 4.4) 
and they were converted into the (+) and (-) form of 22 in the same way as described above for 
diene 4 (R = t-Bu, Chapter 3, Scheme 3.3). 
It appeared that, after deprotection of 22, chirality was almost lost. This is most probably due to 
the strong acidic conditions necessary for removal of the protecting group. Indeed, when chiral 
(+)-daunomycinone was treated with trifluoroacetic acid for 15 minutes at room temperature, 
chirality was diminished by about 50%. It has been reported that anthracyclines undergo 
epimerization at the 7 position of the A ring in the presence of trifluoroacetic acid17. This result 
suggests that for the synthesis of chiral compound 23, it will be better to apply the chiral diene 
4n with R4= Me and R5= p-MeOC6H4. In this case, higher induction can be expected, and the 
chiral group can also be removed under milder acidic conditions. 
он о 
24 23* 22' 
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4.5 Conclusions. 
An essential step in the total synthesis of daunomycin and its derivatives is the introduction of 2 
chiral centers at the 7 and 9 positions of the daunomycinone. After coupling with the chiral 
sugar daunosamine, in most cases it is possible to separate the 7S.9S and 7R.9R diastereomers 
(Chapters 5 and 6), but the biologically active isomer (7S.9S) can only be isolated in no more 
than 50% yield. Therefore, introduction of chirality at an early stage of the total synthesis is 
preferred for successful synthesis of new derivatives. In this chapter, we have shown that it is 
possible to obtain a reasonable to high diastereomeric excess in the Diels-Alder reactions of 
quiñones, such as naphthazarin, juglone, naphthaquinone and benzoquinone using chiral 
l-alkoxy-3-trimethylsilyloxybuta-l,3-dienes. The highest diastereomeric excess was obtained 
using l-[l-(p-methoxyphenyI)-ethoxy]-3-trimethylsilyloxybuta-l,3-diene in the reaction with 
benzoquinone. Only one isomer was detected using 'H-NMR spectroscopy. We tried to use both 
(+)- and (-)-l-[l-phenyl-ethoxy]-3-trimethylsilyloxybuta-l,3-dienes in the Diels-Alder reaction 
with napthazarin in order to synthesize chiral anthracyclines. After introduction of the 
1-trimethylsilylethynyl group (9g to 21, Scheme 4.4), the desired 1S,3S or 1R,3R isomers were 
obtained. However, we have not yet been able to obtain the desired optically active 
daunomycinone (24). as shown in Scheme 4.4, due to epimerization upon removal of the chiral 
alkoxy group under (the necessary strong) acidic conditions. 
4.6 Experimental section. 
General remarks: 
^-NMR-spectra were measured either on a Bruker WH-90 spectrometer or an Bruker AM-400 
spectrometer using Me4Si as internal standard. CDC13 was used as solvent unless otherwise 
stated. Melting points were taken using a Reichert Thermpan microscope and are uncorrected. 
Mass spectra were taken using a double focusing VG 7070 E mass spectrometer. For column 
chromatography, either Merck Silicagel 60 or Merck silicagel Art. 9385 (flash chromatography) 
were used. Dry tetrahydrofuran was distilled from sodium benzophenone ketyl. 
Synthesis of 1-alkoxy-1-buteen-3-ones 13 (general procedure). 
The alcohols (200 mmol) were dissolved in 250 ml of dry toluene and 300-400 mmol of 
l-methoxy-l-buteen-3-one (12) were added. A catalytic amount of /?-toluenesulfonic acid or 
sodium methoxide was added, depending on the type of alcohol used. The reaction mixture was 
refluxed for 1-3 hours, (acid-catalysed) or 10-17 hours (base-catalysed). The formed methanol 
was captured with 4A molecular sieves in Dean-Stark equipment After the reaction was 
completed, Et3N was added (acid-catalysed reaction) and the mixture was evaporated in vacuo. 
The residue was distilled in vacuo and yielded the l-alkoxy-buten-3-ones 13 e j \ Yields, boiling 
points and 'H-NMR shifts are given below for entries 1 -16 (Scheme 4.2 and Table 4.1/4.2): 
entry 1: 13c, Yield; 86 %; b.p.: 59-61°C at 3 mm Hg; 'H-NMR (60 MHz, CDC13): δ=7.3 ppm, 
IH, d, Hj; 0=5.5 ppm, IH, d, H2; δ=2.5 ppm, IH, s, CH; 0=2.1 ppm, 3H, s, COCH,; δ=1.1 ppm, 
3H, d, CH3; δ=0.9 ppm, 2H, m, CH2; 6=0.8 ppm, 3H, t, CH3. 
entry 2: 13d. Yield 78%; b.p.: 80-82°C at 3 mm Hg; JH-NMR (60 MHz, CDC13): 0=7.3 ppm, 
IH, d, Щ; δ=5.5 ppm, IH, d, Η,; δ=3.2 ppm, IH, m, CH; 6=2.1 ppm, 3H, s, COCH3; 6=1.6 ppm, 
IH, m, CH; 6=1.1 ppm, 3H, d, CH3; 6=0.8 ppm, 6H, d, CH3. 
entry 3: 13e, Yield 91%; b.p.: 79-82°C at 1 mm Hg; !H-NMR (60 MHz, CDC13): 6=7.3 ppm, 
IH, d, Hj; 6=5.4 ppm, IH, d, H2; 6=2.2 ppm, IH, m, CH; 6=2.1 ppm, 3H, s, COCH3; 6=1.1 ppm, 
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3H, d, СН3; δ=0.7 ppm, 9H, d, CÍCHjU. 
entry 4: Ùf, Yield 62%; b.p.: 109-110°C at 0.4 mm Hg; JH-NMR (60 MHz, CDCI3): δ=7.5 
ppm, IH, d, J=l l Hz, H^ δ=5.6 ppm, IH, d, J=l l Hz, H2; 6=3.8 ppm, IH, m, CH; 6=2.27 ppm, 
ЗН, s, СОСН3; 6=1.25 ppm, 3H, d, J=6 Hz, CH3; 6=1.0-2.5 ppm, 11H, m, C 6 H n . 
entry 5: 13g, Yield 84%; b.p.: 95-99°C at 0.2 mm Hg; ^-NMR (90 MHz, CDCI3): 6=7.7 ppm, 
IH, d, J=12.4 Hz, Hj; 6=7.2 ppm, 5H, s, C6H5; 6=5.5 ppm, IH, d, J=12.4 Hz, H2; 6=4.7 ppm, 
IH, q, J=6.4 Hz, CH; 6=2.1 ppm, 3H, s, COCH3; 6=1.6 ppm, 3H, d, J=6.4 Hz, CH3. 
entry 6: 13h, Yield 80%; b.p.: 108-111°C at 0.3 mm Hg; JH-NMR (60 MHz, CDCI3): 6=7.3 
ppm, IH, d, Hf, 6=7.1 ppm, 5H, s, C6Hs; 6=5.5 ppm, IH, d, H2; 6=4.7 ppm, IH, t, CH; 6=2.0 
ppm, 3H, s, COCH3; 6=1.9 ppm, 2H, m, CH2; 6=0.9 ppm, 3H, d, CH3. 
entry 7: 13i, Yield 75%; b.p.: 105-107°C at 0.3 mm Hg; ^-NMR (60 MHz, CDC13): 6=7.2 
ppm, IH, d, Щ; 6=7.1 ppm, 5H, s, C6H5; 6=5.5 ppm, IH, d, H2; 6=4.3 ppm, 2H, m, 2 χ CH; 
6=2.0 ppm, 3H, s, COCH3; 6=0.9 ppm, 6H, d, CH3. 
entry 8: 13j, Yield 94%; b.p.: 80-82°C at 2 mm Hg; ^-NMR (60 MHz, CDC13): 6=7.4 ppm, 
IH, d, H,; 6=5.6 ppm, IH, d, H2; 6=4.1 ppm, IH, m, CH; 6=3.4 ppm, 2H, d, OCH2; 6=3.3 ppm, 
3H, s, OCH3; 6=2.2 ppm, 3H, s, COCH3; 6=1.3 ppm, 3H, d, CH3. 
entry 9: 13k, Yield 78%; b.p.: 70-78°C at 3 mm Hg; ^-NMR (60 MHz, CDC13): 6=7.4 ppm, 
IH, d, Щ; 6=5.6 ppm, IH, d, H2; 6=5.5-5.3 ppm, 3H, m, HC=CH2; 6=3.3 ppm, 3H, s, COCHy, 
6=1.3 ppm, 3H, d, CH3. 
entry 10: 13J, Yield 52%; b.p.: 86-93°C at 0.25 mm Hg; Ή-NMR (90 MHz, CDC13): 6=7.5 
ppm, IH, d, J=12.5 Hz, H^ 6=5.6 ppm, IH, d, J=12.5 Hz, H2; 6=4.3 ppm, IH, m, HCO; 6=3.6 
ppm, 2H, t, J=6 Hz, CH2; 6=3.37 ppm, 3H, s, OCH3; 6=2.2 ppm, 3H, s, COCH3; 6=1.80 ppm, 
2H, m, CH2; 6=1.33 ppm, 3H, d, CH·,. 
entry 11: 13m, Yield 88%; b.p.: 99-101°C at 0.2 mm Hg; ^-NMR (60 MHz, CDC13): 6=7.4 
ppm, IH, d, Hj; 6=7.1 ppm, 5H, s, ArH; 6=5.5 ppm, IH, d, H2; 6=3.9 ppm, 2H, d, CH2; 6=3.1 
ppm, IH, m, CH; 6=3.1 ppm, 3H, s, COCH3; 6=1.3 ppm, 3H, d, CH3. 
entry 12:13n, Yield 84%; b.p.: 139-142°C at 0.35 mm Hg; ]H-NMR (90 MHz, CDC13): 6=7.52 
ppm, IH, d, J=13 Hz, Щ; 6=7.27 ppm, 2H, dd, J=8.5 Hz, ArH; 6=6.78 ppm, 2H, dd, J=8.5 Hz, 
ArH; 6=5.63 ppm, IH, d, J=13 Hz, H2; 6=5.05 ppm, IH, q, J=6.3 Hz, CH; 6=3.78 ppm, 3H, s, 
OCH3; 6=2.07 ppm, 3H, s, COCH3; 6=1.57 ppm, 3H, d, J=6.3 Hz, CH3. 
entry 13:13o, Yield 80%; b.p.: 122-128°C at 0.55 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.48 
ppm, IH, d, J=12.4 Hz, Щ; 6=7.17 ppm, 4H, s, ArH; 6=5.62 ppm, IH, d, J=12.4 Hz, H2; 6=4.70 
ppm, IH, q, J=6.3 Hz, CH; 6=2.33 ppm, 3H, s, CH3; 6=2.07 ppm, 3H, s, COCH3; 6=1.57 ppm, 
3H, d, J=6.3 Hz, CH3. 
entry 14: Щ , Yield 38%; b.p.: 110-120°C at 0.2 mm Hg; *H-NMR (90 MHz, CDC13): 6=7.63 
ppm, IH, d, J=12.4 Hz, Щ; 6=7.27 ppm, 4H, m, ArH; 6=5.57 ppm, IH, d, J=12.4 Hz, H2; 
6=5.03 ppm, IH, q, J=6.3 Hz, CH; 6=2.08 ppm, 3H, s, COCH3; 6=1.52 ppm, 3H, d, J=6.3 Hz, 
CH 
entry 15: 13g, Yield 79%; b.p.: 123-127°C at 0.2 mm Hg; 'H-NMR (90 MHz, CDC13): 
6=7.28-7.50 ppm, 5H, m, Hj + ArH; 6=5.60 ppm, IH, d, J=13 Hz, H2; 6=5.15 ppm, IH, q, J=6.3 
Hz, CH; 6=2.12 ppm, 3H, s, COCH3; 6=1.63 ppm, 3H, d, J=6.3 Hz, CH3. 
entry 16:13r, Yield 97%; b.p.: 131°C at 0.2 mm Hg; *H-NMR (90 MHz, CDC13): 6=7.50 ppm, 
IH, d, J=13 Hz, Hj; 6=7.49 ppm, 4H, dd, J=8 Hz, ArH; 6=5.58 ppm, IH, d, J=13 Hz, H2; 6=4.88 
ppm, IH, t, J=7 Hz, CH; 6=2.08 ppm, 3H, s, COCH3; 6=1.82, 2H, m, CH2; 6=0.93 ppm, 3H, t, 
3=7 Hz, CH3. 
Synthesis ofl-alkoxy-3-trimethylsilyloxy-l,3-butadienes 4 (general procedure). 
The buten-3-ones 13 (67.4 mmol) were dissolved in 60 ml of dry acetonitrile. Triethylamine 
(21.2 g, 209 mmol) and trimethylsilylchloride (10.5 g, 96.6 mmol) were added and the reaction 
mixture was stirred at room temperature for one hour. The solvent was evaporated in vacuo and 
the residue was then dissolved in n-pentane. After filtration, the precipitate was washed with 
n-pentane and the combined organic layers were then evaporated in vacuo. The light brown 
residue was distilled under reduced pressure to give the l-alkoxy-3-trimethyIsilyloxybuta-
-1,3-dienes (4). Yields, boiling points and 'H-NMR shifts are given for entries 1-16 (Scheme 4.2 
and Table 4.1/4.2) are given below: 
entry 1: 4c, Yield; 83%; b.p.: 59-60°C at 1 mm Hg; 'H-NMR (60 MHz, CDC13): 6=6.6 ppm, 
IH, d, Щ; 6=5.4 ppm, IH, d, H2; 6=3.9 ppm, 2H, s, H4; 6=2.5 ppm, IH, s, CH; 6=1.1 ppm, 3H, 
d, CH3; 6=0.9 ppm, 2H, m, CH2; 6=0.8 ppm, 3H, t, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
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entry 2: 4d, Yield 88%; b.p.: 65-70°C at 1.5 mm Hg; 'H-NMR (60 MHz, CDC13): 6=6.5 ppm, 
IH, d, Hj; 6=5.4 ppm, IH, d, H2; 6=3.9 ppm, 2H, s, H4; 6=2.1 ppm, IH, m, CH; 6=1.6 ppm, IH, 
m, CH; 6=1.1 ppm, 3H, d, CH3; 6=0.9 ppm, 6H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 3: 4e, Yield 74%; b.p.: 80-82°C at 1 mm Hg; 'H-NMR (60 MHz, CDC13): 6=6.5 ppm, IH, 
d, H]! 6=5.3 ppm, IH, d, H2; 6=4.0 ppm, 2H, s, H4; 6=2.2 ppm, IH, m, CH; 6=1.1 ppm, 3H, s, 
COCH3; 6=0.7 ppm, 9H, d, C(CH3)3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 4: 4f, Yield 52%; b.p.: 97-Í0PC at 0.6 mm Hg; 'H-NMR (60 MHz, CDC13): 6=7.47 ppm, 
IH, d, J=13 Hz, H,; 6=5.57 ppm, IH, d, J=13 Hz, H,; 6=4.0 ppm, 2H, s, H4; 6=2.1 ppm, IH, m, 
CH; 6=1.22 ppm, 3H, d, J=6 Hz, CH3; 6=0.9-2.0"ppm, 11H, d, C6Hn; 6=0.2 ppm, 9H, s, 
OSi(CH3)3. 
entry 5: 4g, Yield 81%; b.p.: 115-120°C at 0.1 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.17 
ppm, 5H, s, ArH; 6=6.53 ppm, IH, d, J=12.4 Hz, H^ 6=5.39 ppm, IH, d, J=12.4 Hz, H2; 6=4.80 
ppm, IH, q, J=6.3 Hz, CH; 6=3.96 ppm, 2H, s, H4; 6=1.60 ppm, 3H, d, CH3; 6=0.2 ppm, 9H, s, 
OSi(CH3)3. 
entry 6: 4h, Yield 80%; b.p.: 119-121°C at 0.1 mm Hg; 'H-NMR (60 MHz, CDC13): 6=7.0 
ppm, 5H, s, ArH; 6=6.4 ppm, IH, d, Щ; 6=5.2 ppm, IH, d, H2; 6=4.5 ppm, IH, t, CH; 6=3.8 
ppm, 2H, s, H4; 6=1.8 ppm, 2H, m, CH2; 6=0.8 ppm, 3H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 7: 4i, Yield 72%; b.p.: 110-115°C at 0.1 mm Hg; 'H-NMR (60 MHz, CDC13): 6=7.0 ppm, 
5H, s, ArH; 6=6.4 ppm, IH, d, Щ; 6=5.2 ppm, IH, d, H2; 6=4.5 ppm, IH, t, CH; 6=3.8 ppm, 2H, 
s, H4; 6=1.9 ppm, IH, m, CH; 6=1.0 ppm, 6H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 8: 4j, Yield 94%; b.p.: 81°C at 1 mm Hg; 'H-NMR (60 MHz, CDCL): 6=6.6 ppm, IH, d, 
H,; 6=5.3 ppm, IH. d, H2; 6=4.0 ppm, 2H, bs, H4; 6=3.4 ppm, 2H, d, OCH2; 6=3.3 ppm, 3H, s, 
OCH3; 6=2.2 ppm, IH, m, CH; 6=1.3 ppm, 3H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 9: 4k, Yield 87%; b.p.: 55-56°C at 0.3 mm Hg; 'H-NMR (60 MHz, CDC13): 6=6.5 ppm, 
IH, d, Щ; 6=5.2 ppm, IH, d, H2; 6=5.0-4.5 ppm, 3H, m, HC=CH2; 6=4.0 ppm, 2H, bs, H4; 
6=1.3 ppm, 3H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 10: 41, Yield 44%; b.p.: 92°C at 0.2 mm Hg; 'H-NMR (90 MHz, CDC13): 6=6.6 ppm, IH, 
d, J=12.5 Hz. Hp 6=5.33 ppm, IH, d, J=12.5 Hz, H2; 6=4.10-3.73 ppm, 2H, s, H4 and Ш, q, J=6 
Hz, HCO; 6=3.42 ppm, 2H, t, J=6 Hz, CH2; 6=3.27 ppm, 3H, s, OCH3; 6=1.73 ppm, 2H, m, 
CH2; 6=1.18 ppm, 3H, d, CH3; 6=0.22 ppm, 9H, s, OSi(CH3)3. 
entry 11: 4m, Yield 76%; b.p.: 111°C at 0.1 mm Hg; 'H-NMR (60 MHz, CDC13): 6=7.1 ppm, 
5H, s, ArH; 6=6.6 ppm, IH, d, Hj; 6=5.2 ppm, IH, d, H2; 6=4.0 ppm, 2H, s, H4; 6=3.9 ppm, 2H, 
d, CH2; 6=2.1 ppm, IH, s, CH; 6=1.3 ppm, 3H, d, CH3; 6=0.2 ppm, 9H, s, OSi(CH3)3. 
entry 12: 4n, Yield 71%; b.p.: 145°C at 0.35 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.23 ppm, 
2H, d, J=8.4 Hz, ArH; 6=6.84 ppm, 2H, d, J=8.4 Hz, ArH; 6=6.67 ppm, IH, d, J=12.4 Hz, Щ; 
6=5.43 ppm, IH, d, J=12.4 Hz, H2; 6=4.82 ppm, IH, q, J=6.3 Hz, CH; 6=4.03 ppm, 2H, s, H4, 
6=3.75 ppm, 3H, s, OCH3; 6=1.50 ppm, 3H, d, J=6.3 Hz, CH3; 6=0.17 ppm, 9H, s, OSi(CH3)3. 
entry 13: 4o, Yield 76%; b.p.: 120-130°C at 0.1 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.13 
ppm, 4H, s, ArH; 6=6.61 ppm, IH, d, J=12.4 Hz, Hj; 6=5.39 ppm, IH, d, J=12.4 Hz, H2; 6=4.80 
ppm, IH, q, J=6.3 Hz, CH; 6=4.00 ppm, 2H, s, H4; 6=2.32 ppm, 3H, s, CH3; 6=1.53 ppm, 3H, d, 
J=6.3 Hz, CH3; 6=0.17 ppm, 9H, s, OSi(CH3)3. 
entry 14: 4rj, Yield 34%; b.p.: 127°C at 0.5 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.24 ppm, 
4H, m, ArH; 6=6.60 ppm, IH, d, J=12 Hz, Hj; 6=5.42 ppm, IH, d, J=12 Hz, H2; 6=4.83 ppm, 
IH, q, J=6.3 Hz, CH; 6=4.05 ppm, 2H, s, H4; 6=1.53 ppm, 3H, d, J=6.3 Hz, CH3; 6=0.17 ppm, 
9H, s, OSi(CH3)3. 
entry 15: 4g, Yield 80%; b.p.: 123-127°C at 0.5 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.53 
ppm, 4H, dd, J=4 and J=8 Hz, ArH; 6=6.67 ppm, IH, s, H^ 6=5.46 ppm, IH, d, J=13 Hz, H2; 
6=4.82 ppm, IH, q, J=6.3 Hz, CH; 6=3.93 ppm, 2H, s, H4; 6=1.39 ppm, 3H, d, J=6.3 Hz, CH3; 
6=0.17 ppm, 9H, s, OSHCHj);,. 
entry 16: 4r, Yield 75%; b.p.: 125°C at 0.65 mm Hg; 'H-NMR (90 MHz, CDC13): 6=7.57 ppm, 
4H, d, J=8 Hz, ArH; 6=6.67 ppm, IH, d, J=13 Hz, H^ 6=5.43 ppm, IH, d, J=13 Hz, H2; 6=4.70 
ppm, IH, t, J=7 Hz, CH; 6=4.08 ppm, 2H, s, H4; 6=1.83, 2H, m, CH2; 6=0.93 ppm, 3H, t, 3=7 
Hz, CH3; 6=0.17 ppm, 9H, s, OSifcH^. 
Reaction ofdienes 4 with naphthazarin \,juglone 2, naphthoquinone 12 and benzoquinone 14 
(General procedure). 
Under an argon atmosphere diene 4 (6.4 mmol; 1.5 equiv.) was added to a solution of 
dienophiles (1, 2, 14 and 15,4.2 mmol) in 40 ml of dry THF. The reaction mixture was stirred at 
room temperature for 16-20 h. Progress of the reaction was followed by TLC (ethyl 
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acetate/n-hexane, 3 : 5). To convert the primary cycloadduct into the more stable ketones (9, 8, 
16 and 17), the cycloadduct was hydrolysed at 0°C by the addition of 2 ml of IN hydrogen 
chloride. After stirring at 0°C for 15 minutes the reaction was quenched by the addition of 50 ml 
of water. The water layer was extracted twice with 50 ml of chloroform and the combined 
organic layers were then dried over anhydrous sodium sulfate. After evaporation in vacuo, the 
residue was dissolved in a small amount of THF (usually 5 ml) and the solution was then added 
to a vigorously stirred solution of n-hexane (75 ml, ratio THF : n-hexane ~ 1 : 15). The 
precipitated cycloadducts (9, 8, 15 and 16) were filtered off and washed with n-hexane. Isolated 
yields of the cycloadducts were 50% - 60%. Melting points, ^-NMR shifts and mass spectra 
are given for entries 1-16 (Scheme 4.1 and Table 4.1/4.2) below. 
entry 1: 8c, Yield 72%; 'H-NMR (90 MHz, CDC13): 6=12.4 ppm, Ш, s, ArOH; 6=8.0 ppm, 2H, 
m, ArH; 6=7.2 ppm, IH, m, ArH; 6=4.6 ppm, IH, m, CH; 6=3.9 ppm, 3H, m; 6=3.6 ppm, 1 H, 
m; 6=2.7-3.1 ppm, 3H, m; 6=0.3-1.4 ppm, 8H, m, contains 1.45H, d, J=6.3 Hz, CH3 and 1.55H, 
d,J=6.3Hz,CH3. 
entry 2: 8d. Yield 74%; *H-NMR (90 MHz, CDC13): 6=12.5 ppm, IH, s, ArOH; 6=7.8 ppm, 
2H, m, ArH; 6=7.2 ppm, IH, m, ArH; 6=4.5 ppm, IH, m, CH; 6=3.7 ppm, 3H, m; 6=3.0-3.2 
ppm, IH, m; 6=2.3-2.8 ppm, 3H, m; 6=1.5-1.0 ppm, IH, m; 6=0.9 ppm, 1.41H, d, J=6.3 Hz, 
CH3; 6=0.2-0.6 ppm, contains: 1.59 H, d, J=6.3 Hz, CH3 and 3H, m, CH3. 
entry 3: 8e, Yield 78%; JH-NMR (90 MHz, CDC13): 6=12.5 ppm, IH, s, ArOH; 6=7.2-7.8 ppm, 
3H, m, ArH; 6=4.5 ppm, IH, m CH; 6=3.6 ppm, 3H, m; 6=2.4-3.1 ppm, 4H, m; 6=0.9 ppm, 
1.27H, d, J=6.3 Hz, CH3; 6=0.6 ppm, 1.73H, d, J=6.3 Hz, CH3; 6=0.5 ppm, 9H, ds, C(CH3)3. 
entry 4: 8f, Yield 45%; *H-NMR (90 MHz, CDC13): 6=12.5 ppm, IH, s, ArOH; 6=7.2-7.8 ppm, 
3H, m, ArH; 6=4.5 ppm, IH, m, CH; 6=3.7 ppm, 3H, m; 6=3.0-3.2 ppm, IH, m; 6=2.3-2.8 ppm, 
3H, m; 6 = 1.0-2.2 ppm, 11H, C 6 H n ; 6=0.9 ppm, 1.37H, d, J=6.3 Hz, CH3; 6=0.5 ppm, 1.63H, 
d,J=6.3Hz,CH3. 
entry 5: 8g, Yield 79%; m.p. 140°C (dec.); m/e: 364 (M+), 244, 184, 105; 'H-NMR (400 MHz, 
CDC13): 6=12.22 ppm, 0.83H, s, ArOH; 6=11.97 ppm, 0.17H, s, ArOH; 6=7.61 ppm, 2H, m, 
ArH; 6=7.21 ppm, 6H, m, ArH; 6=4.31 ppm, IH, m, HCO; 6=3.90 ppm, IH, q, J=6.3 Hz, HCO; 
6=3.50 ppm, 3H, m; 6=2.43 ppm, IH, dd; 6=2.32 ppm, 2H, dd; 6=1.01 ppm, 0.51H, d, J=6.3 Hz, 
CH3; 6=0.66 ppm, 2.49H, d, J=6.3 Hz, CH3. 
entry 6: 8h, Yield 76%; JH-NMR (90 MHz, CDC13): 6=12.5 ppm, 0.80H, s, ArOH; 6=12.2 
ppm, 0.20H, s, ArOH; 6=7.9 ppm, 2H, m, ArH; 6=7.4 ppm, 5H, m, ArH; 6=7.1 ppm, IH, m, 
ArH; 6=4.5 ppm, IH, m, HCO; 6=3.4-3.9 ppm, 4H, m; 6=2.3-2.6 ppm, 3H, m; 6=1.0-1.4 ppm, 
2H, m, CH2; 6=0.6 ppm, 0.6H, t, J=7.2 Hz, CH3; 6=0.4 ppm, 2.4H, t, J=7.2 Hz, CH3. 
entry 7: 8i, Yield 86%; ^-NMR (90 MHz, CDClj): 6=12.5 ppm, 0.75H, s, ArOH; 6=12.3 ppm, 
0.25H, s, ArOH; 6=7.9 ppm, 1.5H, m, ArH; 6=7.4 ppm, 5H, m, ArH; 6=7.1 ppm, 1.5H, m, ArH; 
6=4.6 ppm, IH, m; 6=3.5-3.9 ppm, 4H, m; 6=2.2-2.7 ppm, 3H, m; 6=1.4 ppm, IH, m; 6=0.2-0.5 
ppm, 9H, m, contains: 6H, d, J=6.2 Hz, 2 χ CH3; 
entry 8: «Ц, Yield 77%; !H-NMR (90 MHz, CDC13): 6=12.7 ppm, IH, s, ArOH; 6=8.0 ppm, 2H, 
m, ArH; 6=7.7 ppm, IH, m, ArH; 6=4.9 ppm, 0.35H, m HCO; 6=4.8 ppm, 0.65H, m, HCO; 
6=3.8 ppm, 3H, s, OCH3; 6=3.6 ppm, 2H, bd, CH,; 6=2.7-4.3 ppm, 6H, m; 6=1.1 ppm, 1.05H, d, 
J= 6.3 Hz, CH3; 6=0.7 ppm, 1.95H, d, J= 6.3 Hz. CH3. 
entry 9: 8k, Yield 76%; !H-NMR (90 MHz, CDC13): 6=12.51 ppm, 0.73H, s, ArOH; 6=12.40 
ppm, 0.27H, s, ArOH; 6=7.3-7.9 ppm, 3H, m, ArH; 6=5.4-5.9 ppm, IH, m, C=CH; 6=4.8-5.2 
ppm, 2H, m, C=CH2; 6=4.4 ppm, IH, m, HCO; 6=3.5-3.8 ppm, 3H, m; 6=2.3-2.7 ppm, 3H, m; 
6=0.8 ppm, 0.81H, d, J=6.3 Hz, CH,; 6=0.5 ppm, 2.19H, d, J=6.3 Hz, CH3. 
entry 10: 81, Yield 63%; m.p. 95°C; ^-NMR (400 MHz, CDC13): 6=12.44 ppm, 0.5H, s, 
ArOH; 6=12.40 ppm, 0.5H, s, ArOH; 6=7.92 ppm, 2H, m, ArH; 6=7.53 ppm, IH, m, ArH; 
6=4.33 ppm, IH, m, HCO; 6=3.75 ppm, IH, m; 6=3.64 ppm, 3H, s, OCH,; 6=3.33-3.50 ppm, 
2H, t, J=5 Hz, OCH2; 6=2.58-3.28 ppm, 3H, m; 6=1.29-1.65 ppm, 2H, d, J =6.3 Hz and t, J=5 Hz, 
CH2; 6=1.19 ppm, 1.50H, d, J=6.3 Hz, CH3; 6=0.89 ppm, 1.50H, d, J=6.3 Hz, CH3. 
entry 11: 8m, Yield 88%; 'H-NMR (90 MHz, CDC13): 6=12.4 ppm, 0.53H, s, ArOH; 6=12.2 
ppm, 0.47H, s, ArOH; 6=7.9 ppm, 2H, m, ArH; 6=7.3 ppm, 5H, m, ArH; 6=7.0 ppm, IH, m, 
ArH; 6=4.4 ppm, IH, m, 2HCO; 6=2.8-3.8 ppm, 4H, m; 6=2.5 ppm, 2H, d, J=2.5 Hz, CH2; 
6=2.3-2.6 ppm, 3H, m; 6=0.9 ppm, 1.59H, d, J=6.8 Hz, CH3; 6=0.7 ppm, 1.41H, d, J=6.3 Hz, 
CH3. 
entry 12: 8n, Yield 40%; m.p. 141°C; m/e: 394 (M+), 243, 226, 197, 151, 135; !H-NMR (400 
MHz, CDC13): 6=12.22 ppm, 0.84H, s, ArOH; 6=12.00 ppm. 0.16H, s, ArOH; 6=7.63 ppm, IH, 
ABC, ArH; 6=7.28 ppm, IH, AB, ArH; 6=6.88-7.03 ppm, 4H, m, ArH; 6=4.29 ppm, IH, m. 
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HCO; 6=3.86 ppm, IH, q, J=6.3 Hz, HCO; δ=3.76 ppm, 3H, s, OCH,; 6=3.38-3.67 ppm, 3H, m; 
6=2.45 ppm, IH, dd, J=6.3 Hz; 6=2.33 ppm, 2H, d, J=2.5 Hz; 6=0.99 ppm, 0.48H, d, J=6.3 Hz, 
CH3; 6=0.66 ppm, 2.52H, d, J=6.3 Hz, CH3. 
entry 13: go, Yield 55%; m.p. 140°C (dec.); m/e: 378 (M+), 243, 212, 197, 119; ]H-NMR (400 
MHz, CDCI3): 6=12.25 ppm, 0.84H, s, ArOH; 6=12.03 ppm, 0.16H, s, АгОН; 6=7.63 ppm, 2Н, 
dd, AB, АгН; 6=7.28 ppm, 2H, dd, AB, J=5 Hz, ArH; 6=6.81-7.14 ppm, 3H, dd, J=7.5Hz, ArH; 
6=4.32 ppm, IH, m, HCO; 6=3.87 ppm, IH, q, J=6.3 Hz, HCO; 6=3.40-3.64 ppm, 3H m; 6=2.42 
ppm, IH, dd, J=7.5 Hz; 6=2.19-2.34 ppm, 5H, m; 6=0.95 ppm, 0.49H, d, J=6.3 Hz, CH3; 6=0.65 
ppm, 2.5IH, d, J=6.3 Hz, CH3. 
entry 14: 8p., Yield 44%; m.p. 112-115°C; JH-NMR (400 MHz, CDC13): 6=12.20 ppm, 0.81H, 
s, ArOH; 6=11.98 ppm, 0.19H, s, ArOH; 6=7.57-7.70 ppm, 3H, m, ArH; 6=7.21-7.27 ppm, 4H, 
m, ArH; 6=4.34 ppm, IH, m, HCO; 6=3.95 ppm, IH, q, J=6.3 Hz, HCO; 6=3.49-3.63 ppm, 3H, 
m; 6=2.38 ppm, 3H, m; 6=0.98 ppm, 0.57H, d, J=6.3 Hz, CH3; 6=0.67 ppm, 2.43H, d, J=6.3 Hz, 
CH3. 
entry 15: 8g, Yield 53%; m.p. 114°C; m/e: 432 (M+), 259, 244, 215, 173; *H-NMR (400 MHz, 
CDC13): 6=12.21 ppm, 0.73H, s, ArOH; 6=11.98 ppm, 0.27H, s, ArOH; 6=7.67 ppm, 2H, m, 
ArH; 6=7.53 ppm, 2H, dd, J=8 Hz, ArH; 6=7.28 ppm, IH, m, ArH; 6=7.08 ppm, 2H, dd, J=8 Hz, 
ArH; 6=4.39 ppm, IH, m, HCO; 6=4.11 ppm, IH, q, J=6.3 Hz, HCO; 6=3.42-3.75 ppm. 3H, m; 
6=2.57 ppm, IH, dd, J=3 Hz; 6=2.42 ppm, 2H, dd, J=3 Hz and J=7 Hz; 6=1.04 ppm, 0.81H, d, 
J=6.3 Hz, CH3; 6=0.72 ppm, 2.19H, d, J=6.3 Hz, CH3. 
entry 16: 8r, Yield 78%; m.p. 115-116°C; JH-NMR (400 MHz, CDC13): 6=12.22 ppm, 0.71H, 
s, ArOH; 6=11.99 ppm, 0.29H, s, ArOH; 6=7.65 ppm, IH, m, ArH; 6=7.54 ppm, 2H, d. J=8 Hz, 
ArH; 6=7.26 ppm, 2H, m, ArH; 6=7.06 ppm, 2H, d, J=8 Hz, ArH; 6=4.44 ppm, IH, m, HCO; 
6=3.94 ppm, IH, t, J= 6.3 Hz, HCO; 6=3.39-3.71 ppm, 3H, m; 6=2.31-2.60 ppm, 3H, m; 6=1.17 
ppm, 2H, m, CH2; 6=0.62 ppm, 0.87H, t, J=7 Hz, CH3; 6=0.19 ppm, 2.13H, t, J=7 Hz, CH3. 
entry 1: 9c, Yield; 71%; JH-NMR (90 MHz, CDC13): 6=12.1 ppm, IH, s, ArOH; 6=11.8 ppm, 
IH, s, ArOH; 6=7.3 ppm, 2H, bs, ArH; 6=4.4 ppm. IH, m, HCO; 6=3.4 ppm, 3H, m; 6=3.2 ppm, 
3H, m; 6=0.3-1.4 ppm, 8H, m, contains 1.4 H, d, J=6.3 Hz, CH3 and 1.6 H, d, J=6.3 Hz, CH3. 
entry 2: 9d. Yield 75%; 'Н-NMR (90 MHz, CDC13): 6=12.1 ppm, IH, s, ArOH; 6=11.8 ppm, 
IH, s, ArOH; 6=7.2 ppm, 2H, bs, ArH; 6=4.4 ppm, IH, m, HCO; 6=3.4-3.8 ppm, 3H, m; 
6=3.0-3.3 ppm, IH, m; 6=2.3-3.0 ppm, 3H, m; 6=1.5 ppm, IH, m; 6=0.8 ppm, 1.28 H, d, J=6.2 
Hz, CH3; 6=0.3-0.7 ppm, contains 1.72 H, d, J=6.2 Hz, CH3, 2.56 H, d, 2 CH3 and 3.44 H, d, 2 
CH3. 
entry 3: ?e. Yield 69%; JH-NMR (90 MHz, CDC13): 6=12.03 ppm, 0.65H, s, ArOH; 6=12.01 
ppm, 0.35H, s, ArOH; 6=11.52 ppm, 0.35H, s, ArOH; 6=11.51 ppm, 0.65H, s, ArOH; 6=7.2 
ppm, 2H, bs, ArH; 6=4.4 ppm, IH, m, HCO; 6=3.5 ppm, 3H, m; 6=2.3-3.0 ppm, 4H, m; 6=1.8 
ppm, 1.05H, d, J=6.3 Hz, CH3; 6=1.5 ppm, IH, m; 6=0.3-0.5 ppm, contains 1.95 H, d, J=6.3 Hz, 
CH3, 5.85 H, s, 0(CH3)3 and 3.15 H, s, 0(CH3)3. 
entry 4: ?f, Yield 63%; 'Н-NMR (90 MHz, CDC13): 6=12.1 ppm, IH, s, ArOH; 6=11.8 ppm, 
IH, s, ArOH; 6=7.2 ppm, 2H, bs, ArH; 6=4.4 ppm, IH, m, HCO; 6=3.4-3.8 ppm, 3H, m; 
6=3.0-3.3 ppm, IH, m; 6=2.3-3.0 ppm, 3H, m; 6 = 1.0-2.2 ppm, 11H, C 6 H n ; 6=0.8 ppm, 1.37H, 
d, J=6.2 Hz, CH3; 6=0.4 ppm, 1.63H, d, J=6.2 Hz, CH3. 
entry 5: 9g, Yield 62%; m.p. 138-139.5°C; m/e: 380 (M+), 276, 258, 105; 'H-NMR (400 MHz, 
CDC13): 6=12.11 ppm, IH, s, ArOH; 6=11.88 ppm, 0.15H, s, ArOH; 6=11.58 ppm, 0.85H, s, 
ArOH; 6=7.25 ppm, 5H, s, ArOH; 6=7.07 ppm, IH, s, ArH; 6=7.02 ppm, IH, s, ArH; 6=4.33 
ppm, IH, m, HCO; 6=3.97 ppm, IH, q, J=6.3 Hz, CH; 6=3.39-3.69 ppm, 3H, m; 6=2.52 ppm, 
IH, dd, J=8 Hz; 6=2.42 ppm, 2H, dd, J=8 Hz and J=4 Hz; 6=1.08 ppm, 0.45H, d, J=6.3 Hz, CH3; 
6=0.81 ppm, 2.55H, d, J=6.3 Hz, CH3. 
entry 6: ?h, Yield 67%; ]H-NMR (90 MHz, CDC13): 6=12.3 ppm, 0.75H, s, ArOH; 6=12.0 
ppm, 0.25H, s, ArOH; 6=11.82 ppm, 0.25H, s, ArOH; 6=11.78 ppm, 0.75H, s, ArOH; 6=7.30 
ppm, 5H, s, ArOH; 6=7.1 ppm, 2H, s, ArH; 6=4.4 ppm, IH, m, HCO; 6=3.4-3.9 ppm, 4H, m; 
6=2.3-2.6 ppm, 3H, m; 6=1.0-1.4 ppm, 2H, m, CH2; 6=0.6 ppm, 0.75H, t, J=7.4 Hz, CH3; 6=0.4 
ppm, 2.25H, t, J=7.4 Hz, CH3. 
entry 7: 9i, Yield 48%; *H-NMR (90 MHz, CDC13): 6=12.4 ppm, 0.65H, s, ArOH; 6=12.1 ppm, 
0.35H, s, ArOH; 6=11.8 ppm, IH, s, ArOH; 6=7.4 ppm, 5H, s, ArOH; 6=7.1 ppm, IH, m, ArH; 
6=6.7 ppm, IH, m, ArH; 6=4.5 ppm, IH, m, HCO; 6=3.4-3.9 ppm, 4H, m; 6=2.2-2.7 ppm, 3H, 
m; 6=1.2-1.6 ppm, IH, m; 6=0.6 ppm, 1.05H, d, J=6.2 Hz, 2CH3; 6=0.2-0.5 ppm, m, CH3. 
entry 8: 9j, Yield 80%; ]H-NMR (90 MHz, CDC13): 6=12.31 ppm, 0.33H, s, ArOH; 6=12.29 
ppm, 0.67H, s, ArOH; 6=11.9 ppm, IH, s, ArOH; 6=7.4 ppm, 2H, bs, ArH; 6=4.5 ppm, IH, m, 
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HCO; 6=2.3-3.8 ppm, 6Н, m; δ=3.2 ppm, 3Η, s, ОСН3; δ=2.9 ppm, 2H, d, J=5 Hz, OCH2; 6=1.7 
ppm, IH, m; 6=0.8 ppm, IH, d, J=6.3 Hz, CH3; 6=0.5 ppm, 2H, d, J=6.3 Hz, CH3. 
entry 9: 9k, Yield 62%; ^ N M R (90 MHz, CDC13): 6=12.30 ppm, 0.75H, s, ArOH; 6=12.29 
ppm, 0.25H, s, ArOH; 6=12.0 ppm, IH, s, ArOH; 6=7.4 ppm, 2H, m, ArH; 6=5.4 ppm, IH, m, 
HC=C; 6=4.9-5.1 ppm, 2H, m, H2C=C; 6=4.4 ppm, IH, m, HCO; 6=3.3-3.9 ppm, 3H, m; 
6=2.3-2.7 ppm, 3H, m; 6=0.9 ppm, 0.75H, d, J=6.5 Hz, CH3; 6=0.6 ppm, 2.25H, d, J=6.5 Hz, 
CH3. 
entry 10: 91, Yield 69%; m.p. 99-100°C; !H-NMR (400 MHz, CDClj): 6=12.07 ppm, 0.5H, s, 
ArOH; 6=12.05 ppm, 0.5H, s, ArOH; 6=11.54 ppm, IH, 2 χ s, ArOH; 6=7.22 ppm, 2H, m, ArH; 
6=4.36 ppm, 2H, m, 2 HCO; 6=3.40-3.69 ppm, 3H, m; 6=3.31 ppm, 3H, s, OCH3; 6=3.16 ppm, 
2H, t, J=5 Hz, OCH2; 6=2.28-2.97 ppm, 3H, m; 6=1.08-1.17 ppm, 2H, m; CH2; 6=0.57 ppm, 
1.48H, d, J=6.3 Hz, CH3; 6=0.46 ppm, 1.52H, d, J=6.3 Hz, CH3. 
entry 11: 9m, Yield 55%; ^-NMR (90 MHz, CDCL): 6=12.3 ppm, 0.46H, s, ArOH; 6=12.2 
ppm, 0.54H, s, ArOH; 6=11.7 ppm, IH, s, ArOH; 6=7.3 ppm, 5H, s, ArH; 6=7.0 ppm, 2H, m, 
ArH; 6=4.3 ppm, IH, m, HCO; 6=3.4-3.8 ppm, 3H, m + IH, qd, J=7.3 Hz and J=3 Hz, CH; 
6=3.0-3.3 ppm, 2H, d, J=3 Hz, CH2; 6=2.3-3.0 ppm, 3H, m; 6=0.9 ppm, 1.62H, d, J=7.3 Hz, 
CH3; 6=0.7 ppm, 1.38H, d, J=7.3 Hz, CH3. 
entry 12: 9n, Yield 54%; m.p. 163°C; m/e: 409 (M+), 258, 165, 151,135; JH-NMR (400 MHz, 
CDC13): 6=12.11 ppm, 0.96H, s, ArOH; 6=11.86 ppm, 0.04H, s, ArOH; 6=11.58 ppm, IH, s, 
ArOH; 6=7.26 ppm, 2H, s, ArH; 6=6.72-7.03 ppm, 4H, d, J=7.5 Hz and J=8.8 Hz, ArH; 6=4.30 
ppm, IH, m, HCO; 6=3.90 ppm, IH, q, J=6.3 Hz, HCO; 6=3.77 ppm, 3H, s, OCH3; 6=3.36-3.67 
ppm, 3H, m; 6=2.47 ppm, IH, d, J=7.8 Hz; 6=2.33 ppm, 2H, dd, J=5.3 Hz; 6=1.03 ppm, 0.12H, 
d, J=6.3 Hz, CH3; 6=0.76 ppm, 2.88H, d, J=6.3 Hz, CH3. 
entry 13: 9o, Yield 50%; m.p. 116°C; m/e: 394 (M*), 276, 256, 119; Ή-NMR (400 MHz, 
CDC13): 6=12.12 ppm, 0.82H, s, ArOH; 6=11.89 ppm, 0.18H, s, ArOH; 6=11.60 ppm, IH, s, 
ArOH; 6=7.26 ppm, 2H, s, ArH; 6=6.86-7.13 ppm, 4H, d, J=8.8 Hz, ArH; 6=4.33 ppm, IH, m, 
HCO; 6=3.92 ppm, IH, q, J=6.3 Hz, HCO; 6=3.38-3.69 ppm,3H, m; 6=2.52 ppm, IH, m; 
6=2.32-2.42 ppm, 5H, m p-CH3 and 2H; 6=1.04 ppm, 0.54H, d, J=6.3 Hz, CH3; 6=0.74 ppm, 
2.46H,d,J=6.3Hz,CH3. 
entry 14: 9p., Yield 55%; m.p. 126°C; Ή-NMR (400 MHz, CDC13): 6=12.03 ppm, 0.88H, s, 
ArOH; 6=11.81 ppm, 0.12H, s, ArOH; 6=11.49 ppm, IH, s, ArOH; 6=7.08-7.28 ppm, IH, ArH, 
d, J=7 Hz and 4H, ArH; 6=6.86 ppm, IH, d, J=7 Hz, ArH; 6=4.25-4.39 ppm, IH, m, HCO; 
6=3.97 ppm, IH, q, J=6.3 Hz, HCO; 6=3.36-3.78 ppm, 3H; m; 6=2.42 ppm, 3H, m; 6=1.04 ppm, 
0.24H, d, J=6.3 Hz, CH3; 6=0.75 ppm, 2.76H, d, J=6.3 Hz, CH3. 
entry 15: 9g, Yield 51%; m.p. 114-116°C; m/e: 448 (M+), 276, 258, 231, 175, 173, 105; 
^-NMR (400 MHz, CDC13): 6=12.08 ppm, 0.78H. s, ArOH; 6=11.86 ppm, 0.22H, s, ArOH; 
6=11.51 ppm, IH, s, ArOH; 6=7.53 ppm, 2H, dd, J=8 Hz, ArH; 6=7.19-7.41 ppm, 2H, dd, ArH; 
6=7.08 ppm, 2H, dd, J=8 Hz, ArH; 6=4.40 ppm, IH, m, HCO; 6=4.13 ppm, IH, q, J=6.3 Hz, 
HCO; 6=3.42-3.78 ppm, 3H, m; 6=2.56 ppm, IH, dd, J=3 Hz; 6=2.26-2.48 ppm, 2H, dd, J=3 Hz 
and J=6Hz; 6=1.11 ppm, 0.64H, d, J=6.3 Hz, CH3; 6=0.82 ppm, 2.36H, d, J=6.3 Hz, CH3. 
entry 16: ?r, Yield 78%; m.p. 154-155°C; ^-NMR (400 MHz, CDC13): 6=12.60 ppm, 0.78H, 
s, ArOH; 6=12.38 ppm, 0.22H, s, ArOH; 6=12.06 ppm, IH, s, ArOH; 6=8.04 ppm, 2H, d, 
J=8Hz, ArH; 6=7.78 ppm, 2H, dd, ArH; 6=7.56 ppm, 2H, d, J=8Hz, ArH; 6=4.43 ppm, IH, m, 
HCO; 6=3.94 ppm, IH, q, J=7 Hz, HCO; 6=3.39-3.78 ppm, 3H, m; 6=2.31-2.58 ppm, 3H, m; 
6=1.22 ppm, 2H, m, CH2; 6=0.61 ppm, 0.66H, t, J=7 Hz, CH3; 6=0.26 ppm, 2.34H, t, J=7 Hz, 
CH 
entry 5: 16g, Yield 53%; m.p. 114°C; m/e: 432 (M+), 259, 244, 215, 173; ^l-NMR (400 MHz, 
CDC13): 6=8.08-8.26 ppm, 2H, m, ArH; 6=7.81-7.71 ppm, 2H, m, ArH; 6=7.20 ppm, 5H, s, 
ArH; 6=4.32 ppm, IH, m, HCO; 6=3.89 ppm, IH, q, J=6.3 Hz, HCO; 6=3.44-3.68 ppm, 3H, m; 
6=2.44 ppm, IH, dd, 3=7 Hz; 6=2.32 ppm, 2H, d, J=3 Hz; 6=0.94 ppm, 0.15H, d, J=6.3 Hz, CH3; 
6=0.58 ppm, 2.85H, d, J=6.3 Hz, CH3. 
entry 12: 16n, Yield 60%; m.p. 104-116°C; m/e: 378 (M+), 224, 196, 181, 151, 135; Ή-NMR 
(400 MHz, CDC13): 6=8.03-8.26 ppm, 2H, m, ArH; 6=7.59-7.72 ppm, 2H, m. ArH; 6=6.87 ppm, 
2H, dd, J=7 Hz and J=8.6 Hz, ArH; 6=6.59 ppm, 2H, dd, J=7 Hz and J=8.6 Hz, ArH; 6=4.32 
ppm, IH, m, HCO; 6=3.84 ppm, IH, q, J=6.3 Hz, HCO; 6=3.69 ppm, 3H, s, OCH3; 6=3.43-3.59 
ppm, 3H, m; 6=2.44 ppm, IH, dd, J=7 Hz; 6=2.29 ppm, 2H, d, J=3 Hz; 6=0.92 ppm, 0.35H, d, 
J=6.3 Hz, CH3; 6=0.56 ppm, 2.65H, d, J=6.3 Hz, CH3. 
entry 13: 16o, Yield 50%; m.p. 107°C; m/e: 362 (M*), 224,196,139, 119; !H-NMR (400 MHz, 
CDC13): 6=8.06-8.27 ppm, 2H, m, ArH; 6=7.67-7.85 ppm, 2H, m, ArH; 6=6.81-7.12 ppm, 4H, 
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2dd, J=8 Hz, ArH; 6=4.31 ppm, IH, m, HCO; δ=3.84 ppm, IH, q, J=6.3 Hz, HCO; 0=3.43-3.75 
ppm, 3H, m; 6=2.47 ppm, IH, dd, J=7 Hz; 6=2.22-2.38 ppm, 5H, m, р-СЩ and 2H; 6=0.92 
ppm, 0.24H, d, J=6.3 Hz, CH3; 6=0.56 ppm, 2.76H, d, J=6.3 Hz, CH3. 
entry 14: 16p, Yield 19%; m.p. 114-120°C; m/e: 381 (M+), 224, 196, 155, 141; ]H-NMR (400 
MHz, CDCfj): 6=8.04-8.27 ppm, 2H, m, ArH; 6=7.67-7.89 ppm, 2H, m, ArH; 6=7.22 ppm, 2H, 
d, J=8 Hz, ArH; 6=6.89 ppm, 2H, d, J=8 Hz, ArH; 6=4.37 ppm, IH, m, HCO; 6=3.93 ppm, IH, 
q, J=6.3 Hz, HCO; 6=3.41-3.76 ppm, 3H, m; 6=2.52 ppm, IH, dd; 6=2.24-2.46 ppm, 2H, dd, J=5 
Hz and J=7 Hz; 6=0.93 ppm, 0.15H, d, J=6.3 Hz, CH3; 6=0.47 ppm, 2.85H, d, J=6.3 Hz, CH3. 
entry 15: 16g, Yield 49%; m.p. 110-114°C; m/e: 416 (M+), 224, 196, 181, 145, 127; !H-NMR 
(400 MHz, CDC13): 6=8.10 ppm, 2H, m, ArH; 6=7.78 ppm, 2H, m, ArH; 6=7.49 ppm, 2H, dd, 
J=8 Hz, ArH; 6=7.04 ppm, 2H, dd, J=8 Hz, ArH; 6=4.40 ppm, IH, m, HCO; 6=4.08 ppm, IH, q, 
J=6.3 Hz, HCO; 6=3.43-3.78 ppm, 3H, m; 6=2.57 ppm, IH, dd, J=3 Hz and J=7.5 Hz; 
6=2.33-2.47 ppm, 2H, dd, J=3 Hz and J=7 Hz; 6=1.00 ppm, 0.54H, d, J=6.3 Hz, CH3; 6=0.52 
ppm, 2.46H, d, J=6.3 Hz, CH3. 
entry 5: 16g, Yield 53%; m.p. 128°C; m/e: 298 (M+), 194, 176, 148, 121, 105; •H-NMR (400 
MHz, CDC13): 6=7.25-7.30 ppm, 3H, m, o- and/7-ArH; 6=7.11 ppm, 2H, dd, J=1.6 Hz and J=8.3 
Hz, w-ArH; 6=6.96 ppm, IH, d, J= 10.3 Hz, C=C; 6=6.83 ppm, IH, d, J= 10.3 Hz, C=; 6=4.43 
ppm, 0.05H, q, J=6.3 Hz, HCO; 6=4.26 ppm, 0.95H, m, HCO; 6=4.14 ppm, 0.95H, q, J=6.3 Hz, 
HCO; 6=4.06 ppm, 0.05H, m, HCO; 6=3.49 ppm, IH, m; 6=3.35.3.39 ppm, 2H, m; 6=2.27-2.34 
ppm, 3H, m; 6=1.19 ppm, 0.15H, d, J=6.3 Hz, CH3; 6=1.17 ppm, 2.85H, d, J=6.3 Hz, CH3. 
entry 12: 17n, Yield 49%; m.p. 106°C; m/e: 328 (M+), 176, 147, 135; JH-NMR (400 MHz, 
CDC13): 6=7.03 ppm, 2H, m, ArH; 6=6.97 ppm, IH, d, J=ll Hz, C=C; 6=6.84 ppm, 2H, m, ArH 
and IH, d, J=l l Hz, C=; 6=4.24 ppm, IH, m, HCO; 6=4.09 ppm, IH, q, J=6.3 Hz, HCO; 6=3.78 
ppm, 3H, s, OCH3; 6=3.29-3.50 ppm, 3H, m; 6=2.32 ppm, IH, dd, J=4 Hz; 6=2.25-2.29 ppm, 
2H, dd; 6=1.15 ppm, 3H, d, J=6.3 Hz, CH3 (only 1 isomer visible in NMR spectrum). 
entry 13: 17o, Yield 60%; m.p. 97°C; m/e: 312 (M+), 176, 149, 135, 121; ^-NMR (400 MHz, 
CDC13): 6=7.11 ppm, 2H, m, ArH; 6=7.01 ppm, 2H, m, ArH; 6=6.96 ppm, IH, d, J=10.3 Hz, 
C=C; 6=6.83 ppm, IH, d, J=10.3 Hz, C=; 6=4.23 ppm, IH, m, HCO; 6=4.09 ppm, IH, q, J=6.3 
Hz, HCO; 6=3.47 ppm, IH, m; 6=3.31-3.39 ppm, 2H, m; 6=2.33 ppm, IH, dd; 6=2.31 ppm, 3H, 
s,/7-CH3; 6=2.25-2.29 ppm, 2H, dd; 6=1.17 ppm, 0.1H, d, J=6.3 Hz, CH3; 6=1.15 ppm, 2.9H, d, 
J=6.3 Hz, CH3. 
entry 14: 17p, Yield 52%; m.p. 97-100°C; m/e: 332 (M+), 178, 155, 147, 141; 'H-NMR (400 
MHz, CDCV": 6=7.28 ppm, 2H, d, J=8.3 Hz, ArH; 6=7.03 ppm, 2H, d, J=8.3 Hz, ArH; 6=6.95 
ppm, IH, d, J=10 Hz, C=C; 6=6.81 ppm, IH, d, J=10 Hz, C=; 6=4.41 ppm, 0.1 OH, q, J=6.3 Hz, 
HCO; 6=4.27 ppm, 0.90H, m, HCO; 6=4.15 ppm, 0.90H, q. J=6.3 Hz, HCO; 6=4.05 ppm, 
0.10H, m, HCO; 6=3.51 ppm, IH, m; 6=3.35 ppm, 2H, m; 6=2.32 ppm, 3H, m; 6=1.15 ppm, 3H, 
d,J=6.3Hz, CH3. 
entry 15: 17g, Yield 55%; m.p. 105°C; m/e: 366 (M+), 189, 176, 153, 147, 133; ]H-NMR (400 
MHz, CDC13): 6=7.58 ppm, 2H, d, J=8 Hz, ArH; 6=7.24 ppm, 2H, d, J=8 Hz, ArH; 6=6.99 ppm, 
2H, d, J=11.4 Hz, C=C; 6=6.84 ppm, 2H, d, J=11.4 Hz, C=; 6=4.50 ppm, 0.18H, q, J=6.3 Hz, 
HCO; 6=4.26 ppm, 0.82H. q, J=6.3 Hz, HCO; 6=4.33 ppm, 0.82H, m, HCO; 6=4.09 ppm, 
0.18H, m, HCO; 6=3.53 ppm, IH, m; 6=3.39 ppm, 2H, m; 6=2.43 ppm, IH, dd; 6=2.29-2.39 
ppm, 2H, dd; 6=0.99 ppm, 3H, d, J=6.3 Hz, CH3. 
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CHAPTER 5 
TOTAL SYNTHESIS OF C13,CI4-ETHYNYL DERIVATIVES OF DAUNOMYCIN AND 
4-DEMETHOXYDAUNOMYCIN. 
5.1 Introduction. 
With the synthetic methods developed for anthracyclinones (see Chapters 2 and 3), we have the 
possibility of synthesizing anthracyclines with the acetyl group replaced by a Ci3,C]4-ethynyl 
functionality (Figure 5.1). 
To our knowledge, no such modifications have as yet been investigated. Although modifications 
of the Cj3 acetyl or hydroxy acetyl groups (Figure 5.1) were shown to be of little use (see 
Section 7.4.1), we nevertheless decided to study some ethynyl analogs. There are good reasons 
to expect that this approach could lead to drugs which have reduced cardiotoxicity (see Chapter 
8, section 8.2). 
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5.2 Synthesis of 9-ethvnyl-9-deacetvl derivatives of daunomycin. 
Synthesis of the ethynyl derivatives 2 of daunomycin or 4-demethoxydaunomycin can be 
achieved by omitting the hydrolysis of the trimethylsilylethynyl group to the acetyl functionality 
as described in Chapter 2 (conversion 3/4 to 5/6, Scheme 5.1). 
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After removal of the iert-butyl group with trifluoroacetic acid from 3 and 4, the method of 
Terashima et al.3 was applied to synthesize the corresponding glycosidation products 10/11 and 
12/13 from the compounds 7 and 8 (Scheme 5.2). This method yields exclusively the desired 
α-glycosides. Under standard conditions however, considerable amounts of diglycoside (having 
an additional sugar molecule coupled to position 9) were formed. Diastereomers 10/12 and 
11/13 were formed in almost equal amounts. Unfortunately, the diglycosides of the biologically 
active isomers (10/11) were formed more rapidly than the diglycosides of the other isomers 
(12/13). When the reaction time was prolonged, only the diglycoside of the biologically active 
isomer was found, while very little of the diglycoside of the other isomer was formed. This 
observation has also been reported by Irvine et al.4. We adjusted the conditions to prevent 
formation of the diglycoside. Lowering the temperature to -25°C decreased formation of the 
diglycoside but also made the reaction slower. 
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Separation of the diastereomers 10/12 and 11/13 was very difficult but, could be achieved using 
column chromatography. The isolated yields of 10 and 12 were not very high (25% and 15%, 
respectively) because of the problems with this separation. For the methoxy compounds Ц and 
13, the yields were even lower (8% and 12%, respectively). The formation of the diglycoside 
was competitive with the formation of the mono-glycoside. Separation also appeared to be more 
troublesome. Rf values were very similar in almost all tested solvent combinations. Therefore, 
the Koenings-Knorr method was also used for the glycosidation of 8. This method requires large 
amounts of the chloro sugar 14 (Figure 5.2), HgBr2 and Hg(CN)2 while the reaction time had to 
be prolonged to several days and the reaction temperature was increased to 55°C. No 
diglycosides were formed but this method also yielded unwanted ß-glycosides 15 and 16 (Figure 
5.2). Although separation of the four isomers И, 13, 15 and 16 was very difficult, it was 
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possible to purify compound 11 (isolated yield 30%); the other compounds were isolated as a 
mixture. No further purification of this mixture of isomers was attempted. 
Figure 5.2 
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The assignment of the structure to both pairs of diastereomers 10/12 and 11/13 was based on 
JH-NMR spectral data (shift differences and coupling constants) and optical rotations. 
All four compounds 10-13 were deprotected at the 4' position. The para-nitrobenzoyl group at 
the 4' position was removed by treatment with a solution of 0.1M sodium hydroxide in a 
mixture of dichloromethane and methanol. Compounds 17, ljt and 19 were formed in yields 
between 75 and 80% (Scheme 5.3). Compound 13 was not deprotected because, in this case, we 
were only interested in the biologically active derivative. Deprotection of 12 to 19 was 
necessary for confirmation of the structural assignment. 
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Removal of the trimethylsilyl group from the acetylene function (17) was also possible by 
treatment with tetrabutylammonium fluoride (Scheme 5.4). Our first intention was to synthesize 
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both the ethynyl and 1-trimethylsilylethynyl derivatives of daunomycin and 4-demethoxy-
dannomycin. Unfortunately, deprotection of the 3' nitrogen was not possible without 
concomitant removal of the trimethylsilyl group from the acetylene. 
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By deprotection with 0.1 M sodium hydroxide, both the trifluoroacetyl (at the 2' position) and 
the trimethylsilyl group (C14 position) were removed and HCl addition salts 20/22 and 21 were 
formed (Scheme 5.5). Compounds 20 and 21 were tested in vitro for biological activity and the 
results of these tests are described in Chapter 8. 
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5.3 Conclusions. 
In this chapter, the synthesis of the C13,C14-ethynyl analogs of daunomycin and 4-demethoxy-
daunomycin has been described. Intermediates from the synthesis of daunomycinone and 
4-demethoxydaunomycinone, as described in Chapter 2, were used as starting materials in the 
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synthesis of these new analogs. After removal of the tert-butoxy protection group the aglycones 
(7 and 8) were coupled with the chiral protected sugar L-daunosamine (9) according to the 
method of Terashima and colleagues3. It was possible to separate both pairs of diastereomers 
using column chromatography. After deprotection of the individual diastereomers, we were able 
to isolate the chiral ethynyl analogs of daunomycin (20) and 4-demethoxydaunomycin (21) 
5.4 Experimental section. 
General remarks: 
1H-NMR-spectra were measured either on a Bruker WH-90 spectrometer or an Bruker AM-400 
spectrometer using (CH^Si as internal standard. CDC13 was used as solvent unless otherwise 
stated. Melting points were taken using a Reichert Thermpan microscope and are uncorrected. 
Mass spectra were taken using a double focusing VG 7070 E mass spectrometer. For column 
chromatography either Merck Silicagel 60 or Merck silicagel Art. 9385 (flash chromatography) 
were used. Dry dichloromethane was distilled from CaH2; dry diethyl ether and dry THF were 
distilled from sodium benzophenone ketyl. Obtaining correct elemental analysis for 
anthracyclines is very difficult. In several cases, one molecule of water was included in the 
molecule. Also in literature4 examples have been published that one molecule of 
dichloromethane was included. Sometimes no analysis is given. Compounds must be carefully 
and repeatedly crystallized to obtain satisfactory analytical data. We tried to obtain satisfactory 
analyses for the synthesized compounds. Unfortunately not in all cases we have been successful. 
Cis-(+l-)-7,8,9J0-tetrahydro^J,9Jl-tetrahydroxy-94rimethylsilylethynyl-5,12-naphthacene-
dione (І). 
1.25 g (2.6 mmol) of 3 5 were dissolved in 15 ml of trifluoroacetic acid. After 10 minutes, 
when TLC showed the reaction to be complete, the reaction mixture was quenched with 200 ml 
of water. The aqueous layer was extracted three times with 75 ml of chloroform. The combined 
organic layers were washed with water, dried over anhydrous sodium sulfate and then 
evaporated in vacuo. The residue was purified by column chromatography (ethyl acetate/ 
n-hexane, 3 : 5) to give 0.89 g (81%) of 7. m.p. 208-210°C. ^-NMR (400 MHz) : δ = 0.20 ppm 
(9H, s, Si(CH3)3), δ = 2.24 ppm (IH, dd, J=14.5 Hz and J=5.2 Hz, H8(ax)), δ = 2.65 ppm (IH, dt, 
J=14.5 Hz, J=2.3 Hz and J=2.2 Hz, H8(eq)), δ = 2.97 ppm (IH, d, J=18.8 Hz, H10(ax)), δ = 3.48 
ppm (IH, dd, J=18.5 Hz and J=1.6 Hz, H10(eq)), δ = 3.49 ppm (IH, 7-OH), δ = 3.75 ppm (IH, br 
s, 9-OH), δ = 5.24 ppm (IH, br s, H7), δ = 7.82-8.32 ppm (4H, m, ArH), δ = 13.27 ppm (IH, s, 
ArOH), δ = 13.57 ppm (IH, s, ArOH). 
Cu^-methoxy-yfiPJO-tetrahydro^J^^lJetrahydroxy^-trimethyhilylethynylnathacene-
5,12-dione © . 
0.81 g (1.59 mmol) of 45 was dissolved in 15 ml of trifluoroacetic acid. Progress of the 
reaction was followed by TLC (ethyl acetate/n-hexane, 3 : 5). After 10 minutes the reaction 
mixture was poured into 250 ml of water and then extracted with chloroform until the 
chloroform extract showed no orange color. After evaporation in vacuo the residue was purified 
by column chromatography (3% methanol in chloroform) to give 0.55 g (76%) of 8. m.p. 
235-237°C; MS (FAB) miz: 452 (M+); Ή-NMR (400 MHz) : δ = 0.19 ppm (9H, s, SHCHj^, δ 
= 2.26 ppm (IH, dd, J=14.5 Hz and J=5 Hz, H8(ax)), δ = 2.76 ppm (IH, dt, J=14.5 Hz, J=2.0 Hz 
and J= 2.5 Hz), H8(eq)), δ = 2.96 ppm (IH, d, J=18.6 Hz, H10(ax)), δ = 3.48 ppm (IH, d, J=18.6 
Hz and J=2.0 Hz, Hi„(eq)), δ = 3.54 (Ш, s, 9-OH), δ = 3.68 ppm (IH, d, J=4.0 Hz, 7-OH), δ = 
4.09 (3H, s, OCH3), δ = 5.28 ppm (IH, m, H7), δ = 7.38-8.05 ppm (3H, ArH), δ = 13.29 ppm (IH, s, ArOH), δ = 14.03 ppm (IH, s, ArOH); Anal, caled, for C ^ H ^ O T S Í : С, 63.70; H, 5.35. 
Found: С, 63.51; H, 5.32. 
9-Deacetyl-4-demethoxy-4,-0-p-nitrobenzoyl-3'-N-tñfluoroacetyl-9-trimethylsilylethynyl-
daunomycin (10) and 7,9-bis-epi-9-deacetyl-4-demethoxy-4'-0-p-nitrobenzoyl-3'-N-trifluoro-
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acetyl-9-trimethylsilylethynyldaunomycin (12). 
Under an argon atmosphere, 2.75 ml of trimethylsilyltriflate (14.4 mmol) were added to a 
stirred suspension of 3.55 g of ? (6.6 mmol) and 20 g molecular sieves 4Â in 125 ml of dry 
dichloromethane and 430 ml of dry diethyl ether at -25°C. The mixture was stirred at 0°C for 1 h 
and then cooled to -20°C. A solution of 2.25 g (5.3 mmol) of 7 dissolved in 250 ml of dry 
dichloromethane was then added. After being stirred at the same conditions for 3 hours 
(progress of the reaction was followed by TLC, ethyl acetate/benzene, 1:4), the mixture was 
poured into 1000 ml of a vigorously stirred solution of saturated NaHC03. The organic layer 
was separated and washed with 1000 ml of water and 1000 ml of brine, dried over anhydrous 
sodium sulfate and then concentrated in vacuo. The residue was purified by column 
chromatography (ethyl acetate/toluene, 1 : 16) to give 1.06 g (25%) of diastereomer 10 and 0.64 
g (15%) of diastereomer 12. 
Compound 10: mp· 157-159°C, [a20D] = -18.1° (c=0.105 in dioxane); MS (FAB) mlz: 196 (M+); JH-NMR (400 MHz) : δ = 0.20 ppm (9H, s, Si(CH3)3), δ = 1.31 ppm (3H, d, J=6.5 Hz, 
6'-Me), δ = 2.03-2.19 ppm (2H, m, 2-Η2·), δ = 2.33 ppm (Ш, dd, J= 14.5 Hz and J= 4.8 Hz, 
H8(ax)), δ = 2.64 ppm (Ш, br d,J=14.5 Hz, H8(eq)), δ = 3.02 ppm (IH, d, J=19 Hz, H10(ax)), δ = 
3.57 ppm (IH, d, J=19 Hz, H10(eq)), δ = 3.76 ppm (IH, br s, 9-OH), δ = 4.48-4.58 ppm (2H, m, 
H3. and H5.), δ = 5.17 ppm (IH, m, H7), δ = 5.44 ppm (IH, br s, Η4·), δ = 5.68 ppm (IH, m, H r ) , 
δ = 6.51 ppm (IH, br d, J=7.5 Hz, NH), δ = 7.76-7.83 ppm (2H, m, ArH), δ = 8.22-8.36 ppm 
(6H, m, ArH), δ = 13.29 ppm (IH, s, ArOH), δ = 13.59 ppm (IH, s, ArOH). 
Compound 12: m.p. 160-162°C, [a20^ = -310.7° (c=0.112 in dioxane); MS (FAB) mlz: 
796 (M+); Ή-NMR (400 MHz) : δ = 0.22 ppm (9H, s, Si(CH3)3), δ = 1.27 ppm (3H, d, J=6.5 
Hz, 6'-Me), δ = 1.92-2.18 ppm (3H, m, 2-H2· and H8(ax)), δ = 2.90 ppm (IH, m, H8(eq)), δ = 
3.10 ppm (IH, d, J=19 Hz, H10(ax)), δ = 3.70 ppm (Ш, d, J=19 Hz, H,0(eq)), δ = 4.21 ppm (IH, 
s, 9-OH), δ = 4.59 ppm (IH, m, Η3·), δ = 4.78 ppm (IH, q, J=6.5 Hz. H5.), δ = 5.44 ppm (IH, br 
s, H7), δ = 5.54 ppm (IH, m, Η4·), δ = 5.58 ppm (IH, br d, J=3 Hz, H r ) , δ = 6.36 ppm (IH, br d, 
J=7.5 Hz, NH), δ = 7.85-7.89 ppm (2H, m, ArH), δ = 8.25-8.41 ppm (6H, m, ArH), δ = 13.35 
ppm (IH, s, ArOH), δ = 13.82 ppm (IH, s, ArOH). 
9-Deacetyl^,-Oy-nitrobenzoyl-3'-N-trifluoroacetyl-9-trimethyMlylethynyldaunomycin (11) 
and 7,9-bis-epi-9-deacetyW-O-p -nitrobenzoyl-3 ' -N-trifluoroacetyl-9-trimethyhilylethynyl-
daunomycin (13). 
1.0 ml of trimethylsilyltriflate was added to a stirred suspension of 1.22 g of 9 (2.26 
mmol) and 16 g molecular sieves 4À in a mixture of 150 ml of dry dichloromethane and 50 ml 
of dry diethyl ether at -25°C under an argon atmosphere. The whole mixture was stirred at 0°C 
for 1 h to give a clear solution, which was cooled at -25°C. A solution of 0.8 g (1.8 mmol) of 8 
dissolved in 200 ml of dry dichloromethane was then added and the reaction mixture was stirred 
at -20°C for 3 h. Progress of the reaction was followed by TLC (ethyl acetate/benzene, 1 : 4) 
and, after all of compound 8 had disappeared, the reaction mixture was poured into 800 ml of 
saturated NaHC03 which was vigorously stirred to quench the glycosidation reaction. The 
organic layer was separated, washed with 500 ml of water and 500 ml of brine and dried over 
anhydrous sodium sulfate. After evaporation in vacuo, compounds Π and 13 were separated 
using column chromatography (2% acetone and 0.2% glacial acetic acid in dichloromethane). 
Both purified samples were triturated with n-hexane to give 120 mg (8%) of 11 and 0.170 g 
(12%) of 13. 
Compound Д : m.p. 161-163°C, [a2 0 D] = +6° (c=0.5 in dioxane); MS (FAB) mlz: 826 (M+); JH-NMR (400 MHz): δ = 0.20 ppm (9H, s, Si(CH3)3), δ = 1.29 ppm (3H, d, J=6.5 Hz, 
6'-Me), δ = 2.04 ppm (2H, dd, J=9 Hz and J= 2.3 Hz, 2-Η2·), δ = 2.33 ppm (IH, dd, J=14.7 Hz 
and J=4.9 Hz, H8(ax)), δ = 2.61 ppm (IH, m, H8(eq)), δ = 3.01 ppm (IH, d, J=18.7 Hz, H10(ax)), 
δ = 3.57 ppm (Ш, dd, J=18.7 Hz and J=1.2 Hz, H10(eq)), δ = 3.70 ppm (IH, s, 9-OH), δ = 4.07 
ppm (3H, s, OMe), δ = 4.44-4.55 ppm (2H, m, H3· and Η5·), δ = 5.23 ppm (IH, br s, H7), δ = 
5.46 ppm (IH, m, H4>), δ = 5.71 ppm (IH, br s, H,}, δ = 6.22 ppm (IH, br d, J=7.5 Hz, NH), δ = 
7.37-8.04 ppm (3H, m, ArH), δ = 8.27-8.36 ppm (4H, m, ArH), δ = 13.29 ppm (IH, s, ArOH), δ 
= 14.07 ppm (IH, s, ArOH); Anal. cale, for C 3 2H 3 2F 3N 20 1 4Si. 1 H 2 0: C, 55.45; H, 4.65; N 3.33 
Found: С, 54.72; H, 4.41; Ν, 3.79. 
Compound 13: m.p. 174-176°C, [a2 0 D] = -347.7° (c=0.65 in dioxane); MS (FAB) miz: 826 (M+); Ή-NMR (400 MHz) : δ = 0.22 ppm (9H, s, Si(CH3)3), δ = 1.25 ppm (3Η, d, J=6.5 Hz, 
б'-Ме), δ = 1.90-2.17 ppm (3H, m, 2-Η2· and H8(ax)), δ = 2.86-2.92 ppm (IH, m, H8(eq)), δ = 
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3.08 ppm (IH, d, J=19 Hz, H10(ax)), δ = 3.71 ppm (IH, dd, J=19 Hz and J=1.3 Hz, H10(eq)), δ = 
4.11 ppm (3H, s, OMe), δ = 4.23 ppm (IH, s, 9-OH), δ = 4.52-4.57 ppm (IH, m, Н3·), δ = 
4.76-4.84 ppm (IH, m, Η5·), δ = 5.40 ppm (IH, br s, H7), δ = 5.56 ppm (IH, br s, Η4·), δ = 5.57 
ppm (IH, br s. H,·), δ = 6.27 ppm (IH, br d, J=7.5 Hz, NH), δ = 7.79-8.27 ppm (3H, m, ArH), δ 
= 8.28-8.35 ppm (4H, m, ArH), δ = 13.31 ppm (IH, s, ArOH), δ = 14.23 ppm (IH, s, ArOH). 
9-Deacetyl^,-0-p-nitrohenzoyl-3>-N-trifluoroacetyl-9-trimethyisilylethynyldaunomycin (Π). 
452 mg (1.0 mmol) of 8 were dissolved in 100 ml of dry THF and 2.08 g (8.24 mmol) of 
Hg(CN)2, 0.944 g (2.63 mmol) of HgBr2 and 4.8 g molecular sieves 3Â were added. The 
reaction mixture was stirred under an argon atmosphere at 50-55°C for 2 h. Three IM portions 
of freshly prepared chloro sugar 14 were added at 0, 4 and 22 h, while the temperature was 
maintained at 50-55°C. The chloro sugar 14 was prepared by bubbling anhydrous hydrogen 
chloride into a suspension of 2,3,6-trideoxy-l,4-di-/»-0-nitrobenzoyl-3-trifluoroacetamido-a-L-
/yxo-hexopyranose (9, 540 mg, 1.0 mmol) in dry 16 ml of dichloromethane at 0°C for 3 min The 
mixture was allowed to stand at room temperature for 10 min, filtered to remove the precipitated 
^-nitrobenzoic acid, and evaporated. The residue was dissolved in 8 ml of dry dichloromethane 
and added to the reaction mixture. Additional 2.08 g (8.24 mmol) of Hg(CN)2, 0.944 g (2.63 
mmol) of HgBr2 and 4.8 g molecular sieves 3Â were added at 4 h. The total reaction time after 
the first addition of 14 was 25 h. The reaction mixture was filtered, the solids were washed with 
THF and the combined organic layers were evaporated and the residue was triturated with 300 
ml of chloroform and filtered. The filtrate was washed twice with a solution of 100 ml 30% KI 
and once with water. After drying over anhydrous sodium sulfate and evaporation in vacuo the 
residue was purified by column chromatography (silicagel 60H, ethyl acetate/benzene, 1 : 4) to 
give 248 mg (30%) of 11. Besides Π an equal amount of 13 and small amounts of 15 and 16 
were isolated. 
9-Deacetyl-4-demethoxy-3'-N-trifluoroacetyl-9-trimethylsilylethynyldaunomycin (17). 
Under an argon atmosphere and at 0°C, 6.5 ml of 0.1 M sodium hydroxide were added to a 
stirred solution of 0.5 g (0.63 mmol) of 10 in 4 ml of dichloromethane and 260 ml of methanol. 
The purple solution was stirred at room temperature for 5 minutes at 0°C. Glacial acetic acid 
was added to the reaction mixture until the color of the solution became bright orange. 400 ml of 
ethyl acetate and 400 ml of brine were added to the reaction mixture. The organic layer was 
washed twice with 125 ml of brine, dried over anhydrous sodium sulfate and evaporated in 
vacuo. The residue was purified by column chromatography (dichloromethane/acetone, 9 : 1) to 
give 0.31 g (76%) of 17. m.p. 140-142°C, [a 2 0 D] = +237° (c=0.076 in dioxane); MS (FAB) miz: (Al (MH+); ^-NMR (400 MHz) : δ = 0.20 ppm (9Η, s, Si(CH3)3), δ = 1.34 ppm (3H, d, J=6.5 
Hz, б'-Ме), δ = 1.79-2.03 ppm (2H, m, 2-H2>), δ = 2.01 ppm (IH, br s, 4'-OH), δ = 2.28 ppm (IH, dd, J=14.7 Hz and J=4.5 Hz, H8(ax)), δ = 2.62 ppm (IH, m, H8(eq)), δ = 3.01 ppm (IH, d, 
J=19 Hz, H,0(ax)), δ = 3.60 ppm (IH, dd, J=19 Hz and J=1.5 Hz, H10(eq)), δ = 3.64-3.69 ppm (IH, m, H4·), δ = 3.92 ppm (IH, s, 9-OH), δ = 4.19-4.26 ppm (IH, m, H3>), δ = 4.32-4.38 ppm (IH, q, J=6.5 Hz, H5.), δ = 5.19 ppm (IH, dd, J=4 Hz and J=2 Hz, H7), δ = 5.53 ppm (IH, br d, 
J=4 Hz, H
r
) , δ = 6.65 ppm (IH, br d, J=8 Hz, NH), δ = 7.82-7.86 ppm (2H, m, ArH), δ = 
8.33-8.38 ppm (2H, m, ArH), δ = 13.35 ppm (IH, s, ArOH), δ = 13.63 ppm (IH, s, ArOH). 
9-Deacetyl-4-demethoxy-9-ethynyl-3'-N-trifluoroacetyl-daunomycin (17a). 
178 mg tetrabutylammonium fluoride were added to a solution of 244 mg of 17 in 25 ml 
of THF. The mixture was stirred at room temperature under an argon atmosphere for 5 minutes. 
100 ml of water and 100 ml of chloroform were added to the reaction mixture and the aqueous 
layer was extracted twice with 100 ml of chloroform. The combined organic layers were washed 
with brine, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was 
purified by column chromatography (dichloromethane/acetone, 7 : 3) to give 130 mg of 17a 
(60%). m.p. 146-148°C, [α2<\^ = +289° (c=0.076 in dioxane); MS (FAB) mlz: 575 (M+); 
!H-NMR (400 MHz) : δ = 1.31 ppm (3H, d, J=6.5 Hz, б'-Ме), δ = 1.80-2.08 ppm (3H, m, 2-H2. 
and H8(ax)), δ = 2.18 ppm (IH, br s, 4'-OH), δ = 2.57 ppm (IH, s, СЬС-Н), δ = 2.87 ppm (IH, 
m, H8(eq)), δ = 3.10 ppm (IH, d, J=19 Hz, Hi0(ax)), δ = 3.71 ppm (IH, d, J=19 Hz, H10(eq)), δ = 
3.62 ppm (IH, m, Η4·), δ = 4.30 ppm (IH, s, 9-OH), δ = 4.31 ppm (IH, m, Η3·), δ = 4.59 ppm 
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(IH, m, H5.), 6 = 5.41 ppm (IH, m, H7), δ = 5.51 ppm (IH, br s, H,.), δ = 6.64 ppm (IH, br d, 
J=8 Hz, NH), δ = 7.83-7.88 ppm (2H, m, ArH), δ = 8.35-8.40 ppm (2H, m, ArH), δ = 13.41 ppm 
(IH, s, ArOH), δ = 13.79 ppm (IH, s, АЮН); Anal. cale, for C2 8H24F3N09. 1 H 2 0: C, 56.66; H, 
4.42; N 4.36. Found: С, 57.06; H, 4.45; Ν, 4.60 
9-Deacetyl-3'-N-trifluoroacetyl-9-trimethylsilylethynyldaunomycin (18). 
Sodium hydroxide (0.1M, 3.3 ml) was added to a stirring solution of 248 mg (0.3 mmol) 
of И in 3 ml of dichloromethane and 100 ml of methanol at 0°C under an argon atmosphere. 
The deep purple solution was stirred at 0°C for 3 minutes. Glacial acetic acid was added to the 
reaction mixture until the color of the solution became bright orange. 150 ml of ethyl acetate and 
150 ml of brine were added to the reaction mixture. The organic layer was washed twice with 75 
ml of brine and dried over anhydrous sodium sulfate. Filtration and concentration in vacuo gave 
an orange residue, which was purified by column chromatography (chloroform/methanol/ 
glacial acetic acid, 100 : 1 : 0,5) to give 156 mg (77%) of 18. m.p. 159-163°C; [ a 2 0 ^ = +290° 
(c=0.07 in dioxane); 'H-NMR (400 MHz) : δ = 0.20 ppm (9H, s, Si(CHj)3), δ = І .ЗЗррт (ЗН, 
d, J=6.5 Hz, 6'-Me), δ = 1.78-2.09 ppm (2H, m, 4'-OH and 2-Η2·), δ = 2.28 ppm (IH, dd, J=14.7 
Hz and J=4.5 Hz, H8(ax)), δ = 2.60 ppm (IH, m, H8(eq)), δ = 2.99 ppm (IH, d, J=19 Hz, 
HiQ(ax)), δ = 3.59 ppm (IH, dd, J=19 Hz and J=1.5 Hz, H10(eq)), δ = 3.63-3.67 ppm (IH, m, 
Н Д δ = 3.90 ppm (IH, s, 9-OH), δ = 4.08 ppm (3H, s, OMe), δ = 4.20 ppm (IH, m, Η3·), δ = 
4.33 ppm (IH, q, J=6.5 Hz, Η5·), δ = 5.21 ppm (IH, m, H7), δ = 5.54 ppm (IH, br d, J=3.8 Hz, 
H
r
) , δ = 6.58 ppm (IH, br d, J=8.5 Hz, NH), δ = 7.38-8.06 ppm (3H, m, ArH), δ = 13.32 ppm 
(IH, s, ArOH), δ = 14.04 ppm (IH, s, ArOH); Anal. cale, for C32H3 6F3NOnSi. 1 H 2 0: C, 55.25; 
H, 5.22; N 2.01. Found: С, 55.24; H, 5.07; Ν, 2.12. 
7,9-Bis-epi-9deacetyl-4^emethoxy-3'-N-trifluoroacetyl-9-trimethykilylethynyldaunomycin 
(19). 
At 0°C and under an argon atmosphere 11.8 ml of a 0.1M sodiumhydroxide solution was 
added to a solution of 0.9 g (1,13 mmol) of 12 in 7 ml of dichloromethane and 475 ml of 
methanol. The deep purple solution was stirred at 0°C for 20 minutes and progress of the 
reaction was monitored by TLC (dichloromethane : acetone, 9 : 1 ) . Glacial acetic acid was 
added to the mixture until the colour of the solution became orange. Ethylacetate (750 ml) and 
brine (750 ml) were added to the reaction mixture. The organic layer was washed with twice 
with 200 ml of brine and dried over anhydrous sodiumsulfate. After filtration and evaporation in 
vacuo the orange residue was purified by column chromatography (dichloromethane : acetone, 9 
: 1) to give 0.58 g of 19 (80%). m.p. 138-140°C, [a20^ = -375° (c=0.0885 in dioxane). •H-NMR 
(400 MHz) : δ = 0.20 ppm (9H, s, Si(CH3)3), δ = 1.31 ppm (3H, d, J=6.5 Hz, 5'-Me), δ = 
1.82-1.95 ppm (3H, m, 2-H2· and 4'-OH), δ = 2.01 ppm (IH, dd, J=14.7 Hz and J=3.5 Hz, 
H8(ax)), δ = 2.86 ppm (IH, d, J=14.7 Hz, H8(eq)), δ = 3.09 ppm (IH, d, J=19 Hz, H10(ax)), δ = 
3.60-3.64 ppm (IH, m, Η4·), δ = 3.70 ppm (IH, d, J=19 Hz , H10(eq)), δ = 4.23 ppm (IH, br s, 
9-OH), δ = 4.25-4.30 ppm (IH, m, Η3·), δ = 4.57 ppm (IH, q, J=6.5 Hz, % ) , δ = 5.41 ppm (IH, 
br d, J=4 Hz, H7), δ = 5.48 ppm (IH, s, H r ) , δ = 6.64 ppm (IH, br d, J=8 Hz, NH), δ = 7.84-7.88 
ppm (2H, m, ArH), δ = 8.35-8.39 ppm (2H, m, ArH), δ = 13.37 ppm (IH, s, ArOH), δ = 13.79 
ppm (IH, s, ArOH); Anal. cale, for C3iH3 2F3N09Si. 1 H 2 0: C, 55.93; H, 5.15; N 2.10. Found: 
C, 55.71; H, 4.92; N, 2.39. 
9-Deacetyl-4-demethoxy-9-ethynyl-daunomycin (20). 
30 ml of 0.1M sodium hydroxide were added to a solution of 0.16 g (0.23 mmol) of 17 in 
3 ml of acetone. The reaction mixture was stirred at room temperature for 30 minutes under an 
argon atmosphere. Progress of the reaction was monitored by TLC (water/ acetic acid/ 
methanol/ chloroform, 12 : 26 : 54 : 160). The pH of the reaction mixture was adjusted to 9 with 
IM hydrogen chloride solution and extracted with chloroform (approximately 5 times) until a 
chloroform extract showed no orange color of the reaction product. The combined organic layers 
were washed with water and dned over anhydrous sodium sulfate. After filtration and 
evaporation in vacuo, the residue was dissolved in a minimal amount of chloroform/methanol (9 
: 1) and 0.4 ml of 0.6M hydrogen chloride in methanol and 50 ml of dry diethyl ether were 
added. The orange powder that precipitated was filtered off to give 84 mg (70%) of 20. m.p. 
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177-179°C, [a20^ = +189° (c=0.037 in dioxane); MS (FAB) mlz: 633 (M+); JH-NMR (400 
MHz, DMSO) : δ = 1.16 ppm (3H, d, J=6.5 Hz, 6*-Me), δ = 1.74 ppm (IH, d, J= 9 Hz, H,.(ax)), 
δ = 1.90 ppm (IH, t, J=12 Hz, H2.(eq)), δ = 2.13 ppm (IH, dd, J=13 Hz and J=6.5 Hz, H8(ax)), δ 
= 2.43 ppm (IH, d, J=13 Hz, H8(eq)), δ = 2.5 ppm (IH, s, C=C-H), δ = 2.91 ppm (IH, d, J=18 
Hz, H10(ax)), δ = 3.08 ppm (IH, d, J=18 Hz, H10(eq)), δ = 3.42 ppm (IH, m, Η3·), δ = 3.59 ppm (IH, br s, H4.), δ = 4.03 ppm (IH, q, J=6.5 Hz, Η5·), δ = 5.41 ppm (IH, m, H7), δ = 5.32 ppm (IH, br s, Η,·), δ = 5.47 ppm (IH, br s, 4'-OH), δ = 5.95 ppm (IH, s, 9-OH), δ = 7.96 ppm (ЗН, 
br s, З'-ЫНО, δ = 7.93-7.96 ppm (2H, m, АгН), δ = 8.21-8.24 ppm (2Η, m, АгН), 6 = 13.23 ppm 
(IH, s, АЮН), δ = 13.53 ppm (IH, s, ArOH). 
9-Deacetyl-9-ethynyl-daunomycin (21). 
156 mg (0.23 mmol) of 18 were dissolved in a minimal amount of acetone. Sodium 
hydroxide (0.1M, 26 ml) was then added and the reaction mixture was stirred at room 
temperature under an argon atmosphere for 30 minutes. Progress of the reaction was followed by 
TLC (water/Glacial acetic acid/Methanol/Chloroform, 12 : 26 : 54 : 160). After the pH of the 
reaction mixture had been adjusted to 9 with IM hydrogen chloride, the solution was extracted 
with 100 ml of chloroform until a chloroform extract showed no orange color of the reaction 
product. The combined organic layers were washed with water and dried over anhydrous sodium 
sulfate. After filtration and evaporation in vacuo, the residue was dissolved in a minimal amount 
of chloroform/methanol (9/1). After adding 0.7 ml of 0.6M hydrogen chloride in methanol and 
100 ml of diethyl ether were added, the HCl salt 21 (98 mg, 78%) was precipitated as an orange 
powder, m.p. 227-230°C, [ a 2 0 ^ = +93° (c=0.0475 in dioxane); !H-NMR (400 MHz, DMSO) : δ 
= 1.16 ppm (3H, d, J=6.5 Hz, б'-Ме), δ = 1.65-1.91 ppm (2H, m, 2 Η2·), δ = 2.13 ppm (ЗН, dd, 
J=13 Hz and J=6.5 Hz, H8(ax)), δ = 2.35 ppm (IH, d, J=13 Hz, H8(eq)), δ = 2.66 ppm (IH, s, 
C=C-H), δ = 2.88 ppm (IH, d, J=18 Hz, Hi0(ax)), δ = 3.07 ppm (IH, d, J=18 Hz, H10(eq)), δ = 
3.34 ppm (IH, m, H·,.), δ = 3.56 ppm (IH, br s, H4.), δ = 3.98 ppm (ЗН, s, OCH3), δ = 4.08 ppm (IH, q, J=6.5 Hz, Η5·), δ = 4.98 ppm (IH, m, H7), δ = 5.30 ppm (IH, br s, H r ) , δ = 5.47 ppm (IH, br s, 4'-OH), δ = 5.95 ppm (IH, s, 9-OH), δ = 7.63-7.66 ppm (IH, m, ArH), δ = 7.86-7.89 
ppm (2H, m, ArH), δ = 7.90 ppm (3H, br s, 3'-NH3), δ = 13.20 ppm (IH, s, ArOH), δ = 14.06 
ppm (IH, s, ArOH). 
7,9-Bis-epi-9-deacetyl-4-demethoxy-9-ethynyl-daunomycin (22). 
250 mg (0.39 mmol) of compound 19 were dissolved in 5 ml of acetone. 50 ml of 0.1M 
sodium hydroxide solution were added and the reaction mixture was stirred for 30 minutes at 
room temperature under an argon atmosphere. Progress of the reaction was monitored by TLC 
(water/acetic acid/methanol/chloroform, 12 : 26 : 54 : 160). After the pH of the reaction mixture 
had been adjusted to 9 with IM hydrogen chloride, the solution was extracted with 100 ml of 
chloroform until the chloroform extract showed no orange color of the reaction product. The 
combined organic layers were washed with water and dried over anhydrous sodium sulfate. 
After filtration and evaporation in vacuo the residue was dissolved in a minimal amount of a 
mixture of chloroform/methanol (9/1). After adding 0.7 ml of 0.6M hydrogen chloride in 
methanol and 100 ml of diethyl ether, the HCl salt of 22 (140 mg, 70%) precipitated as an 
orange powder, m.p. 160-162°C, [a2 0 D] = -280° (c=0.0275 in dioxane); MS (FAB) mlz: 480 (M+-C1); JH-NMR (400 MHz, DMSO) : δ = 1.14 ppm (3H, d, J=6.5 Hz, б'-Ме), δ = 1.60-1.95 
ppm (2H, m, H2.(ax) and H2.(eq), δ = 2.14 ppm (IH, dd, J=14 Hz and J=5 Hz, H8(ax))6 = 2.43 
ppm (IH, d, J=13 Hz, H8(eq)), δ = 2.66 ppm (IH, s, C=C-H), δ = 2.98 ppm (IH, d, J=18 Hz, 
Hj0(ax)), δ = 3.07 ppm (IH, d, J=18 Hz, H10(eq)), δ = 3.42 ppm (IH, m, Η3·), δ = 3.59 ppm (IH, 
br s, Η4·), δ = 4.00 ppm (IH, q, J=6.5 Hz, Η5·), δ = 5.26 ppm (IH, m, H7), δ = 5.24 ppm (IH, br 
s, H
r
) , δ = 5.80 ppm (IH, br s, 4'-OH), δ = 6.31 ppm (IH, s, 9-OH), δ = 7.83 ppm (3H, br s, 
3'-NH3), δ = 7.96-7.99 ppm (2H, m, ArH), δ = 8.27-8.29 ppm (2H, m, ArH), δ = 13.27 ppm (IH, 
s, ArOH), δ = 13.49 ppm (IH, s, АЮН). 
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respectively. 
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CHAPTER 6 
TOTAL SYNTHESIS OF PYRIDINE D RING DERIVATIVES OF DAUNOMYCIN. 
6.1 Introduction. 
Severe cardiotoxicity is a serious problem for the medical application of anthracycline 
antibiotics such as daunomycin and adriamycin. The generation of reactive oxygen species such 
as 0 2 ", H 2 0 2 and OH-, has been used to explain the anti-tumor activity of the anthracycline 
antibiotics. However, it can also be used to explain their cardiotoxicity. Since anthracyclines 
accumulate in the heart, and cardiac tissue is not able to protect the cell from oxidative lesions, 
the one-electron reduction of these compounds to their radical anions, which will yield reactive 
oxygen species, may play an important role in cardiotoxicity1. Modifications of the redox 
potential of the anthracyclinone part (aglycone) may influence both the anti-tumor activity and 
the cardiotoxicity2 (see also Chapter 7). This redox potential can most easily be affected by 
substituents in the D ring of the aglycone. Introduction of a nitrogen atom in the D ring will 
affect the redox potential. Furthermore, the nitrogen atom provides an extra position for 
protonation or interaction with an electrophilic receptor molecule. 
In 1990 and 1991, Kita et al.3,4 published a synthesis method for D ring pyridine 1 and D ring 
pyrazine 2 analogs of 11-deoxydaunomycin (Figure 6.1). Although they were able to synthesize 
the D ring indole 3 derivative of daunomycin, they did not describe the synthesis of the D ring 
pyridine derivative of daunomycin. 
Figure 6.1 
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Introduction of a nitrogen atom in the D ring is theoretically possible in four positions. We 
chose to synthesize the 1-N and 4-N derivatives of daunomycin because they may be accessible 
using l-aza-buta-l,3-dienes in the Diels-Alder reaction with quiñones5. 
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6.2 Synthesis of D ring pyridine analogs of daunomvcinone. 
In Chapter 3 we described the synthesis of the complete ABC fragment of daunomvcinone. This 
fragment, available on a gram scale, was used as starting material for the synthesis of new D 
ring derivatives of daunomycin. The intended synthesis of pyridine D ring derivatives could be 
accomplished by Diels-Alder reaction of the ABC fragment with l-aza-buta-l,3-dienes. 
l-(Dimethylamine)-3-methyl-l-aza-buta-l,3-diene 4 has been successfully applied by Potts et 
aL5 in the Diels-Alder reaction with quiñones, such as juglone 5 and naphthazarin 6 to yield 
aza-anthraquinones 1_1 and 12 (Scheme 6.1). 
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In the cycloaddition of juglone 5, the azadiene showed high regioselectivity. The strong 
electron-donating dimethylamino group causes the azadiene to react as an electron-rich diene 
with the highest HOMO coefficient on the γ-carbon atom. In the Diels-Alder reaction of 4 with 
naphthazarin 6, cycloadduct 10, derived from the 1:1 cycloadduct by loss of dimethylamine, was 
isolated together with the oxidized product 12 and the addition product of dimethylamine to 
naphthazarin, 2-(dimethylamino)-5,8-dihydroxy-l,4-naphthoquinone5. When argon was bubbled 
through the reaction mixture at 40-45°C, the dimethylamine was removed and cycloadduct 10 
was isolated in a yield of 84%. After air oxidation by heating 10 with potassium carbonate in a 
methanol/water mixture, cycloadduct 12 was isolated with an overall yield of 77%. 
The cycloaddition of azadiene 4 with dienophile 13 (Scheme 6.2) was expected to proceed in a 
similar way as described for naphthazarin 6 (Scheme 6.1). 
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In orientating experiments, cycloaddition with the ABC fragment appeared to be much slower at 
room temperature. Due to the slow conversion, extensive decomposition of the ABC fragment 
13, leading to compound 16 (Figure 6.2), was observed, probably caused by elimination of 
terf-butyl alcohol and water from 13 by the basic amines in the reaction mixture. 
Figure 6.2 
Therefore, we decided to perform the cycloaddition under high pressure (6 - 15 kbar at room 
temperature). It was expected that, under these conditions, the reaction would be accelerated and 
that elimination of dimethylamine, which may cause side reactions, would thus be avoided. 
The high pressure Diels-Alder reaction of diene 4 with the ABC fragment 13 gave a complex 
mixture of products. The best results were obtained with dichloromethane as solvent. After 
evaporation of the solvent in vacuo, the JH-NMR spectrum of the crude reaction mixture 
(treated with oxygen) showed the presence of pyridine ring containing products 14 and 15 but 
also other pyridine containing products lacking the fért-butoxy group (typical pyridine protons at 
8.4 and 8.9 ppm were present). Furthermore, the reaction mixture contained considerable 
amounts of the salt (CH3)2NH2+ CI" which had been formed from dimethylamine and 
dichloromethane at high pressure6. After chromatographic separation, 14 and 15 were obtained 
pure. A third compound without the tert-butoxy group was isolated in a yield of 40%. Probably, 
a mixture of 17 and 18 (Figure 6.3) had been formed. It was not possible to separate these 
compounds by chromatography. No conclusions can be drawn from the ^-NMR spectra, due to 
the (expected) absence of differences in phenolic hydroxy proton shifts between 17 and 15. 
Figure 6.3 
17 18 
This result, which was quite surprising, indicated that, also under high pressure conditions 
dimethylamine was eliminated from the initial 1:1 cycloadduct. The formation of 17/18 can be 
explained by the reaction sequence give in Scheme 6.3 (given for compound 17 only). 
When the reaction was performed in THF, compounds 17/18 became the main products after 
evaporation in vacuo of the solvent. In dichloromethane, base-catalysed elimination of tert-butyl 
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alcohol was probably retarded because dimethylamine reacts under high pressure with the 
solvent. 
Scheme 6 3 
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After reaction under high pressure conditions, a maximum of 25-30% of aromatized 
cycloadducts 14 and 15 were isolated. The regioselectivity of the Diels-Alder reaction depended 
on the dienophile used. A ratio of 1:2 between the formed products 14 and 15 was found. 
Separation of the mixture of 14 and 15 was possible using column chromatography, but was 
rather difficult because of absorption of nitrogen containing molecules to the column material. 
The Diels-Alder reactions of 13 with the diene 4 has also been performed at normal pressure 
giving the Diels-Alder adducts in the same ratios but lower isolated yields as described above. 
Subsequently, 1,4-elimination of the dimethylamine and oxidation either with Pb(OAc)4 or air 
oxidation on silicagel gave the aromatic products 14 and 15. 
The azadiene reacts as a 1-substituted electron-rich diene having the highest HOMO coefficient 
at the γ atom. Analogously to the cycloadducts obtained from the reaction of 13 with 1 
substituted electron-rich alkenes, compound 15 (see Scheme 6.1) is expected to be the major 
regioisomer (see also Chapter 3, compounds 9 and 10). Further evidence was obtained from the 
NMR data of the regioisomers. The largest shift difference between both aromatic hydroxy 
protons was found for 14. This was comparable with the shift difference in daunomycinone and 
its regioisomer7. NOE-difference NMR spectroscopy also gave the same indication, although 
very small, for the assignment of structures 14 and 15. For compound 14, a small NOE effect 
was found on protons at C4 and C7 of the A and D rings after irradiation of one of the aromatic 
hydroxy protons (see Scheme 6.2 for numbering). Attempts to crystallize one of these 
compounds for X-ray diffraction have not yet been successful. 
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In order to influence the regiochemistry and to make 14 more readily available and, also to find 
additional proof for the regiochemistry, dienophile 22 was used in the Diels-Alder reaction with 
diene 4 (Scheme 6.4) 
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For compound 22, we expected the highest LUMO coefficient to be on carbon atom 6 (opposite 
to the hydrogen bridge, see also Chapter 2). In the cycloaddition with diene 4, this should lead to 
cycloadduct 14 (Scheme 6.4). Compound 22 was synthesized from 13 by regioselective 
protection of the 5-hydroxy group with CaH2 and/7-nitrobenzyI chloroformate (see also Chapter 
3). In Chapter 2, we showed that the regioselective protection of related anthraquinones 
influenced the regioselectivity of the Diels-Alder reaction. 
The ratio of 14 : 15 (1 : 2) from the reaction of diene 4 and dienophile 13 changed to 7 : 3 when 
dienophile 22 was used. The /7-nitrocarbobenzoxy group was spontaneously removed under 
these basic reaction conditions. The moderate regioselectivity found in the conversion of 22 can 
be ascribed to partial removal of the protecting group from 22 before reaction with diene 4. This 
may be caused by dimethylamine liberated after the cycloaddition reaction. 
The ratios were determined using 'H-NMR spectroscopy from integration of the aromatic 
hydroxy protons between 13 and 14 ppm. As we needed both pyridine D ring analogs of 
daunomycinone, we applied both dienophiles 13 and 22 in combination with diene 4 for the 
preparation of the cycloadducts 14 and 15. 
The 2-trimethylsilylethynyl functionality of compounds 14 and 15 was hydrolysed into the 
desired acetyl group by treatment with mercury (II) oxide and dilute sulfuric acid (Scheme 6.5). 
The hydrolysis of these compounds was much slower than for the non-pyridine D ring analogs. 
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The reaction was, however, accelerated by using an ultrasonic cleaning bath. We then observed 
subsequent partial deprotection of the terf-butoxy group. Compounds 23 and 24 were formed in 
an overall yield (for hydrolysis and deprotection) of 80-90%. 
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6.3 Synthesis of D ring pyridine analogs of daunomvein. 
The racemic aglycones 23 and 24 were coupled with the appropriately protected L-daunosamine 
25 under the conditions developed by Terashima and colleagues9. Successive addition of 
trimefhylsilyltriflate and a solution of the aglycone in dichloromethane to a suspension of 
molecular sieves 4Â and sugar 25 in a mixture of anhydrous diethyl ether and anhydrous 
dichloromethane at -15°C for 3 h gave an inseparable mixture of the two diastereomeric 
α-glycosides 26 and 27 (Scheme 6.6). Only α-glycosides were formed due to stabilization of the 
intermediate cation at Cj ' by the lone pair of the oxygen from the/>-nitrobenzoyl group at C4'9. 
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In this way glycosides 26 and 27 were isolated in a yield of 42% and 41%, respectively, as a 
mixture of diastereomers. In addition to small amounts of diglycoside 28, the unreacted 
aglycone was recovered and could be used again. 
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Chromatographic separation of this mixture of diastereomers was not possible using a variety of 
solvent combinations. 
The N,0-diprotected α-glycosides 26 and 27 were deprotected (Scheme 6.7) at the 4'-hydroxy 
group by adding one equivalent of sodium hydroxide to a solution of the glyscoside in 
dichloromethane and methanol, to give the N-protected α-glycosides 29 and 30 in a yield of 
40% - 50% (mixture of diastereomers). 
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Formation of the biologically more active HCl salts of the pyridine D ring analogs of 
daunomycin 31 and 32 can be accomplished by deprotection of the trifluoroacetate in a solution 
of 0.1M sodium hydroxide followed by addition of 0.6M HCl in methanol (Scheme 6.8). 
All HCl salts of the pyridine D ring derivatives have been tested in vitro for anti-tumor activity 
(see Chapter 8). Since all compounds were tested as mixtures of diastereomers and the 
diastereomeric mixture of 32 shows an acceptable activity, we tried to separate those 
diastereomers. In the ^-NMR spectra of 29 and 30 it was clearly seen that two diastereomers 
were present, in a ratio of approximately 1:1 (integration of the aromatic hydroxy protons). 
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The shifts of the aromatic hydroxy protons for the two diastereomers of compound 29 were 
clearly different (13.65 ppm and 13.81 ppm, respectively). For compound 30, these values were 
13.43 ppm and 13.58 ppm. 
Efforts to separate Ν,Ο-diprotected 27 were, as earlier mentioned, not successful. We did not try 
to separate the diastereomeric mixture of 32, because of its low solubility in organic solvents (32 
is only soluble in water and in methanol) and its instability when using chromatography. 
Therefore, our efforts were focused on the separation of the distereomers of 30. With centrifugal 
thin-layer chromatography using chloroform, methanol (2%) and glacial acetic acid (0.4%) as 
eluent, we were able to separate the diastereomers 30a and 30b (Scheme 6.9). 
Both diastereomers were converted into their HCl salts (32a and 32b) and tested for anti-tumor 
activity (see Chapter 8). 
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6.4 Conclusions 
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New pyridine D ring analogs of daunomycinone have been synthesized by an extension of the 
method as described in Chapter 3. Cycloaddition between dienophile 13 and diene 4 and 
subsequent hydrolysis resulted in the formation of two new daunomycinone analogs with a 
nitrogen atom at the 4 and 1 positions and a methyl group at 2 and 3 positions, 23 and 24, 
respectively. When using /7-nitrobenzyloxycarbonyl-protected dienophile 22, the regioselectivity 
of the Diels-Alder reaction was reversed. The Diels-Alder reactions were performed under high 
pressure to reduce the reaction time and to increase the yields. Quite surprisingly, 
1,4-elimination of dimethylamine also occurred under high pressure. 
Both daunomycinone analogs 23 and 24 were coupled with the chiral protected sugar 
L-daunosamine according to the method developed by Terashima et al.9. After removal of the 
protecting groups both pyridine D ring analogs of daunomycin were isolated as a mixture of 
diastereomers 31 and 32. For analog 32, we were also successful in the separation of both 
diastereomers 32a and 32b. 
6.5 Experimental section. 
General remarks: 
^-NMR-spectra were measured either on a Bruker WH-90 spectrometer or an Bruker AM-400 
spectrometer using Me4Si as internal standard. CDC13 was used as solvent unless otherwise 
stated. Melting points were taken using a Reichert Thermpan microscope and are uncorrected. 
Mass spectra were taken using a double focusing VG 7070 E mass spectrometer. For column 
chromatography, either Merck Silicagel 60 or Merck silicagel Art. 9385 (flash chromatography) 
were used. Chromatotron Model 7924T from Harrison Research (Palo Alto, US) was used for 
centrifugal thin-layer chromatography. Dry dichloromethane was distilled from CaH2 and dry 
diethyl ether was distilled from sodium benzophenone ketyl. Obtaining correct elemental 
analysis for anthracyclines is very difficult. In several cases, one molecule of water was 
included in the molecule. Also in literature13 examples have been published that one molecule 
of dichloromethane was included. Sometimes no analysis is given. Compounds must be 
carefully and repeatedly crystallized to obtain satisfactory analytical data. We tried to obtain 
satisfactory analyses for the synthesized compounds. Unfortunately not in all cases we have 
been successful. The numbering used for the compounds of this experimental section is 
illustrated below for structures 14 and 15. Both 14 and 15 are racemic mixtures of cis isomers. 
* = Racemic mixture of as-7,9-OtBu,OH 
Cis-(+/-)-7A9J0-tetrahydro-4^za-7-tert-butoxy-2-methyl-6,9Jl-trikydroxy-9-(trimethylsilyl-
ethynyl)-naphthacene-5,12-dione fl4) and Cis-(+l-)-7,8,9,10-tetrahydro-l- aza-7-tert-butoxy-3-
methyl-6,9,11-trihydroxy-9-(trimethylsilylethynyl) -naphthacene-5,12-dione (15). 
0.75 g (6.6 mmol) of 2-methyl-2-propenal-N,N-dimethylhydrazone 4^ was added to a 
solution of 1.07 g (2.5 mmol) of Π in 15 ml of dichloromethane and divided over two high 
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pressure reaction vessels of 7.5 ml. A catalytic amount of hydroquinone was added to avoid 
polymerization and the reaction vessels were kept under high pressure (12 kbar) for 5 hours at 
room temperature. The reaction mixture was evaporated in vacuo and stirred for 1 h in 20 ml of 
diethyl ether to extract the excess diene and dienophile. The orange solid was filtered off and 
separated by column chromatography (1% methanol in dichloromethane) to give 100 mg (8%) 
of 14, 270 mg (22%) of 15 and 420 mg (40%) of a mixture of 17/18. 
Compound Ы: m.p. 229-231°C; MS (FAB+) mlz: 494 (MH+); EI peakmatch: found: 
493.19207 (cale. 493.1920); ]H-NMR (400 MHz): δ = 0.20 ppm (9H, s, Si(CH3)3), δ = 1.41 ppm (9H, s, C(CH3)3), δ = 2.01 ppm (IH, d, J=14.5 Hz, H8(ax)), δ = 2.59 ppm (3H, s, З-СН,), δ = 
2.76 ppm (IH, d, J=14.5 Hz, H8(eq)), δ = 3.05 ppm (IH, d, J=20 Hz, H10(ax)), δ = 3.67 ppm (IH, d, J=20 Hz, H]0(eq)), δ = 5.37 ppm (IH, brs, H7), δ = 5.91 ppm (IH, s, 9-OH), δ = 8.39 
ppm (IH, s, ArH), δ = 8.91 ppm (IH, s, ArH), δ = 13.23 ppm (IH, s, ArOH), δ = 13.80 ppm (IH, 
s, ArOH); Anal. cale, for C 2 7H 3 1N0 6Si: C, 65.70; H, 6.33; N, 2.84. Found: С, 65.07; H, 6.33; N, 
2 78 
Compound 15: m.p. 258-260°C; MS (FAB+) miz: 494 (MH+); Ή-NMR (400 MHz): δ = 
0.22 ppm (9Η, s, Si(CH3)3), δ = 1.41 ppm (9H, s, C(CH3)3), δ = 2.01 ppm (IH, d, J=14.5 Hz, 
H8(ax)), δ = 2.59 ppm (3H, s, 3-CH3), δ = 2.76 ppm (IH, d, J=14.5 Hz, H8(eq)), δ = 3.08 ppm (IH, d, J=20 Hz, H10(ax)), δ = 3.70 ppm (IH, d, J=20 Hz, H10(eq)), δ = 5.37 ppm (IH, brs, H7), 
δ = 5.87 ppm (IH, s, 9-OH), δ = 8.44 ppm (IH, s, ArH), δ = 8.94 ppm (IH, s, ArH), δ = 13.46 
ppm (IH, s, ArOH), δ = 13.56 ppm (IH, s, ArOH); Anal. cale, for C 2 7H 3 1N0 6Si: C, 65.70; H, 
6.33; N, 2.84. Found: С. 65.31; Η, 6.31; Ν, 2.87. 
Compound 17/18: *H-NMR (400 MHz, CDC13, CD3OD): δ = 0.23 ppm (9H, s, Si(CH3)3), δ 
= 2.18-2.21 ppm (2H, H8), δ = 2.70 ppm (3H, s, 3-CH3), δ = 2.94-2.96 ppm (2Η, Н7)), δ = 3.16 
ppm (IH, d, J=18.5 Hz, H10(ax)), δ = 3.31 ppm (IH, d, J=18.5 Hz, H l0(eq)), δ = 3.97 ppm (IH, 
brs, 9-OH), δ = 8.54 ppm (IH, s, ArH), δ = 8.97 ppm (IH, s, ArH), δ = 13.33 ppm (IH, s, 
ArOH), δ = 13.52 ppm (IH, s, ArOH); Anal. cale, for C,3H,3N05Si: C, 65.54; H, 5.50; N, 3.32. 
Found: С, 65.84; H, 5.58; N, 3.34. 
Diels-Alder reaction of diene 4 and dienophile 22. 
0.75 g (6.6 mmol) of 2-rnethyl-2-propenal-N,N-dimethylhydrazone 41 1 and 1.5 g (2.5 
mmol) of 22 l à in 15 ml of dichloromethane were converted as described for dienophile 10 to 
give 260 mg (22%) of Ы and 110 mg (9%) of 15. The compounds were identical as in the 
previous reaction. 
Cis-(+l-)-9-acetyl-4-aza-2-methyl-6,7,9,ll-tetrahydroxy-7,8,9,10-tetrahydronaphthacene-5,12-
dione (23) and Cis-(+l-)-9-acetyl-l-aza-3-methyl-6,7,9,ll-tetrahydroxy-7,8,9,10- tetrahydro-
naphthacene-5,12-dione (24). 
0.3 g (1.38 mmol) of mercury(II) oxide was added to a solution of 0.57 g (1.16 mmol) of Ì4 
or 15 in 22 ml of dichloromethane and 11 ml of 6N sulfuric acid. The reaction mixture was 
sonicated in an ultrasonic cleaning bath for 24 h and then poured into 75 ml of IM HCl. The 
reaction mixture was extracted with chloroform (3 χ 50 ml) and the organic phase was dried 
over anhydrous sodium sulfate. After filtration, evaporation in vacuo and purification by column 
chromatography (chloroform/methanol/glacial acetic acid, 40 : 1 : 0.4) gave 0.38 g (86%) of 23 
or 24. 
Compound 23: m.p. 163-165°C; MS (EI+) mlz: 383 (M+), peakmatch found: 383.10062 
(cale. SeS.lOOSìf^H-NMR (400 MHz) : δ = 2.19 ppm (IH, dd, J=14.5 Hz and J=4.9 Hz, H8(ax)), 
δ = 2.35 ppm (IH, dt, J=14.5 Hz, H8(eq)), δ = 2.44 ppm (3H, s, COCH3), δ = 2.60 ppm (3H, s, 
3-CH3), δ = 2.99 ppm (IH, dt, J=18.7 Hz and J=2.2 Hz, H10(ax)), δ = 3.22 ppm (IH, dd, J=18.7 
Hz and J=2.2 Hz, H10(eq)), δ = 3.77 ppm (IH, d, J=5 Hz, 7-OH), δ = 4.54 ppm (IH, s, 9-OH), δ 
= 5.36 ppm (IH, brs, H7), δ = 8.46 ppm (IH, d, J=2 Hz, ArH), δ = 8.96 ppm (IH, d, J=2 Hz, 
ArH), δ = 13.42 ppm (IH, s, ArOH), δ = 13.68 ppm (IH, s, ArOH). 
Compound 24: m.p. 197-199°C; MS (EI+) mie: 383 (M+); 'H-NMR (400 MHz) : δ = 2.20 
ppm (IH, dd, J=14.5 Hz and J=4.8 Hz, H8(ax)), δ = 2.39 ppm (IH, dt, J=14.5 Hz and J=2.1 Hz, 
H8(eq)), δ = 2.44 ppm (3H, s, COCH3), δ = 2.60 ppm (3H, s, 3-CH3), δ = 3.00 ppm (IH, d, 
J=18.7 Hz, H10(ax)), δ = 3.24 ppm (IH, dd, J=18.7 Hz and J=2.1 Hz, H]0(eq)), δ = 3.84 ppm (IH, d, J=6.5 Hz, 7-OH), δ = 4.51 ppm (IH, s, 9-OH), δ = 5.34 ppm (IH, brs, H7), δ = 8.47 ppm (IH, d, J=2 Hz, ArH), δ = 8.96 ppm (IH, d, J=2 Hz, ArH), δ = 13.41 ppm (IH, s, ArOH), δ = 
13.43 ppm (IH, s, ArOH). 
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4-Aza-4-demethoxy-2-methyl-4'-0-p-nitrobenzoyl-y-N-trifluoroacetyldaunomycin and 7,9-
bis^pi-4-aza-4^emethoxy-2-methyl-4'-0-p-nitrobenzoyl-3'-N-trißuoroacetyldaunomycin (26). 
Under an argon atmosphere, 0.27 ml of trimethylsilyl trinate (1.4 mmol) was added to a 
suspension of 360 mg of 25 (0.66 mmol) and 2 g molecular sieves 4À in a mixture 27 ml of dry 
dichloromethane and 23 ml of dry diethyl ether at -30°C. The mixture was stirred at 0°C for 1 h 
and then cooled to -15°C. A solution of 200 mg (0.52 mmol) of 23 in 55 ml of dichloromethane 
was added and the mixture was then stirred at -15°C for 3 h. Progress of the reaction was 
followed by TLC (ethyl acetate/benzene, 1 : 4 ) . The mixture was poured into a vigorously 
stirred solution of 350 ml of saturated aqueous NaHC03 and the aqueous layer was extracted 
with dichloromethane. The combined organic layers were washed with 100 ml of water and 100 
ml of brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The residue 
was purified by preparative centrifugal thin layer chromatography (dichloromethane/acetone, 9 : 
1) to give, after trituration with n-hexane, 165 mg (42%) of 26 (mixture of diastereomers): m.p. 
179-180°C; MS (FAB) mlz: 758 (MH+); *H-NMR (400 MHz): δ = 1.25-1.28 ppm (3H, 2 χ d, 
J=6.3 Hz, 5'-CH3), δ = 1.98-2.23 ppm (3H, m, H2.(ax)), H2.(eq) and H8(ax)), δ = 2.33-2.53 ppm (IH, m, H8(eq)), δ = 2.42 and 2.44 ppm (3H, 2 χ s, COCH3), δ = 2.60 and 2.62 ppm (ЗН, 2 χ s, 
З-СН3), δ = 2.95-3.08 ppm (IH, 2 χ d, J=19.3 Hz, H10(ax)), δ = 3.24-3.34 ppm (IH, 2 χ d, 
J=19.3 Hz, H10(eq)), δ = 4.28 and 4.51 ppm (IH, 2 χ s, 9-OH), δ = 4.40-4.70 ppm (2H, m, % , 
Η5·), δ = 5.25-5.75 ppm (3H, m, H r , H4. and H7), δ = 6.61-6.66 ppm (IH, 2 χ d, J=7.5 Hz, NH), 
δ = 8.25-8.35 ppm (4H, m, ArH), δ = 8.43-8.47 ppm (IH, ArH), δ = 8.90-8.97 ppm (IH, ArH), δ 
= 13.08 and 13.11 ppm (IH, 2 χ s, ArOH), δ = 13.66 and 13.82 ppm (Ш, 2 χ s, ArOH). 
\-Aza-4-demethoxy-3-methyl-4'-0-p-nitrobenzoyl-V-N-trifluoroacetyl-daunomycin and 7,9-
bis-epi-l-aza-4-demethoxy-3-methyl-4'-0-p-nitrobezoyl-3'-N-trißuoroacetyl-daunomycin (27). 
Under an argon atmosphere, 0.21 ml of trimethylsilyl tonfiate (1.11 mmol) was added to a 
suspension of 283 mg of 25 (0.52 mmol) and 3.5 g molecular sieves 4À in 22 ml of dry 
dichloromethane and 18 ml of dry diethyl ether at -30°C. The reaction mixture was stirred at 
0°C for 1 h and then cooled to -15°C. 155 mg (0.41 mmol) of a solution of 24 in 45 ml of 
dichloromethane were then added and the reaction mixture was stirred at -15°C for 3 h. Progress 
of the reaction was monitored by TLC (ethyl acetate/benzene, 1:4) . The mixture was poured 
into a vigorously stirred solution of 250 ml of saturated aqueous NaHC03 and the aqueous layer 
was extracted with dichloromethane. The combined organic layers were washed with 100 ml of 
water and 100 ml of brine, dried over anhydrous sodium sulfate, filtered and evaporated in 
vacuo. The residue was purified by preparative thin-layer chromatography (dichloromethane/ 
acetone, 9 : 1) to give, after trituration with n-hexane, 126 mg (41%) of 27 (mixture of 
diastereomers): m.p. 192°C (dec.); MS (FAB) mlz: 758 (MH+); ]H-NMR (400 MHz): δ = 
1.26-1.31 ppm (3H, 2 χ d, J=6.6 Hz, S'-CHj), δ = 1.97-2.23 ppm (3H, m, H2-(ax)), H,.(eq) and 
H8(ax)), δ = 2.36-2.53 ppm (IH, m, H8(eq)), δ = 2.42-2.45 ppm (3H, 2 χ s, COCH3), δ = 
2.61-2.62 ppm (ЗН, 2 χ s, 3-CH3), δ = 3.00-3.11 ppm (IH, 2 χ d, J=19.2 Hz, H10(ax)), δ = 
3.29-3.38 ppm (IH, 2 χ d, J=19.2 Hz, H10(eq)), δ = 4.23 and 4.43 ppm (IH, 2 χ s, 9-OH), δ = 
4.42-4.71 ppm (2H, m, H
r
, Η5·), δ = 5.34-5.68 ppm (ЗН, m, H r , H4. and H7), δ = 6.37-6.47 ppm (IH, 2 χ d, J=7.5 Hz, NH), δ = 8.27-8.35 ppm (4H, m, ArH), δ = 8.46-8.48 ppm (IH, ArH), δ = 
8.96-8.98 ppm (IH, ArH), δ = 13.38 ppm (IH, s, ArOH), δ = 13.47 and 13.61 ppm (IH, 2 χ s, 
ArOH). Anal. cale, for C ^ H ^ N - p ^ l H 20): C, 54.15; H, 4.12; N, 5.42. Found: С, 54.18; H, 
3.84; Ν, 5.37. 
4-Aza-4-demethoxy-2-methyl-3'-N-trifluoroacetyldaunomycin and 7,9-bis-epi-4-aza-4-deme-
thoxy-2-methyl-3'-N-trifluoroacetyldaunomycin (29). 
300 mg (0.4 mmol) of 26 were dissolved in 3.9 ml of dichloromethane and 150 ml of 
methanol at 0°C under an argon atmosphere. 4.0 ml of 0.1M sodium hydroxide was added and 
the reaction mixture was stirred under the same conditions for 20 minutes. Progress of the 
reaction was monitored by TLC (dichloromethane/acetone, 9 :1) . Glacial acetic acid was added 
to the reaction mixture until the color of the solution became bright orange. 240 ml of ethyl 
acetate and 240 ml of brine were added to the reaction mixture and the organic layer was 
washed twice with 80 ml of brine, dried over anhydrous sodium sulfate and evaporated in vacuo. 
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The residue was purified by preparative thin-layer chromatography (5% methanol in 
chloroform) to give 106 mg (44%) of 29 (mixture of diastereomers): m.p. 183-185°C; ^-NMR 
(400 MHz): δ = 1.30 and 1.32 ppm (3H, 2 χ d, J=6.6 Hz, 5'-CH3), δ = 1.85-2.20 ppm (4H, m, 
H,.(ax)), H2.(eq), H8(ax) and 2'-OH), δ = 2.32-2.50 ppm (IH, 2 χ brd, J=14.8 Hz, H8(eq)), δ = 
2.41 and 2.43 ppm (3H, 2 χ s, COCH3), δ = 2.60 and 2.61 ppm (ЗН, 2 χ s, 3-CH3), δ = 2.99-3.10 
ppm (IH, 2 χ d, J=19.2 Hz, H10(ax)), δ = 3.27-3.35 ppm (IH, 2 χ d, J=19.2 Hz, H10(eq)), δ = 
3.63-3.73 ppm (IH, Η4·), δ = 4.22-4.48 ppm (2H, H3· and Η5·), δ = 4.33 and 4.51 ppm (IH, s, 
9-OH), δ = 5.28-5.57 ppm (2H, H
r
 and H7), δ = 6.71-6.77 ppm (IH, J=7.5 Hz, NH), δ = 
8.46-8.48 ppm (IH, d, ArH), δ = 8.96-8.98 ppm (IH, 2 χ d, ArH), δ = 13.16 ppm (Ш, s, ArOH), 
δ = 13.65 and 13.82 ppm (IH, 2 χ s, ArOH). Anal. cale, for C ^ H ^ F ^ O ] , , : С, 55.27; H, 4.47; 
N 4.60. Found: С, 54.91; H, 4.29; Ν, 4.55 
l-Aza-4-demethoxy-3-methyl-3'-N-tnßuoroacetyldaunomycin (30a) and 7,9-bis-epi-l-aza-
-A-demethoxy-3-methyl-3'-N-trifluoroacetyldaunomycin (30b). 
207 mg (0.27 mmol) of 27 in 16 ml of dichloromethane and 110 ml of methanol at 0°C 
under an argon atmosphere were converted with 2.7 ml of 0.1M sodium hydroxide and the 
reaction mixture was stirred under the same conditions for 20 minutes. Progress of the reaction 
was monitored by TLC (dichloromethane/acetone, 9 : 1). Glacial acetic acid was added to the 
reaction mixture until the color of the solution became bright orange. 150 ml of ethyl acetate and 
150 ml of brine were added to the reaction mixture and the organic layer was washed twice with 
80 ml of brine, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was 
purified by preparative thin-layer chromatography (5% methanol in chloroform) to give 75 mg 
(45%) of 30 (mixture of diastereomers): JH-NMR (400 MHz): δ = 1.28-1.32 ppm (3H, 2 χ d, 
J=6.6 Hz, 5'-CH3), δ = 1.83-2.23 ppm (4H, m, H2(ax)), H2.(eq), H8(ax) and 2'-OH), δ = 
2.33-2.53 ppm (IH, m, H8(eq)), δ = 2.42-2.45 ppm (3H, 2 χ s, COCHj), δ = 2.60-2.61 ppm (ЗН, 
2 χ s, 3-CH3), δ = 3.00-3.11 ppm (IH, 2 χ d, J=19.2 Hz, H]0(ax)), δ = 3.29-3.40 ppm (IH, 2 χ d, 
J=19.2 Hz, H10(eq)), δ = 3.63-3.73 ppm (IH, Η4·), δ = 4.20-4.54 ppm (3H, 9-OH, H3· and Η5·), δ 
= 5.25-5.55 ppm (2H, m, H
r
 and H7), δ = 6.37-6.47 ppm (IH, J=8.5 Hz, NH), δ = 8.46-8.48 
ppm (IH, ArH), δ = 8.96-8.98 ppm (IH, ArH), δ = 13.40 ppm (IH, s, ArOH), δ = 13.43 and 
13.58 ppm (IH, 2 χ s, ratio " 1 : 1 , ArOH). 
It was possible to separate the diastereomers of 30 by centrifugal thin layer chromatography 
(0.4% glacial acetic acid, 2% methanol, 97.6% chloroform) to give 68 mg (26%) of 30a and 35 
mg (13%) of 30b from 325 mg of 27. 
Compound 30a: m.p. 164-167°C; a 2 0 D = 252° (c = 0.04 in dioxane); MS (FAB) т/г: 609 (MH+); Ή-NMR (400 MHz) : δ = 1.31 ppm (3H, d, J=6.6 Hz, 5'-CH3), δ = 1.87 ppm (IH, m, 
J=13.2 Hz and J=4.0 Hz, H2.(ax)), δ = 2.03 ppm (IH, dt, J=13.2 Hz and J=5.2 Hz, H2.(eq)), δ = 
2.10 ppm (IH, s, 4'-OH), δ = 2.16 ppm (IH, dd, J=14.8 Hz and J=4 Hz, H8(ax)), δ = 2.35 ppm (IH, dt, J=14.8 Hz, 3=2 Hz and J=2 Hz, H8(eq)), δ = 2.43 ppm (3H, s, COCH3), δ = 2.60 ppm (3H, s, 3-CH3), δ = 3.01 ppm (IH, d, J=19 Hz, H]0(ax)), δ = 3.31 ppm (IH, dd, J=19 Hz and J=2 
Hz, H10(eq)), δ = 3.70 ppm (IH, brs, Η4·), δ = 4.20-4.32 ppm (3H, m, Η3·, H5· and 9-OH), δ = 
5.25 ppm (IH, dd, J=4 Hz and J=2 Hz, H7), δ = 5.49 ppm (IH, d, J=4.0 Hz, H r ) , δ = 6.75 ppm (IH, brd, J=8.6 Hz, NH), δ = 8.45 ppm (IH, d, J=1.8 Hz, ArH), δ = 8.95 ppm (IH, d, J=1.8 Hz, 
ArH), δ = 13.38 ppm (IH, s, ArOH), δ = 13.41 ppm (IH, s, ArOH); Anal. cale, for 
C 2 8 H 2 7 F 3 N 2 O 1 0 . l H 2 0: C, 53.68; H, 4.67; N, 4.47. Found: C, 53.76; H, 4.40; N, 4.56. 
Compound 30b: m.p. 139-142°C; a 2 0 D = -248° (c = 0.05 in dioxane); MS (FAB) mlz: 609 (MH+); Ή-NMR (400 MHz) : δ = 1.29 ppm (3H, d, J=6.6 Hz, 5'-CH3), δ = 1.86 ppm (IH, dd, 
J=13.5 Hz and J=5.1 Hz, H2.(ax)), δ = 1.92-2.05 ppm (3H, m, H2(eq), 4'-0H and H8(ax)), δ = 
2.41 ppm (3H, s, COCH3), δ = 2.47 ppm (IH, brd, J=14.8 Hz, H8(eq)), δ = 2.61 ppm (3H, s, 
3-CH3), δ = 3.08 ppm (IH, d, J=19.4 Hz, H10(ax», δ = 3.34 ppm (IH, dd, J=19.4 Hz and J=1.2 
Hz, H10(eq)), δ = 3.64 ppm (IH, brs, Η4·), δ = 4.27-4.36 ppm (IH, m, Η3·), δ = 4.47 ppm (IH, q, 
J=6.6 Hz, Η5·), δ = 4.48 ppm (IH, s, 9-OH), δ = 5.36 ppm (IH, d, J=3.3 Hz, Η Γ ), δ = 5.54 ppm (IH, brs, H7), δ = 6.78 ppm (IH, brd, J=8.6 Hz, NH), δ = 8.46 ppm (IH, d, J=1.4 Hz, ArH), δ = 
8.96 ppm (IH, d, J=1.4 Hz, ArH), δ = 13.38 ppm (IH, s, ArOH), δ = 13.56 ppm (IH, s, ArOH); 
Anal. cale, for Ο^Η^Ρ-,Ν^,,,.Ι H 2 0: C, 53.68; H, 4.67; N, 4.47. Found: C, 53.37; H, 4.43; N, 
4.49. 
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4-Aza-4-demethoxy-2-metfiyldaunomycin and 1, 9-bis-epi-4-aza-4-demethoxy-2-methyl-dauno-
mycin (31). 
The deep purple solution of 96 mg (0.16 mmol) of a mixture of 29 in 20 ml of 0.1M sodium 
hydroxide was stirred for 30 minutes at room temperature under an argon atmosphere. Progress 
of the reaction was monitored by TLC (water/glacial acetic acid/methanol/chloroform, 12 : 26 : 
54 : 160). The pH of the solution was adjusted to 8 with a solution of IM HCl and extracted 
several times with 75 ml of chloroform until the organic layer showed no orange color of the 
product. The combined organic layers were washed with water and brine, dried over anhydrous 
sodium sulfate, filtered and evaporated in vacuo. The residue was dissolved in a minimal 
amount of a mixture of chloroform and methanol (9:1). After 0.3 ml of 0.6M HCl in methanol 
and 50 ml of diethyl ether were added, 60 mg (69%) of the HCl salt precipitated as a mixture of 
diastereomers of 31. MS (FAB) mlz: 575 (M+). 
l-Aza-4-demethoxy-3-methyldaunomycin (32a) and 7,9-bis-epi-l-aza-4-demethoxy-3-methyl-
daunomycin (32b). 
The deep purple solution of 63 mg (0.10 mmol) of a mixture of 30 in 12 ml of 0.1 M sodium 
hydroxide was stirred for 30 minutes at room temperature under an argon atmosphere. Progress 
of the reaction was monitored by TLC (water/glacial acetic acid/methanol/chloroform, 12 : 26 : 
54 : 160). The pH of the solution was adjusted to 8 with IM HCl and extracted several times 
with 50 ml of chloroform until the organic layer showed no orange color of the product. The 
combined organic layers were washed with water and brine, dried over anhydrous sodium 
sulfate, filtered and evaporated in vacuo. The residue was dissolved in a minimal amount of a 
mixture of chloroform and methanol (9 : 1). After 0.2 ml of 0.6M HCl in methanol and 25 ml of 
diethyl ether were added, 40 mg (70%) of the HCl salt precipitated as a mixture of 
diastereomers. 
Mixture of diastereomers 32: a 2 0 D = -67°, (c = 0.075 in methanol); MS (FAB) mlz: 575 (M+); Compound 32a: a 2 0 D = 106°, (c = 0.05 in methanol); MS (FAB) mlz: 513 (MH+-C1); 
^-NMR (400 MHz, D20) : δ = 1.24 ppm (3H, d, J=6.6 Hz, 5'-CH3), δ = 1.86-2.0 ppm (3H, m, 
H2.(ax), H2.(eq) and H8(ax)), δ = 2.25 ppm (IH, brs, H8(eq)), δ = 2.41 ppm (3H, s, COCH3), δ = 
2.52 ppm (3H, s, 3-CH3), δ = 2.86 ppm (IH, d, J=18 Hz, HJ0(ax)), δ = 3.07 ppm (IH, d, J=18 
Hz, H10(eq)), δ = 3.60-3.66 ppm (IH, m, Η3·), δ = 3.76 ppm (IH, brs, H A δ = 4.26 ppm (IH, q, 
J=6.6 Hz, H5.), δ = 4.87 ppm (IH, brs, H7), δ = 5.45 ppm (IH, d, Н Д δ = 8.31 ppm (IH, s, 
АгН), δ = 8.77 ppm (IH, s, ArH). 
Compound 32b: m.p. 168-170°C; a 2 0 D = -156°, (e = 0.045 in methanol); MS (FAB) mlz: 
513 (МН+-С1-);Ж-ЫМК (400 MHz, D20) : δ = 1.19 ppm (3H, d, J=6.6 Hz, 5'-CH3), δ = 
1.82-2.15 ppm (4H, m, H2.(ax), H2.(eq), H8(ax) and H8(eq)), δ = 2.43 ppm (3H, s, COCH3), δ = 
2.52 ppm (3H, s, 3-CH3), δ = 2.82 ppm (IH, d, J=18 Hz, HJ0(ax)), δ = 3.00 ppm (IH, d, J=18 
Hz, H10(eq)), δ = 3.60-3.66 ppm (IH, m, Η3·), δ = 3.73 ppm (IH, brs, Щ), δ = 4.29 ppm (IH, q, 
J=6.6 Hz, Ης.), δ = 4.96 ppm (IH, brs, H7), δ = 5.35 ppm (IH, d, HjO, δ = 8.13 ppm (IH, s, 
ArH), δ = 8.74 ppm (IH, s, ArH). 
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CHAPTER 7 
OVERVIEW OF BIOLOGICAL ACTIVITIES OF KNOWN DAUNOMYCIN AND 
ADRIAMYCIN DERIVATIVES. 
7.1 Introduction. 
The anthracyclines are the class of anti-tumor drugs compounds with the widest spectrum of 
activity against human cancers1. For more than 20 years daunomycin (1) and adriamycin 
(doxorubicin) (2, Figure 7.1) have been amongst the most widely prescribed and effective 
anti-tumor agent. Best results have been obtained against carcinoma of the ovary, lung, breast 
and leukemias. 
The high therapeutic index of these anti-tumor drugs, and also the severe acute cardiotoxicity, 
has stimulated intensive research into the (semi-/total) synthesis of these compounds and their 
analogs. Most of these analogs have been obtained from semi-synthesis. Since isolation of 
daunomycin from a colony of Streptomyces peucetius was optimized and the compound was 
readily available, most chemists have used daunomycin as a starting material in their search for 
new, more active and less toxic derivatives1". 
Figure 7.1 
О ОН О 
MeO O OH ¿ 
Af NHj.HCI 
OH 
Many groups have tried to accomplish total synthesis of daunomycin and its derivatives. Some 
of these approaches have been (partially) successful and several new derivatives have been 
synthesized and tested for their biological activity. However, so far, none of these new 
derivatives have been able to completely replace adriamycin or daunomycin in clinical use1*. 
In this chapter, an overview is given of which mechanisms of action are responsible for the 
anti-tumor activity of the anthracyclines. Their severe cardiotoxicity and attempts towards the 
development of new, less cardiotoxic derivatives are discussed. Examples of modifications of 
several moieties within the molecule are given and their influences on anti-tumor activity are 
summarized. 
1 R - H 
2 R = OH 
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7.2 Anti-tumor activity and mechanism of action. 
From reviews the following five mechanisms appear to have a major contribution to the 
anti-tumor activity of daunomycin and its derivatives: 
1 Intercalation between DNA bases. 
2 Free radical formation. 
3 Covalent binding of reactive metabolites to DNA. 
4 Topoisomerase II-mediated DNA strand breaks. 
5 Interaction with the Cell membrane. 
For the first four mechanisms, anthracycline must be present in the cell nucleus in order to 
become cytotoxic. In contradiction to this, the occurrence of cytotoxicity in the extracellular 
presence of adriamycin, linked to a polymer, supports evidence for an interaction of 
anthracyclines with the cell membrane. 
Intercalation in the DNA strand (Figure 7.2) was the first mechanism proposed for the cytotoxic 
activity and is widely supported2"5. This intercalation will block DNA and RNA synthesis 
within the cell. Free radical formation (Figure 7.3), which might occur after intercalation, may 
result in DNA damage and would then contribute to cytotoxicity6. 
Figure 7.2 
Adrumycin-DNA 
compiei 
Daunomycin and other anthracyclines can undergo both one- and two-electron reduction to give 
the corresponding semiquinone (Figure 7.3, 3) or the dihydroquinone (Figure 7.5, 5)7. A range 
of flavin-centered, NADPH-dependent reductases are capable of accomplishing one-electron 
reduction of anthracyclines (1 -* 3)8. The reduced drug can, in tum, reduce molecular oxygen to 
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Superoxide (»02~) and/or hydrogen peroxide ( H 2 0 2 ) 9 . With hydrogen peroxide only, it can 
produce the highly reactive hydroxyl radical ·ΟΗ. The formed superoxide is converted into 
hydrogen peroxide (Figure 7.3) which, in the presence of FeII+, is converted into the hydroxyl 
radical (·ΟΗ). It has been proposed that the anti-tumor activity of anthracyclines is due to the 
formation and reaction of »OH with cellular macromolecules (Figure 7.3)9. 
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Furthermore, adriamycin7 but not daunomycin, has been shown to be able to reduce Feni+ to 
FeII+. Both the Fen+ and the oxidized adriamycin is able to form the reactive «OH (Figure 7.4). 
Figure 7.4 
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The hydroquinone 5 (Figure 7.5) formed directly via a two electron reduction can lose the sugar 
moiety to give the intermediate enone 6. This enone intermediate will react further with 
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nucleophiles present in the cell (e.g., amines) io 
Figure 7.5 
Over the last few years, it has become clear that the capability of anthracyclines to stimulate the 
cleavage of DNA by the enzyme topoisomerase II (DNA forms a cleavable complex with 
topoisomerase II) must be considered as a potential mechanism of cytotoxicity (Figure 7.611). 
This mechanism is also supported by the fact that adriamycin-resistant cell lines show a 
decrease in either the activity of topoisomerase II or in the formation of a cleavable complex 
with the drug12a-b. 
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This resistance towards adriamycin treatment usually occurs after several treatment periods with 
the drug. The lack of response to one drug is usually accompanied by cross-resistance to several 
other, structurally unrelated agents. This is called Multi-Drug Resistance (MDR)13, and it makes 
the development of new derivatives that lack cross-resistance or the co-administration of 
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so-called cross-resistance modifiers very important14,148. 
The extracellular cytotoxicity of anthracyclines (mechanism 5) has been reviewed by Tritton15. 
In vitro experiments with adriamycin covalently linked with a polymer supported the theory that 
anthracyclines are also active without entering the cell16. The sequence starts with interaction of 
adriamycin on the cell membrane. This triggers a series of interactions that finally lead to DNA 
damage and death of the cell. Tritton also mentions unpublished data that intranuclear 
adriamycin alone cannot cause cytotoxicity. Extracellular adriamycin must also be present 
In conclusion, it can be stated that the mechanism of action of adriamycin and analogs is 
variable, complex and still only partially understood. For the cytotoxicity of anthracyclines, all 
of the discussed mechanisms will probably contribute to the cytoxicity and the overall effect. 
7.3 Cardiotoxicity of anthracyclines. 
Common side effects of most anticancer drugs are bone marrow toxicity and gastro-intestinal 
toxicity, manifesting as fatigue and nausea, respectively. The severity of the side effects 
determines the maximum tolerated dose (MTD). However, anthracycline treatment is more 
frequently accompanied by cardiotoxicity, which develops after repeated treatment. Congestive 
heart failure is often observed after treatment with high doses of anthracyclines or after 
prolonged treatment with lower doses17a,b. 
Biophysical studies have indicated that there is a strong electrostatic interaction between the 
positively charged amine of the anthracycline and highly anionic cardiolipins18. These 
cardiolipins, diphosphatidylglycerols, are a major component of mitochondrial membranes, 
which are present in abundance in cardiac tissue. A correlation between drug-cardiolipin 
association and cardiotoxicity was found. The formed complex is believed to alter the 
membrane environment and it can even cause cell death. 
Free radical formation and consequent superoxide anion production, which are also responsible 
for the cytotoxicity, is also one of the causes for the severe cardiotoxicity19. The heart appears to 
be particularly sensitive to damage by free-radical attack20. Selective damage to the heart may 
also occur by formation of adriamycinol (the 13-dihydro metabolite formed by aldo-keto 
reductase from adriamycin), which seems to accumulate more than adriamycin in the heart. This 
and the fact that adriamycinol is equally active in the formation of free radicals makes it 
possible that the 13-dihydro metabolite is one of the major causes for this cardiotoxicity21. 
7.4 Approaches to more cytotoxic and less cardiotoxic new anthracycline derivatives. 
In order to develop an anti-tumor drug with higher cytotoxic activity and substantially lower 
cardiotoxic effects many new derivatives of anthracyclines have been synthesized l e ·22 ·23 . 
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Weiss1" estimated that the final number will be well in excess of 2,000. A large number have 
been evaluated at the National Cancer Institute, Bethesda, MD, USA. Most of these derivatives 
have been obtained by semi-synthesis; however this technique certainly limits the number of 
accessible derivatives. 
Within the molecules of daunomycin and adriamycin, there are 4 major moieties for 
modification (for numbering, see Figure 7.1): 
/- Side chain modifications at C13 and C14: 
Functional sites which are easily accessible for semi-synthesis of new derivatives are C 1 3 and 
C 1 4 (Figure 7.1). The carbonyl at C 1 3 has been reduced to the dihydro derivative or the 13-deoxy 
analog. The Cj 3 carbonyl has also been functionalized by forming various hydrazones. Esters, 
ethers or amines of adriamycin have been obtained by reaction of 14-bromodaunomycin with 
sodium salts of carboxylic acids, alcohols or amines, respectively22. 
One of these derivatives, Zorubicin or Rubidazone 8 (Figure 7.7) is currently marketed in France 
and is active against acute leukaemias1·22. Several American investigators have, however, found 
that it has no advantages over daunomycin or adriamycin1. 
AD-32 9 (Figure 7.7), a derivative modified both in the side chain and sugar moiety, was 
discovered in 1973. At that time, drug formulation and solubility problems prevented further 
development after Phase I clinical trials, although the compound showed greater anti-tumor 
activity and less cardiotoxicity than the parent compound. Less toxicity in general was also 
found during preclinical testing. At the moment, this compound is being re-evaluated as a 
treatment for bladder cancer, and Phase I studies have been completed1*. 
Some of these derivatives look very promising in in vitro tests or even in in vivo tests, such as 
on L-1210 or P-388 cells (Figure 7.7) but, so far, none of them has been shown to be able to 
replace daunomycin or adriamycin in their clinical use1*. 
Figure 7.7 
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2- Modifications in the ВС rings: 
With respect to redox potential and free radical formation, one can expect that modifications in 
the ВС rings will have a great influence. Most of the modifications made to the ВС rings of the 
anthracycline are obtained through total synthesis. Examples of this are the γ-pyrone (10) and 
γ-thiapyrone (11) derivatives. Compound 10 has been tested and appeared to be cytotoxic25. An 
influence on free radical formation and mechanistic considerations have been the motivation to 
synthesize these analogs. By modifying the quinone structure, chemists had hoped to influence 
both cytotoxicity and cardiotoxicity in a positive way. 
Another group of totally synthetic analogs were the deoxy analogs. Both the synthetic 
availability and the fact that aclarubicin (12, an active compound marketed in Japan and France) 
has no functionality at the 11 position led to chemists developing several 11-deoxydaunomycin 
derivatives (e.g., 13). An example of asymmetric synthesis of 11-deoxydaunomycinons has been 
published by Nanita et aL26. They also describe this type of derivative as more active and less 
toxic. 
Figure 7 8 
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6- and 11-O-methyl derivatives (14 and 15) have also been developed to influence the redox 
potential of the quinone part. An unexpected ВС ring imino derivative was found during 
treatment of daunomycin and adriamycin with methanolic ammonia. Although the 5-imino 
derivatives27 16 and 17 (more active and less cardiotoxic) looked very promising during in vivo 
and in vitro tests, they are not currently being investigated in Phase I or II clinical trials. 
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None of the derivatives of daunomycin or adriamycin with а ВС rings modification is currently 
being marketed or investigated in Phase I or II clinical trials1. 
3- Modifications in the D ring : 
Modifications in the D ring are expected to have an influence on the redox potential and free 
radical formation. 
One of the first D ring derivatives of daunomycin was carminomycin. This 4-demethyl 
derivative of daunomycin, also active against various tumors, was isolated by a Russian group28 
in 1973. The anti-tumor activity of this derivative appears to be inferior to that of adriamycin. 
Another very promising derivative of daunomycin is 4-demethoxydaunomycin. This compound, 
synthesized by Arcamone and colleagues in 197629 was found to be much more active (T/C24 of 
261 versus 179 for daunomycin) and could be administered orally (both daunomycin and 
adriamycin must be intravenously injected). Although used worldwide for acute leukemias 
(intravenous only), 4-demethoxydaunomycin has not replaced daunomycin or adriamycin 
because of its limited bioavailability after oral administration. 
Most of the other known D ring derivatives are only available via total synthesis. Only small 
amounts have been synthesized because of the often very long and difficult synthetic routes to 
the final products. Arcamone's group30,31 have synthesized 1,4-dimethyl 18, 2,3 dimethyl 19, 
1,4-dichloro 20, 2,3-dichloro 21 and (2,3-a)benzo-4-demethoxydaunomycins 22. All of these 
structures were tested in vitro for cytotoxicity and in vivo for anti-tumor activity in a L1210 
leukemia in mice and the results are given in Figure 7.10. All analogs showed high cytotoxic 
activity, but in vivo tests showed lower anti-tumor activity compared to 4-demethoxy­
daunomycin. The lack of efficacy of the chloro derivatives 20 and 21 was ascribed to a different 
in vivo metabolism. 
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More recently, the synthesis of 2-fluoro and 3-fluoro-4-demethoxydaunomycin have been 
published32 as part of a program to probe the interaction of DNA with intercalating agents. No 
biological test results were given, but it would be interesting to compare the test results of these 
Figure 7 10 
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compounds with those of the chloro derivatives. 
4- Modification in sugar moiety : 
In the continuing search for new derivatives, many modifications have been made to the sugar 
moiety33. All natural sugars have been attached to the aglycone. Nowadays, new sugar 
derivatives are still being synthesized and tested22. 
One of the most successful and clinically used derivatives is 4'-epiadriamycin 23 (Figure 7.11). 
The difference with adriamycin is the equatorial hydroxy group at the 4 position of the sugar 
daunosamine. This derivative is active against different tumors34 to daunomycin and 
adriamycin. The reduced cardiotoxicity of 4'-epiadriamycine (although the applied dose is 
higher) is also responsible for the fact that this compound is becoming used more often in the 
clinic1. In contrast to adriamycin, 4'-epiadriamycin is more rapidly metabolized and has the 
possibility to form glucuronides, which facilitates the excretion process33*. 
Other promising derivatives which are currently being evaluated in Phase I or Phase Π clinical 
trials are 4'-deoxy-4'-iodoadriamycin 243 5 (Figure 7.11) and a series of morpholino adriamycins 
25-2736·37 (Figure 7.11). The morpholino compounds have a greater anti-tumor potency than 
adriamycin (25 was shown to be 40 times more potent than adriamycin in in vitro cytotoxicity 
assays), are less cardiotoxic and may have a different mechanism of action. 
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7.5 Conclusions. 
Although more than 2,000 derivatives of daunomycin and adriamycin have been synthesized and 
some of them have been tested for biological activity, none has shown a clear cut advantage 
over adriamycin such that it has replaced the parent compound in the clinic. Many of the 
advantages observed in vitro (higher cytotoxicity and lower cardiotoxicity) disappeared in vivo 
or in Phase I clinical trials. 
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It seems that simple modifications of functional groups, such as esterfication of the hydroxy 
groups or iminisation of carbonyl groups, in the aglycone does not lead to better adriamycin 
derivatives. The question arises whether these simple modifications transform the new drug into 
a "prodrug". After administration, the parent is formed and, although the derivative looks very 
potent in in vitro or simple in vivo tests, no advantages in cytotoxicity or reduced cardiotoxicity 
are then to be found over the parent drug. 
Changing the ВС part of the aglycone has also not so far given better derivatives, although a 
tremendous influence was expected on the redox potential and the free radical formation. 
The most promising derivatives for clinical use at the moment are idarubicin (4-demethoxy-
daunomycin, only obtainable through total synthesis) and 4'-epirubicin (4'-epiadriamycin, 23) 
having a modified sugar part. Together with daunomycin and adriamycin, these drugs are 
currently clinically used worldwide although 4'-epirubicin is not used in the USA. Three other 
anfhracyclines are currently being marketed: in Japan and France: Pirarubicin (although 
4*-tetrahydropyranyl derivative of adriamycin) and Aclarubicin 12; and, in France only, 
Zorubicin 8. The most promising new drugs in development (the morphonyl derivatives 25-27) 
also have a modified sugar moiety. 
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CHAPTER 8 
BIOLOGICAL ACTIVITIES OF NEW DERIVATIVES OF DAUNOMYCIN AND 
ADRIAMYCIN. 
8.1 Introduction. 
Although more than 2,000 derivatives of daunomycin (1, Figure 8.1) and adriamycin (2, Figure 
8.1) have been synthesized1 and their test results as anti-tumor agents have been disappointing2, 
one has to realize that majority of the tested derivatives have been obtained by obvious 
transformations of functional groups in the aglycone. Relatively few compounds have been 
tested in which the aglycone was changed in such a way that can only be achieved by total 
synthesis. 
Still less compounds have been tested in which both the aglycone and the sugar part are 
different from daunomycin or adriamycin, although AD-32 3 (Figure 8.1), a derivative with a 
C1 3,Cj4 side chain and sugar modification, shows the advantages of this approach1. 
Figure 8.1 
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In the preceding Chapters 5 and 6, total syntheses of derivatives of daunomycin have been 
described. The methods were originally developed for the total synthesis of daunomycin and 
4-demethoxydaunomycin. However, the flexibility of our approach has allowed derivatization in 
several steps during the total synthesis. 
In this chapter, we present the biological test results of some new derivatives which can only be 
obtained by total synthesis. Our main goal was to decrease the cardiotoxicity in comparison with 
the parent compound. 
On the basis of the published results described in Chapter 7, we selected three possible moieties 
for modification which fit well in our synthetic approach: 
the acetyl side chain was replaced by an ethynyl group; 
the D ring was replaced by a pyridine ring; 
the amino group in the sugar part was protected by a trifluoroacetyl group. 
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The flexibility of our total synthesis method allowed all possible combinations of these three 
alterations without major changes in the synthetic approach. 
8.2 Сіз.Сц ethynyl analogs of daunomycin. 
By replacing the acetyl group by the ethynyl group, we hoped, because another route of 
metabolism is expected, to prevent the formation of daunomycinol (13-dihydro daunomycin). As 
described earlier (section 7.3), the formation of daunomycinol may be one of the major 
contributions to cardiotoxicity, since the formed 13-dihydro analog tends to accumulate in the 
heart3·4. 
The synthetic route used provided the opportunity to test some new and promising side-chain 
derivatives of daunomycin. Although many groups have introduced the acetyl function by using 
ethynyllithium (for instance, Kelly et al.5), no one has reported the synthesis and testing of the 
ethynyl derivative of daunomycin. The introduction of the acetyl group at the 9 position of 
daunomycin was accomplished by addition of 2-trimethylsilylethynyllithium to 4 and hydrolysis 
of this ethynyl function 5 to the acetyl group 6 (Scheme 8.1). 
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Several ethynyl derivatives of daunomycin and 4-demethoxydaunomycin were synthesized and 
tested for biological activity (Figure 8.2, 7a - 10a and 7b - 9b). The synthesis of these 
compounds was described in Chapter 5. 
The compounds were tested by Dr. Lelieveld of the ITRI-TNO Institute, Rijswijk (The 
Netherlands) for in vitro cytotoxicity using a propidium iodide staining technique6. The method 
is similar to the MTT assay7 with the exception that propidium iodide is used instead of a 
tetrazolium salt to quantify the number of cells. 
The following 5 human tumor cell lines were used: A204 rhabdomyosarcoma (A cells), MCF-7 
mammary carcinoma (M cells), T-24 bladder carcinoma (T cells), WiDr colon tumor (W cells) 
and IgR-37 melanoma (Z cells). These are representative for the cell types against which 
daunomycin and derivatives are usually active. As a reference, 4 known compounds 
(daunomycin 1, adriamycin 2, 4-demethoxydaunomycin 11a and 7,9-bis-epi-4-demethoxy-
daunomycin lib) were also tested at the same time in the same screens. In order to perform the 
experiment, the cell lines were maintained in continuous logarithmic cultures in Dulbecco's 
medium supplemented with 10% fetal bovine serum, together with penicillin (100 IU/ml) and 
streptomycin (100 μg/ml). The cells were mildly trypsinized for passage and for use in 
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experiments. All compounds were dissolved in a small volume of DMSO and the solutions were 
diluted with full growth medium (Dulbecco's MEM + 10% fetal bovine serum) to the desired 
concentration. The plates with tumor cells were prepared and, after 2 days, different amounts of 
the test compounds were added. Each amount was tested in duplicate. After 5 days, the plates 
were treated with a special medium78 and cells were counted by a photomultiplier. This resulted 
in the ІСзд values (the concentration at which 50% inhibition of cell growth occurs) as presented 
in Tables 8.1-8.3. 
The results obtained from these test experiments for the compounds shown in Figure 8.2 are 
collected in Table 8.1. All compounds were tested blind under a coding system HRM. 
7a R, = H, R2 = C=C-Si(Me)3, R3 = COCF3 (HRM03) 
8a R, = H, R2 = C=CH, R3 = COCF3 (HRM04) 
9a R, = H, R2 = C=CH, R3 = H HCl (HRM01) 
10a R,= OMe, R2 = C=CH, R3 = H HCl (HRM12) 
1 Rj = OMe, R2 = COCH3, R3 = H HCl, daunomycin (HRM06) 
2 HRM 08 R, = OMe, R2 * COCH2OH, R3 = H HCl, adriamycln (HRM08) 
11a HRM 05 R, = H, R2 = COCH3, R3 = H HCl, 4-demethoxydaunomycm (HRM05) 
7b R, = H, R2 - C=C Si(Me)3, R3 = COCF3 (HRM07) 
8b Ri = H, R2 - C=CH, R3 = COCF3 (HRM02) 
9b R, = H, R2 = C=CH, R3 = H HCl (HRM09) 
l i b HRM 10 R, = H, R2 = COCH3, R3 = H HCl, 7,9-bis-epi-4-demethoxydaunomycin (HRM10) 
Table 8 1 
COMPOUND 
1 _ 
2 7 b 
11a 
11b 
7a 
8a 
9a 
10a 
7b 
8b 
9b 
A204 
1 
5 
< 0 3 
243 
97 
14 
' 0 3 
21 
2116 
1363 
302 
MCF7 
1 
5 
< 0 3 
420 
151 
14 
1 
39 
2846 
3212 
745 
T24 
4 
16 
< 0 3 
728 
444 
75 
2 
140 
6780 
4369 
1143 
WiDr 
3 
12 
< 0 3 
372 
156 
43 
4 
87 
2495 
1047 
501 
lgR37 
1 
5 
< 0 3 
469 
146 
18 
2 
63 
16510 
3177 
618 
\CX values in ng/ml (ICg^the drug concentration at 50% inhibition of cell growth after 5 days of treatment) 
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In accordance with published results8, our test results show that 4-demethoxydaunomycin 11a is 
much more active than daunomycin 1 or adriamycin 2 in these test cell lines. These test results 
also confirm that the stereochemistry of the 7 and 9 positions is essential. The 7R.9R derivatives 
7b-9b and l ib (optical isomers with unnatural configuration) are not active. Differences that 
can be identified in this series of analogs is the difference in lipophilicity. The ICJQ values show 
a decrease in the sequence 7b > 8b > 9b > l ib, from which we may conclude that 
trifluoroacetyl protection of the nitrogen atom of the sugar moiety or trimethylsilyl protection of 
the ethynyl group deactivates the molecule. 
By comparison of the 7S.9S analogs with the natural stereochemistry, the same conclusion about 
protection of the N atom or the ethynyl group can be drawn (7a > 8a > 9a > 11a). The lowest 
IC50 values (below the detection limit of 0.3 ng/ml) were found for 4-demethoxydaunomycin. 
The values of the analog 8a are quite low and almost comparable with those of adriamycin. 
When we compared the IC^ values of the newly synthesized ethynyl derivatives 9a (0.3-4) and 
10a (21-140) with the acetyl compounds 11a (all < 0.3) and 1 (1-4) respectively, the conclusion 
is justified that replacement of the acetyl group by an ethynyl group deactivates the molecule 
with respect to cytotoxicity. It is interesting to note in this respect that the effects of D ring 
modification and C^.C^ side-chain modification are additive in these in vitro tests. 
However, in comparison with the IC^ values of adriamycin, the IC^ values of both new 
analogs were sufficiently interesting to perform further testing (9a: slightly lower IC^, than 
adriamycin, values comparable with daunomycin and 10a: values somewhat higher than 
adriamycin). If the cardiotoxicity of both compounds is considerably less than for daunomycin, 
these analogs might become interesting. For this reason, we finally selected 3 compounds 
(8a-10a) for further investigation in an in vivo test. The cardiotoxicity was also determined for 
these derivatives. The results are given in section 8.4, together with the results for the most 
promising D ring derivative. 
8.3 Biological activity of new D ring analogs of daunomycin. 
Only a few D ring derivatives have been synthesized and tested for anti-tumor activity because 
most of these derivatives can only be made by total synthesis. The most active, clinically used 
derivative of daunomycin is still the D ring derivative, 4-demethoxydaunomycin. Total synthesis 
of 4-demethoxydaunomycin has been the subject of many publications9,98. The majority of these 
methods have been directed towards 4-demethoxydaunomycin10 only and do not allow the 
synthesis of other D ring derivatives. 
Results from the few derivatives tested show that alterations in the D ring have a strong effect 
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on cytotoxicity (see Chapter 7, section 7.2). 
With the methods described in Chapters 2 and 3, it is possible to obtain new D ring analogs of 
daunomycin. The only limitation is the availability of precursor dienes. 
8.3.1 Daunomycin analogs with a pyridine D ring. 
The study of a daunomycin analog with a pyridine D ring was intriguing for several reasons. 
With respect to its shape, the molecule is closely related to the very potent 
4-demethoxydaunomycin (11a). On the other hand, the pyridine ring will affect the redox 
potential of the quinone-BC part and, consequently, the formation of radicals (see paragraph 
7.2). Finally, the nucleophilic nitrogen offers an additional position for protonation or 
interaction with electrophilic binding sites. 
Our goal was to synthesize a non-substituted D ring with the N atom in either the 4 or 1 position. 
Because of the easy availability of substituted l-aza-3-methylbutadienes and the published 
possibilities for Diels-Alder reactions with these dienes (see Chapter 6), we started with the 
synthesis of 4-aza-2-methyI-4-demethoxy (16) and l-aza-3-methyl-4-demethoxy (17) analogs of 
daunomycin. The synthesis of these compounds is described in Chapter 6. Because of 
difficulties encountered with the separation of the 7S.9S and 7R,9R isomers, all of these 
compounds were first tested as mixtures of diastereomers. For analog 17, we succeeded in the 
separation of both diastereomers (Figure 8.3, 17a/17b) and these separated isomers were also 
tested for their cytotoxicity, together with 17. 
In view of the lower cytotoxicity found for the ethynyl analogs of 4-demethoxydaunomycin, we 
decided not to synthesize the corresponding ethynyl analogs of the pyridine D ring derivatives. 
Table 8.2 shows the IC50 values of the hetereocyclic daunomycin derivatives. Again, as 
reference, the I C ^ values for daunomycin 1, adriamycin 2 and 4-demethoxydaunomycin П а are 
given. The same test method was used as described in section 8.2. 
The position of the nitrogen atom in the D ring certainly seems to have an influence on the IC5Q 
values. If compounds 16 and 17 are compared, a decrease in the IC50 values is observed when 
the nitrogen is in the 1 position. 
Compound 17 was tested twice. In the first trial, when compounds 16 and 17 were tested, 
adriamycin was used as internal reference. In a second trial, when we tested compounds 17a and 
17b. compound 17 was used as internal reference. Differences in I C ^ values were found for all 
cell lines. 
Although the differences are not very large, the conclusion is justified that compound 17 is the 
most active compound. In all five cell line tests, the lowest ICgg values were obtained for 17. 
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Compound 16, with the N atom at the 4 position and the methyl group at the 2 position, is 
clearly the least active compound. 
Figure 8 3 
H,C 
OH ' OH 
16- (HRM15, Rac. rrwrt. of cis-7,9-OR,OH) 17j (HRM11/17, Rac mixt of ci8-7,9-OR,OH) 
Table 8 2 
ІСзд VALUES OF ANTHRACYCLINES1,2,11a and 14-17 TESTED AGAINST HUMAN TUMOR CELL LINES 
COMPOUND 
1 
2 
11a 
1? 
* 
17 
17* 
17a 
17b 
TRIAL 
2 
2 
2 
A204 
1 
4 
< 0 3 
171 
45 
153 
15 
1378 
MCF-7 
1 
6 
<0 3 
334 
67 
118 
17 
1182 
T24 
4 
18 
< 0 3 
949 
173 
140 
17 
512 
WiDr 
3 
16 
< 0 3 
779 
139 
434 
38 
3625 
lgR37 
1 
6 
< 0 3 
459 
77 
67 
7 
713 
ІСзд values in ng/ml ( I C ^ the drug concentration at 50%inhibrtion cell growth after 5 days of treatment) 
compound 17 tested twice in different trials 
Bearing in mind that the two compounds were tested as mixtures of diastereomers (7R.9R and 
7S.9S) and the activities may increase using only the natural isomer, we decided to separate and 
test both isomers of compound 17 (Chapter 6). These test results are given in Table 8.3. For the 
determination of these I C ^ values, compound 17 was also used as internal standard and, in 
Table 8.3, the adjusted values are given. Only this will allow us to compare the I C ^ values of 
17a with those of daunomycin 1. and adriamycin 2. 
When we compare the I C ^ values of adriamycin 2 with the adjusted ICJQ values of compound 
17a, we see that these values are almost identical and that both compounds possess almost 
identical cytoxicity towards all tested cell lines. 
Although there is no improvement in the cytotoxicity of compound 17a compared with 
daunomycin I or adriamycin 2, the decision was made to do additional tests with this 
compound. This decision was made because an acceptable cytotoxicity together with a reduced 
cardiotoxicity, and the possibility to overcome drug resistance, play an important role in the 
acceptance of a new anti-tumor drug in clinical use. 
Table 8 3 
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О ОН о 
H,C' M J U U I
 Г О Н 
н,с 
-сн, 
17· (HRM 18) 17b (HRM 19) 
Values of 17а and 17b adjusted to internal standard compound 17 
COMPOUND 
2 
17a 
17 
17b 
A204 
4 
4 
45 
405 
MCF7 
6 
10 
67 
671 
T24 
18 
21 
173 
632 
WIDr 
16 
12 
139 
1161 
lgR37 
6 
θ 
77 
820 
ICgg values in ng/ml ( ІС
И
 = the drug concentration at 50% inhibition of cell growth after 5 days of treatment) 
Because of the difficulties encountered with the separation of 17a and 17b (see Chapter 6, 
section 6.2), compound 17 (a mixture of diastereomers) was used initially, prior to further 
testing. Together with the three compounds 8a-10a (see paragraph 8.2), compound 17 was tested 
in a L1210 in vivo system and the acute toxicity and cardiotoxicity were determined. The results 
of these test are described below. 
8.4 In vivo test (L-1210) and (cardio)toxicity tests of new anthracyclines. 
A: Acute toxicity: Maximum Tolerated Dose andlor50% Lethal Dose (LD50). 
In order to establish the optimal dose for the L1210 in vivo tests, the acute toxicity of these 
drugs was estimated. For this purpose, mice were treated with a single intraperitoneal injection 
of the drug11. They were observed for a period of 30 days and acute drug toxicity was estimated 
by determining the MTD (Maximum Tolerable Dose) and/or the L D ^ (Lethal Dose to 50% of 
test animals). These estimations (Table 8.4) were used in the determination of optimal doses for 
the L1210 in vivo test. 
As can be expected from earlier published results8, the tolerated doses of the N-trifluoroacetyl 
protected compound 8a are much higher than for the corresponding HCl salt 9a. The difference 
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between the ethynyl daunomycin derivative 10a and the ethynyl 4-demethoxydaunomycin 
analog ?a is also not unexpected. The value for the LD^, for 17 looks promising, certainly since 
the optimal doses of this compound are lower. The normally used optimal dose13 for in vivo 
L1210 testing for daunomycin 1, adriamycin 2 and 4-demethoxydaunomycin 11a are 2.9, 2.9 
and 0.6 mg/kg, respectively. 
Table 8.4 
LDJQ values of compounds 8a -10a and V7 as estimated by Lelieveld13 
COMPOUND 
8§ 
9a 
10a 
17 
Estimated \.DM value 
50-150 mg/kg 
8 mg/kg 
20-50 mg/kg 
20-50 mg/kg 
B: In vivo L1210 test. Mouse bearing lymphoblastic leukaemia. 
The L1210 system (lymphoblastic leukaemia) is, together with the P388 system (lymphatic 
leukaemia system), one of the most used test systems to compare in vivo anti-tumor activity of 
new and existing drugs. After the in vitro test on human tumor cell lines, the most promising 
new analogs are usually tested in vivo to see whether the observed anti-tumor activity is still 
seen. If both tests are successful, the next step is usually a study against solid mouse tumors or 
against human tumors in nude mice. The leukaemia cell line L1210 arose in 1948 in the spleen 
and lymph nodes of an 8 month-old female DBA mouse following skin painting with 0.2% 
3-methylcholanthrene in ether12. Since then, this lymphoblastic leukaemia in DBA/2 or related 
hybrid mice has been used for the determination of anti-tumor activity of drugs. The 
Radiobiological Institute of TNO in Rijswijk (The Netherlands), at which our compounds have 
been tested, introduced the L1210 leukaemia in 1969. The used method is described in reference 
13. 
The test results are given in Table 8.5. Compound 9a, which looked very promising in the in 
vitro tests, now appears to be inactive and the T/C value is even less than 100%. As expected, 
the derivative of 4-demethoxydaunomycin was used at the lowest dose level. It is possible that 
the results would be better if the dose was lowered even further. At the tested dose levels the 
compound might still be too toxic and cause acute toxicity. All we see at the moment is an 
increase of the T/C value at lower doses. Further investigations will be necessary to establish the 
optimal dose level. 
The N-trifluoroacetyl derivative 8a was administered, as expected, at the highest dose level in 
this test. Reduction from 140 mg/kg to 70 mg/kg gave an increase in the T/C value (110 to 170). 
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A value of 170 is comparable with the value of adriamycin in other L1210 tests. The high dose 
level and the limited solubility (see also cardiotoxicity test) make the usability of this compound 
questionable. The T/C value might be further increased by lowering the dose level, as an optimal 
value between anti-tumor activity and (acute) toxicity is usually observed at a certain dose. 
The daunomycin analog 10a was tested in a separate trial. A group of 5 mice was tested and the 
variation in the dose was between 15 and 25 mg/kg. The variation in T/C values was between 
140 and 180%. The fact that the dose of 20 mg/kg had the lowest T/C value was of some 
interest. As with 8a, this compound was classified as active but not spectacularly so. The higher 
dose compared to the 4-demethoxy analog 9a corresponds with the difference in dose/activity 
relationship between daunomycin and 4-demethoxydaunomycin. 
Compound 17, tested as a mixture of diastereomers, appeared to be very active at the tested 
level of 40 mg/kg (T/C = 225%). Increase or decrease of the dose was followed by a decrease in 
the T/C value. In this case, the optimum between anti-tumor activity and toxicity level was 
established. The fact that long-term survivors were found was also very promising. None of the 
other tested compounds resulted in any long term survivors. For this compound, the 
cardiotoxicity test became very important 
Table 8 5 
In vivo anti-tumor activity of compounds Ba - 10a and 17 tested with 0ВАУ2 mee bearing L1210 (lymphoblastic leukaemia) 
COMPOUND 
control 
8a 
9a 
10a 
я 
DOSE 
(mg/kg) 
0 
70 
100 
140 
4 5 
6 0 
8 0 
15 
20 
25 
30 
40 
50 
MEAN BODY WEIGHT (g) 
day1 
251 
261 
260 
250 
250 
255 
256 
28 
29 
30 
24 4 
259 
251 
day5 
259 
256 
235 
228 
226 
208 
19 9 
236 
236 
232 
day 7 
27 4 
26 1 
24 3 
219 
216 
186 
18 1 
24 6 
24 8 
23 2 
day 8 
29 
29 
29 
MST 
(day) 
10 
17 
13 
11 
9 
8 
7 
18 
14 
16 
15 
22 5 
16 
T/C 
100 
170 
130 
110 
90 
80 
70 
180 
140 
180 
150 
225 
160 
LTS 
079 
076 
0/6 
0/6 
076 
076 
0/6 
075 
075 
0/5 
1Л 
2« 
06 
С: In vitro/in vivo test for cardiotoxicity. 
Usually, the cardiotoxicity of anthracyclines and other anti-tumor antibiotics is determined by 
treatment of a group of animals with test compounds for a long period of time. Cardiac lesions 
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are then scored after death. Over the last few years, acute models have been developed to allow 
prediction of chronic cardiotoxicity15. An acute model is, of course, much faster than a chronic 
model and there are indications that chronic cardiotoxicity might be caused by accumulation of 
several acute effects15. These tests were performed at the Department of Oncology in 
cooperation with the Department of Pharmacochemistry of the Free University of Amsterdam 
(The Netherlands). The compounds were tested for their negative inotropic effect on the isolated 
mouse left atrium, as described by De Jong et a/.15.At several concentrations of the drug, during 
a period of 2 hours, the decrease in the basal contractile force of the atrium was measured. The 
influence of the drug on the heart rate was established. A semi-logarithmic plot of the obtained 
ratios vs. the concentration was made (Dose Response Curve, DRC) and the ІС5П (drug 
concentration resulting in 50% decrease of the initial (basal) contractile force) were determined. 
In addition to the newly synthesized compounds 8a - 10a and 17 adriamycin was measured as 
reference. 
The results shown in Table 8.6 lead to the following conclusions. 
the solubility of 8a is very low. The value measured at 30 μΜ is 78 ± 9%. Because micelles 
were even formed at 1 μΜ, it might be concluded that the free concentration in the organ 
bath was 1 μΜ or less. Adriamycin 2 gave a contractile force of 75 ± 8% at a concentration 
of 3 μΜ, which makes 8a at least as cardiotoxic as adriamycin. 
compound 9a is 4 times more cardiotoxic than adriamycin 2. 
the cardiotoxicity level of 10a is comparable with that of adriamycin (17.2 vs 21.9). 
compound 17 is less cardiotoxic than adriamycin. The values for these two compounds are 
42.9 and 21.9, respectively. 
Table β 6 
Cardiotoxicity test of compounds 2, 8a - 10a and 17 
COMPOUND 
2 
fa 
9 · 
10a 
17 
Cone 
(μΜ) 
3 
10 
30 
nova 
3 
10 
30 
3 
10 
30 
30 
50 
100 
Number of 
experiments 
2 
4 
5 
% of basal 
contracten force 
75 ± 8 
6 0 ± 6 
46 + 7 
ues measured because of limited solubility 
4 
3 
4 
2 
4 
4 
4 
4 
3 
60 + 6 
3 2 ± 8 
33 + 2 
84 ± 6 
61 ± 6 
39 ± 7 
5 9 ± 6 
49 ± 1 6 
22 ± 5 
ICgQ (μΜ) 
219 
477 
172 
429 
Correlation 
coefficient 
1000 
-
1000 
0 985 
95 
8.5 Conclusions. 
From the daunomycin and adriamycin analogs that we synthesized (Chapters 5 and 6), 15 were 
tested in vitro against five human tumor cell lines. The compounds with the unnatural 
stereochemical configuration (R,R) on the 7 and 9 positions (7b - 9b) were expected to have low 
or no cytotoxicity. This was indeed the case, and no further development or testing has been 
carried out with these analogs. The other derivatives (7a - 10a) with the natural stereochemical 
conformation (S,S) appeared to be active in these in vitro tests. Because of the relatively high in 
vitro activity compared to daunomycin and adriamycin, compounds 8a, 9a and 10a were 
selected for further testing. 
Compound 8a is the N-trifluoroacetyl derivative of ?a. As might be expected, when comparing 
for instance optimal doses in P388 tests of daunomycin and N-trifluoroacetyl-daunomycin8, the 
LD5Q value of the N-protected derivative was higher. However, when we compare the T/C 
values of 8a and 9a, the in vivo test showed a higher T/C value for 8a. As explained earlier, the 
T/C value of 9a may be higher at lower doses. The T/C value of 8a also does not seem to be 
optimized. Further testing will be necessary to confirm these expectations, although cardio-
toxicity tests show that both compounds are more cardiotoxic than adriamycin. 
The in vivo test results for 10a are rather confusing. The highest T/C values were found at 2 
different dose levels (15 and 25 mg/kg), whereas at the dose level of 20 mg/kg the T/C is lower. 
When T/C values of daunomycin (T/C = 150 at 4 mg/kg8) and adriamycin (T/C = 141 at 2.9 
mg/kg8) are compared with the value of 10a (T/C = 180 at 15 mg/kg), it cannot be concluded 
that replacement of an acetyl of hydroxyacetyl group by an ethynyl group has a positive 
influence on the T/C. Although the T/C value is higher, the dose is also 4-5 times higher than for 
daunomycin and adriamycin. Certainly, 10a is slightly more cardiotoxic than adriamycin. For 
10a, further tests at dose levels below 15 mg/kg are also required before the conclusion can be 
drawn that replacement of the acetyl group by the ethynyl group has a positive influence (or not) 
on the anti-tumor activity of the analog. A lower cardiotoxicity level would support the 
assumption that the metabolism routes of the tested compounds are different. Our results, 
however, do not allow such a conclusion at this moment. 
The last group of tested analogs, obtained by total synthesis, contain a nitrogen atom in the D 
ring. Because of the difficulties that were encountered with the separation of the diastereomers 
(7R.9R and 7S.9S, configurations of the aglycones), all these compounds were tested as a 
mixture of diastereomers, which were present in almost equal amounts. This means that only 
50% of the compound possess anti-tumor activity (compare analogs 11a and l ib, see Table 8.1). 
From the tested analogs (16 and 17), compound 17 appeared to have the highest in vitro activity. 
Although the cytotoxicity of 16 was only slightly lower the decision was made to do further 
testing only with 17. Small amounts of both diastereomers were isolated and also tested in vitro. 
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Surprisingly, the natural isomer (7S.9S) appeared in average more than 8 times as potent as the 
mixture of diastereomers and was comparable with that of adriamycin (Table 8.2). 
The mixture of diastereomers (17) was tested in vivo (LI 210) for anti-tumor activity. After an 
estimation of the LD^ value (20-50 mg/kg), a T/C value of 225 (dose 40 mg/kg) was found for 
17. Two long term survivors (> 60 days) were also reported. This means that those mice had 
recovered from the effects of the injection of tumor cells. Furthermore, the cardiotoxicity test 
showed that this analog was less cardiotoxic than adriamycin. These results are very promising 
and further testing is required. The next step will be a study against solid mouse tumors or 
against human tumors in nude mice. Before the next step is taken, more material must be made 
available. The synthesis of 17 must be optimized and the separation of diastereomers must be 
improved. In further testing, it is advisable to use only diastereomer 17a. Cardiotoxicity then 
might be considerably lower and the L1210 test might results in even more long term survivors 
when repeated with 17a. 
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grown to 1.5 χ 109, they will cause death of the mice. The cell line is maintained by 
weekly transfer of 105 leukaemic cells injected i.p. into hybrid mice. Since 1990, male 
DBA/2 mice have been used as recipients in experimental work. On several occasions, 
batches of L1210 leukaemia were frozen in liquid nitrogen. Since 1980, an ampoule with 
cells is thawed at least twice a year. This procedure is followed to minimize the chance of 
changes in behaviour and/or properties of the leukaemic cells. Test method: At day 0,105 
L1210 cells were injected into a male DBA/2 mice. After 24 hours, the drugs were 
administered to a group of 6 mice. All drugs were suspended in 2% carboxymethyl-
cellulose and administered intraperitoneally as a single injection in a volume of 10 ml/kg. 
Each drug was tested at three dose levels. The highest dose (approx. LD50 value) was 
expected to show some toxicity. The untreated control group consisted of 9 mice. The 
average body weight of the group was determined several times and the survival time of 
the mice was recorded. The results are expressed as median survival time (MST) of treated 
over control mice (T/C%). The number of long term survivors was also determined (> 60 
days). 
Skipper, et al., Cancer Chemother. Rep., 1964,35,1. 
De Jong, J., Schoofs, P.R., Onderwater, R.C.A., Pinedo, H.M., Van der Vijgh,, WJ.F. and 
Bast, Α.,Res. Commun. Chem. Pathol Pharmacol, 1990,68, 275. 
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SUMMARY 
In 1957 a red pigment was isolated from a colony of Streptomyces peucetius which was called 
daunomycin (1, Figure S.l). Six years later the compound was shown to have an anti-tumor 
activity. In 1969 the isolation of adriamycin 2 from a variant strain of Streptomyces peucetius 
named caesius was reported. This compound, which is in clinical use since 1974, now still 
belongs to the most widely used anti-tumor antibiotics as it has the widest spectrum of 
anti-tumor activity of all chemofherapeutic agents. 
Figure S.l 
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Over the past 30 years an intensive research has been stimulated in order to find new and more 
active derivatives. Most of these methods were semi-synthetic. Only a few total syntheses of 
new adriamycin analogs have been described. The goal was to develop a method which allowed 
the highest possibility for variations in both structure and substituents. 
The coupling of the aglycone 3 and the sugar daunosamine 4, as well as the synthesis of the 
sugar, were well described in the literature1"6. The work in this thesis is mainly focused towards 
the synthesis of the aglycone. Although the aglycone can be synthesized by several methods, the 
Diels-Alder approach is chosen. A priory several Diels-Alder strategies are possible 5 (Figure 
S.2) but, the methods described in this thesis all start from the commercially available 
naphthazarin 6. 
Figure S.2 
In Chapter 2 a multigram synthesis of the aglycones (+/-)-daunomycinone 3 (R = H) and 
(+/-)-4-demethoxydaunomycinone via route 1 (A + BCD, Figure S.2) is described. When 
repeating the method of Kelly et al.7 some serious problems were encountered. 
MeO 
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In order to control the regioselectivity a mono/7-nitrobenzyloxycarbonyl protected naphthazarin 
was used. To prevent the tedious oxidation of the /»-nitrobenzyloxycarbonyl protected 
cycloadduct 7 (Figure S.3), the oxidized cycloadduct of naphthazarin 6 (Figure S.2) and 
l-methoxy-l,3-cyclohexadiene is protected. 
Figure S.3 
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In this way oxidized and protected cycloadduct is isolated on a multigram scale. Also the use of 
l-terf-butoxy-3-trimethylsilyloxybuta-l,3-diene instead of l,3-bis-trimethylsilyloxybuta-l,3-
diene improves the solubility and stability of the hydrolyzed cycloadduct. In the subsequent 
Grignard reaction of 8 with 2-trimethylsilylthynyllithium the stereoselectivity is strongly 
controlled by the tert-butoxy group which results in the exclusive formation of the 
cis-7-terf-butoxy-9-hydroxy compound 9 (Figure S.3). The use of 2-trimethylsilylthynyllifhium 
also reduces the number of ethynyl equivalents from 30 to 6. In this way both 
(+/-)-daunomycinone and (+/-)-4-demethoxydaunmycinone are synthesized on a gram scale with 
overall yields of 20% and 30%, respectively. The method as described in this Chapter has also 
been the basis for the synthesis of the new Сіз.С^ ethynyl analogs of daunomycin and 
4-demethoxydaunomycin as described in Chapter 5. 
In Chapter 3 the synthesis of (+/-)-daunomycinone is described following the ABC + D method 
(route 2, Figure S.2) which was originally developed by Krohn et al. This route is modified, 
improved and is used for the synthesis of new pyridine D ring analogs as described in Chapter 6. 
Diels-Alder reaction of naphthazarin 6 (Figure S.2) and l-terf-butoxy-3-trimethylsilyloxy-
buta-l,3-diene gives after oxidation the ABC fragment 10 (Figure S.4). Also here control of the 
stereoselectivity by the teri-butoxy group in the subsequent reaction with 2-trimethylsilylthynyl­
lithium results in the exclusive formation of the cis-l-fórf-butoxy-3-hydroxy compound 11a 
(Figure S.4). In comparison to Krohn et α/.8 the tedious separation by preparative thin layer 
chromatography of the cis- and trans-l,3-dihydroxy compound 12 (Figure S.4) is prevented. 
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The subsequent Diels-Alder reaction of 11a with l-methoxy-l,3-cyclohexadiene gives as a main 
product the cycloadduct with the undesired regiochemistry. In order to prevent formation of the 
unwanted regioisomer compound 11a is protected with/»-nitrobenzyl chloroformate to give l ib 
with a yield of 70%. Besides lib, small amounts of the other mono protected compound (8 
position), the diprotected compound (5 and 8 positions) and 11a are isolated. In the Diels-Alder 
reaction the regioselectivity is reversed, although, not completely (9 : 1). After oxidation (under 
the basic conditions of the oxidation the trimethylsilyl group is removed) and deprotection, the 
regioisomers are separated by column chromatography and compound 13 (Figure S.5) is 
converted into (+/-)-daunomycinone. 
Figure S.5 
ОН О 
MeO OH O O-t-Bu 
13 гас mixt. oí cis-7,90tBu,OH 
In Chapter 4, an attempt towards the synthesis of optically active aglycones 3 (Figure S.l) is 
described. It is shown that it is possible to obtain the cycloadducts with a reasonable to high 
diastereomeric excess when using chiral l-alkoxy-3-trimethylsilyloxybuta-l,3-dienes in the 
Diels-Alder reaction with quiñones such as naphthazarin, juglone, naphthoquinone and 
benzoquinone. Especially in the reaction of benzoquinone 14 with l-[l-(p-methoxyphenyl)-
ethoxy]-3-trimethylsilyloxybuta-l,3-diene 15 a high d.e. is obtained, only one isomer 16 
(Scheme S.l) is detected by *H-NMR spectroscopy. When the alkoxy group in 15 contained π or 
ρ electrons in the appropriate position the diastereomeric excess is larger than can be expected 
on account of the size of that particular group. This is explained using the perpendicular model 
of Siegel et aß. 
о о _ . 
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When using the S-(-)-diene 15 (R=H) derived from S-(-)-l-phenylethanol the absolute 
configuration (S) of the newly formed chiral center of compound 16 (R=H) is determined by 
X-ray analysis. 
Scheme S.l 
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When applying the optical active diene 15 (R=H) in the Diels-Alder reaction with naphthazarin 
for the synthesis of the optically active aglycone, according to the method as described in 
Chapter 2, problems are encountered with the removal of the chiral alkoxy group. After 
Diels-Alder reaction, subsequent oxidation, introduction of the ethynyl group and transformation 
of that ethynyl group into an acetyl group an optically active compound is obtained. When the 
chiral alkoxy group is removed using trifluoroacetic acid, compound 12 is obtained (Figure S.4) 
but, this compound lost optical activity. Further investigations have to be focused on the use of 
an appropriate chiral alkoxy group which can be removed under mild acidic conditions to 
prevent epimerization of 12. 
In Chapter 5, the synthesis of new Cj3,C14-analogs of daunomycin 17 (X=OMe) and 
4-demethoxydaunomycin 17 (X=H, Figure S.6) are described. These aglycones are prepared 
using the method as described in Chapter 2. 
Figure S.6 
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According to the literature method of Terashima et al.4 the aglycones 18 are coupled with the 
protected sugar daunosamine 19. After coupling of the sugar, separation of diastereomers is 
possible. The ethynyl analogs of daunomycin and 4-demethoxydaunomycin are prepared and 
tested on anti-tumor activity. The results of these test are reported in Chapter 8. 
Chapter 6 describes the total synthesis of new pyridine D ring derivatives of daunomycin. The 
ABC ring fragments 1 la/1 lb (Figure S.4), as synthesized in Chapter 3, are used in the 
Diels-Alder reaction with l-(dimethylamine)-3-methyl-l-aza-buta-l,3-diene 20 to give the 
cycloadducts 21 and 22 after 1,4-elimination, oxidation and deprotection (Figure S.7). 
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X 
20 
H,C 
О OH 
= - S K C H 3 ) 3 
OH 
H,C 
• = - S K C H 3 ) 3 
OH 
О OH O-t-Bu — О OH Ò-t-Bu 
* = гас. mixt, of os-7,9-OlBu,OH 
22 
103 
The reactions are performed under high pressure (15 kbar). By using the /7-nitrobenzyIoxy-
carbonyl protecting group it is possible to influence the regioselectivity (ratio 21 : 22 is 1 : 2 for 
dienophile 11a. the ratio is 7 : 3 for dienophile lib). At normal pressure conversion is much 
slower and decomposition of the ABC fragment is observed due to the elimination of water and 
terf-butyl alcohol. 
The 2-trimethylsilylethynyl groups are hydrolyzed to the desired acetyl groups using HgO and 
diluted sulfuric acid. The racemic aglycones are coupled with the protected daunosamine (19. 
Figure S.6) to give the corresponding protected D-ring analogs of daunomycin 23 and 24 (Figure 
S.8). 
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After deprotection, the HCl salts of the new D ring analogs are obtained and these are tested as 
racemic mixtures on their anti-tumor activity. The results of these tests are given in Chapter 8. 
For compound 24 it was possible to separate the diastereomers and both diastereomers are also 
tested on anti-tumor activity. 
In Chapter 7 an overview is given of the biological activities of daunomycin and its derivatives. 
According to the literature five mechanisms contribute to the anti-tumor activity of this class of 
compounds. The mechanism of action is variable, complex and still partly understood. The most 
common side effect is the dose related cardiotoxicity. 
Much effort has been devoted to the development of new analogs with a higher cytotoxic effect 
and a substantial lower cardiotoxicity. Most of these analogs were obtained by semi-synthesis. 
The anthracyclinones have 4 major moieties for modification (Figure S.9). 
- Modification of the С 1 3 .С 1 4 side chain. 
- Modification of the ВС rings. 
- Modifications of the D ring. 
- Modification of the sugar moiety. 
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Although more than 2,000 derivatives have been synthesized and a part of them were tested on 
their biological activity, none of them ever could replace the parent compound in clinical use. 
In Chapter 8 the test results of the new derivatives of daunomycin and their intermediates, as 
reported in the Chapters 5 and 6, are described. All new compounds are tested on their in vitro 
toxicity using five different human tumor cell lines. The test results show that the 
stereochemistry at position 7 and 9 is essential for the activity. From the Cl3,Cu ethynyl 
derivatives in general the HCl salts are the most active compounds and protection of the 
З'-nitrogen group or the 4'-hydroxy group results in lower cytotoxic activity. Both compounds 
with a pyridine D ring show good promise. The HCl salt of 28 shows the highest activity (the 
compound is tested as pair of diastereomers). Four compounds are further investigated. The 
LDso, in vivo L1210 cytotoxicity and in vitro cardiotoxicity are determined for compounds 25 -
28 (Figure S.10). 
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The results so far are promising for further testing of compound 28. In further testing, it is 
advisable to use only the 7S,9S diastereomer 28a. This compound shows a 8-10 times higher in 
vitro activity than the (1:1) mixture of diastereomers of 28. 
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SAMENVATTING 
In 1957 werd een rode kleurstof, die daunomycine l (Figuur S.l) werd genoemd, geïsoleerd uit 
een stam van microorganismen genaamd Streptomyces peucetius. Zes jaar later werd de 
antitumoractiviteit van deze verbinding aangetoond. In 1969 werd een tweede verbinding 
genaamd adriamycine 2, geïsoleerd uit een variant van de oorspronkelijk stam, Streptomyces 
peucetius caesius. Deze verbinding, die al sinds 1973 in de kliniek wordt toegepast, is heden ten 
dage nog steeds een van de meest gebruikte antitumorverbindingen met het grootste 
werkingsgebied van alle bestaande antitumorverbindingen. 
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Gedurende de laatste 30 jaar is veel onderzoek gedaan om nieuwe en nog actievere derivaten te 
ontwikkelen. De meeste van deze methoden waren semi-synthetisch. Er zijn maar weinig 
voorbeelden beschreven waarin nieuwe derivaten zijn gemaakt via totaalsynthese. Doel van het 
onderzoek was om een zo flexibel mogelijke methode te ontwikkelen. 
Zowel het koppelen van het aglycon 3 met de suiker daunosamine 4 als de synthese van de 
suiker zijn beschreven in de literatuur1"6. Daarom concentreet het onderzoek in dit proefschrift 
zich voornamelijk op de synthese van het aglycon. Hoewel het aglycon op verschillende 
manieren gemaakt kan worden is gekozen voor de Diels-Alder benadering. Op zich zijn 
meerdere Diels-Alder Strategien mogelijk 5 (Figuur S.2) maar dit proefschrift beschrijft enkele 
benaderingen die uitgaan van het commercieel verkrijgbare naftazarine 6. 
Figuur S.2 
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Hoofdstuk 2 beschrijft de synthese via route 1 (A + BCD, Figuur S.2) van de aglyconen 
daunmycinon 3 (R = H) en 4-demethoxydaunomycinon, op multigram schaal. Wannner daarbij 
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de route van Kelly et al.7 wordt gevolgd, ontstaan er serieuze problemen. Kelly gebruikt 
naftazarine dat beschermd is met een /юга-nitrobenzyloxycarbonyl groep om de Diels-Alder 
reactie regioselectief te laten verlopen. Om de niet reproduceerbare oxydatie van het gevormde 
cycloadduct 7 (Figuur S.3) te vermijden is een methode ontwikkeld om het cycloadduct van 
naftazarine en l-methoxy-l,3-cyclohexadieen te maken wat vervolgens regioselectief 
beschermd wordt met de door Kelly gebruikte beschermgroep. 
Figuur S.3 
O O-p-NCBz о ' " О 0 ' И o 
S - T M S 
СН30 О н , 0 СНэО 0 . н О Oí-Bu CHa¿ ¿^ о O-t-Bu 
7 8 9 гас mengsel van cis-7,9-OtBu,OH 
Op deze manier is mogelijk om het beschermde cycloadduct op multigram schaal te isoleren. 
Het gebruik van l-tert-butoxy-3-trimethylsilyloxy-l,3-butadieen in plaats van 1,3-bistrimethyl-
silyloxy-l,3-butadieen levert een stabieler en beter oplosbaar cycloadduct op. In de daarop 
volgende Grignard-reactie met 2-trimethylsilylethynyllithium wordt de stereoselectiviteit 
bepaald door de terf-butoxy groep, met als gevolg dat alleen de cis-7-te/ï-butoxy-9-hydroxy 
verbinding wordt gevormd. Door gebruik te maken van 2-trimethylsilylethynyllithium kan het 
aantal ethynyl equivalenten teruggebracht worden van 30 naar 6. Op deze manier kan op een 
schaal van meerdere grammen zowel (+/-)-daunomycinon als (+/-)-4-demethoxydaunomycinon 
gesynthetiseerd worden met een overall opbrengst van respectievelijk 20% en 30%. De methode 
zoals beschreven in Hoofdstuk 2 is ook gebruikt voor de synthese van de C13,C14-ethynyl 
derivaten van daunomycine en 4-demethoxydaunomycine zoals beschreven in Hoofdstuk 5. 
In Hoofdstuk 3 is de synthese van (+/-)-daunomycine beschreven volgens de ABC + D methode 
(route 2, Figuur S.2) zoals oorspronkelijk ontwikkeld door Krohn et al.6. Deze methode is 
aangepast, verbetert en uiteindelijk gebruikt voor de synthese van nieuwe prydine ring-D 
derivaten zoals beschreven in Hoofdstuk 6. De Diels-Alder reactie van naftazarine 6 met 
l-te/t-butoxy-3-trimethylsilyloxy-l,3-butadieen resulteert na oxydatie in de vorming van het 
ABC fragment 10 (Figuur S.4). Ook hier zorgt de teri-butoxy groep voor de gewenste 
stereoselectiviteit in de Grignard-reactie met het 2-trimethylethynyllithium en wordt uitsluitend 
de gewenste cis-l-terr-butoxy-3-hydroxy verbinding 11a gevormd (Figuur S.4). 
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Diels-Alder reactie van verbinding Па en l-methoxy-l,3-cyclohexadieen geeft als 
hoofdproduct het cycloadduct met de verkeerde regiochemie. Om te voorkomen dat deze 
verkeerde regio-isomeer ontstaat is verbinding 11a regioselectief beschermd met de 
/>-nitrobenzyloxy carbonylgroep. Verbinding 11b wordt daarbij gevormd in een opbrengst van 
70%. Naast deze verbinding worden ook de verbindingen gevormd met de beschermgroep op de 
8 positie en de dubbel beschermde verbinding met de beschermgroep op de 5- en de 8-positie. 
Eveneens wordt een kleine hoeveelheid van de uitgangsstof teruggevonden. In de Diels-Alder 
reactie van 11b blijkt dat de regioselectiviteit omgekeerd is, hoewel nog steeds een gedeelte 
(10%) van de verkeerde regio-isomeer wordt gevormd. Na oxydatie en ontscherming zijn de 
regio-isomeren gescheiden via kolomchromatografie. Door de basische omstandigheden van de 
oxydatie is de trimethylsilylgroep afgesplitst. Verbinding 13 (Figuur S.5) is via de in Hoofdstuk 
2 beschreven methoden omgezet in (+/-)-daunomycinon. 
Figuur s.5 
он o 
MeO OH O O-t-Bu 
13 racemisch mengsel van cis-7,9-OtBu,OH 
In Hoofdstuk 4 is een aanzet tot de synthese van de optisch actieve aglyconen 3 beschreven 
(Figuur S.l). Modelstudies hebben aangetoond dat het mogelijk is om Diels-Alder producten 
met redelijke tot hoge diastereomere overmaat te verkrijgen wanneer gebruikt gemaakt wordt 
van chirale l-alkoxy-3-trimethylsilyloxy-l,3-butadienen in de Diels-Alder reactie met 
naftazarine, juglon, naftochinon en benzochinon. In de reactie van benzochinon 14 met 
l-[l-(p-methoxyphenyl)ethoxy]-3-trimethylsilyloxybuta-l,3-diene 15 kan een zeer hoge 
diastereomere overmaat verkregen worden. Met behulp van ^-NMR spectroscopie kan slechts 
een diastereoisomeer waargenomen worden van verbinding 16 (Schema S.l). Wanneer de 
alkoxy groep in verbinding 15 op de juiste positie π- of p-electronen bevat, wordt een hogere 
diastereomere overmaat gevonden dan verwacht kan worden op grond van het verschil in grootte 
van de aryl en de methyl groep. Een verklaring hiervoor is gegeven met behulp van het 
'perpendicular' model zoals beschreven door Siegel et al9. 
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Door middel van X-ray kristallografie is de absolute configuratie (S) van het gevormde chirale 
centrum van verbinding 16 vastgesteld. Deze verbinding is verkregen via de Diels-Alder reactie 
van het S-(-)-dieen 15 (R = H), gemaakt vanuit S-(-)-l-phenylethanol, met benzochinon. 
Bij gebruik van het optisch actieve dieen 15 (R=H) in de synthese van het optisch actieve 
aglycon via de Diels-Aider reactie met naftazarine zoals beschreven in Hoofdstuk 2, blijkt dat er 
problemen zijn bij het verwijderen van de chirale hulpgroep. Na Diels-Alder reactie en 
vervolgens oxydatie, invoering van de ethynyl groep en omzetting van die ethynyl groep in een 
acetyl groep wordt een optisch actieve verbinding verkregen. Bij het verwijderen van de 
hulpgroep met behulp van trifluorazijnzuur wordt wel verbinding 12 (Figuur S.4) verkregen, 
maar de optische activiteit is verdwenen. Verder onderzoek zal er op gericht moeten zijn om een 
geschikte chirale alkoxy groep te vinden die verwijdert kan worden onder mild zure 
omstandigheden zonder epimerisatie van verbinding 12. 
In Hoofdstuk 5 wordt de synthese van nieuwe C13,C]4-ethynyl derivaten van daunomycine 17 
(X=OMe) en 4-demethoxydaunomycine 17 (X=H, Figuur S.6) beschreven. De aglyconen zijn 
gesynthetiseerd via de in Hoofdstuk 2 beschreven methode. 
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Volgens de literatuur methode van Terahima et al.4 zijn deze aglyconen 18 gekoppeld met de 
beschermde daunosamine suiker 19. Na koppeling met de suiker is het mogelijk om de 
diastereoisomeren te scheiden. De ethynyl derivaten van zowel daunomycine als 4-demethoxy­
daunomycine zijn geïsoleerd en getest op hun antitumoractiviteit. De resultaten van deze tests 
staan beschreven in Hoofdstuk 8. 
Hoofdstuk 6 beschrijft de totaal synthese van nieuwe pyridine ring-D derivaten van 
daunomycine. De ABC fragmenten 11a en 11b (Figuur S.4), waarvan de synthese is beschreven 
in Hoofdstuk 3, zijn gebruikt in de Diels-Alder reactie met l-(dimethylamine)-3-methyl-l-aza-
-1,3-butadieen 20. Na 1,4-eliminatie, oxydatie en ontscherming zijn de regio-isomere 
verbindingen 21 en 22 geïsoleerd (Figuur S.7). 
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De reacties zijn uitgevoerd onder hoge druk (15 kbar). Door gebruik te maken van de 
/»-nitrobenzyloxycarbonyl beschermgroep kan de regioselectiviteit van de reactie te worden 
beïnvloed. Zonder beschermgroep (dieen 11a) is de verhouding tussen verbindingen 21 en 22 1 : 
2, terwijl met beschermgroep (dieen 11b) de verhouding 7 : 3 is. Bij normale druk is de reactie 
veel langzamer en wordt ontleding van het ABC-fragment waargenomen via eliminatie van 
water en te/t-butanol. 
De 2-trimethylsilylethynyI groep is met behulp van HgO en verdund zwavelzuur omgezet in de 
acetyl groep. De racemische aglyconen zijn gekoppeld met de beschermde daunosamine-suiker 
19 (Figuur S.6) en de beschermde pyridine ring-D derivaten van daunomycine 23 en 24 zijn 
geïsoleerd (Figuur S.8). 
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Na ontscherming is het mogelijk om de HCl-zouten van de nieuwe ring-D derivaten te isoleren 
Deze zijn als mengsel van diastereoisomeren getest op hun antitumoractiviteit. De resultaten van 
deze tests zijn beschreven in Hoofdstuk 8. Voor verbinding 24 bleek het mogelijk om beide 
diastereoisomeren te scheiden en te testen op hun antitumoractiviteit 
In Hoofdstuk 7 wordt een overzicht gegeven van de biologische activiteiten van daunomycine 
en derivaten. Volgens de literatuur zijn er vijf mechanismen die bijdragen aan de antitumor-
werking van deze klasse van verbindingen. Het totale werkingsmechanisme is mede daardoor 
variabel, complex en nog steeds niet helemaal opgehelderd. De meest optredende nevenwerking 
van deze verbindingen is de aan de dosis gerelateerde cardiotoxiciteit. 
Veel aandacht is in de literatuur besteed aan de ontwikkeling van nieuwe derivaten met een 
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hogere cytotoxiciteit en een aanzienlijk lagere cardiotoxiciteit. De meeste derivaten zijn 
gemaakt via semi-synthese. The anthracyclinonen kunnen op vier belangrijke plaatsen gewijzigd 
worden (Figuur S.9). 
- Aanpasing van de Ci 3,C 1 4 zij keten. 
- Aanpassing van het BC ringsysteem. 
- Aanpassing van de ring-D. 
- Aanpassing van de suiker eenheid. 
R3 = H (daunomycin) 
R3 = H (adriamycin) 
R3 = H (carmynomycln) 
R3 = H (idarubicin) 
R3 ж ОН (4'-ерргиЬюіп) 
Hoewel tot nu toe meer dan 2000 nieuwe derivaten zijn gesynthetiseerd en een gedeelte daarvan 
is getest op biologische activiteit, is er nog geen derivaat gevonden dat adriamycine heeft 
vervangen in de klinische toepassing. 
In Hoofdstuk 8 zijn de biologische testresultaten weergegeven van de nieuwe daunomycine 
derivaten en hun intermediairen zoals beschreven in de Hoofdstukken 5 en 6. Alle nieuwe 
verbindingen zijn getest op de in-vitro toxiciteit met behulp van vijf verschillende humane 
tumorcellijnen. De testresultaten tonen aan dat de stereochemie op de posities 7 en 9 essentieel 
zijn voor de activiteit. Van de C13,C14-ethynyl derivaten zijn de HCl-zouten de meest actieve 
verbindingen. Bescherming van de З'-amino of de 4'-hydroxy groep resulteerd in een lagere 
cytotoxiciteit. Beide verbindingen met een pyridine ring-D vertonen een hoge activiteit. De 
testresultaten van het HCl zout van verbinding 28 lijken veelbelovend, zeker gezien het feit dat 
deze verbinding werd getest als mengsel van diastereoisomeren. Vier verbindingen 25-28 zijn 
verder getest op hun LD5 0, in-vivo cyctoxiciteit (L1210 test) en in-vitro carditoxiciteit. 
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25 X = H, R = COCF3 (HRM04) 
26 X = H, R = HHCI(HRM01) 
27 X - OMe, R = H HCl (HRM12) 
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De resultaten voor verbinding 28 lijken tot nu toe erg goed. Wanneer verdere tests worden 
uitgevoerd is het aan te raden om alleen de 7S.9S diastereomeer van verbinding 28a te 
gebruiken. Deze verbinding blijkt een 8 tot 10 maal hogere in-vitro cytotoxiciteit te geven dan 
het (1:1) mengsel van diastereoisomeren van 28. 
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